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Abstract 
This thesis describes the synthesis of iron oxide nanoparticles for use as contrast agents in 
biomedical imaging, specifically for MRI. The limitations of single imaging modalities can be 
overcome by the synergistic combination of two or more imaging techniques, e.g. the low sensitivity 
but high resolution of MRI complements the high sensitivity but low resolution of PET. The large 
surface area of superparamagnetic iron oxide nanoparticles (SPION) allows relatively simple 
functionalisation. The large size of a single combined nanoparticle MRI/PET probe would slow down 
in vivo movement, diminishing radioactivity before reaching its target. Pre-targeting using a 
magnetic nanoparticle followed by the injection of the radio-labelled molecule at the correct time 
will ensure radioactivity remains sufficiently high. Thus, the investigation of dual-modality probe 
development is also a focus of the thesis. 
Chapter 2 discusses the preparation of iron oxide nanoparticles with a core diameter of 6 nm via the 
high temperature thermal decomposition of iron salts. Direct modification to the surface of the 
nanoparticles was carried out using various small molecules with differing anchoring groups, the 
most successful being sodium alendronate, a bisphosphonate ligand. 
Chapter 3 describes the further functionalisation of the nanoparticles. One way this was achieved 
was by the incorporation of PEG chains of different lengths to increase water solubility and 
biocompatibility. Functionalisation with a strained alkyne for eventual in vitro/in vivo copper-free 
cycloaddition with an azide group was also achieved. The PET moiety was designed to be a 68Ga-
azido-DOTA complex. Prior to radiolabelling with gallium-68, the copper-free cyclised resultant 
nanoparticles were characterised by the use of lanthanide analogues (Eu, Tb and Gd). Eu and Tb 
allowed for fluorescence spectroscopy, while the Gd allowed for relaxivity measurements to be 
carried out. Unexpected fluorescence results were observed for the Eu and Tb analogues.  
The Gd-NP conjugates are further investigated in Chapter 4. Combination of both a T1 and T2 moiety 
results in changes to the relaxivity of the resultant nanoparticle which can act as a dual-weighted 
MRI probe. The relaxivities are found to vary with modifications to the nanoparticle construct. 
Finally, preliminary in vitro experiments with macrophages were carried out to investigate whether 
there was significant preferential uptake between M1 and M2 macrophages. A single-chain variable 
fragment (scFv) specific to Fractalkine, a chemokine important in the progression of atherosclerosis 
was prepared, for use as a targeting moiety towards the imaging of vulnerable plaque. 
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Abbreviations 
°C degrees Celsius 
γ gyromagnetic ratio 
ΔJ difference in angular momentum levels 
λem emission wavelength 
λex excitation wavelength 
μ micro- 
ν frequency 
τ luminescence lifetime 
acac acetylacetonate 
ATR attenuated total reflectance  
B0 magnetic field 
BP bisphosphonate 
BSA bovine serum albumin 
CA contrast agent 
CT computed tomography 
d doublet 
D distance between two PEG molecules on nanoparticle surface 
Da Dalton 
dd doublet of doublets 
DCM dichloromethane 
DLS dynamic light scattering 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DO3A-tBu 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
DTPA diethylene triamine pentaacetic acid 
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E energy 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ELISA enzyme-linked immunosorbent assay 
ESI electrospray ionisation 
Et ethyl 
FID free induction decay 
h Planck’s constant 
IONP iron oxide nanoparticle 
IR infrared 
kDa kilodalton 
LDL low density lipoprotein 
Ln lanthanide 
M Molar 
m multiplet 
m spin quantum number 
m/z mass /charge ratio 
MALDI matrix-assisted laser desorption/ionisation 
Me methyl 
mins minutes 
mmol millimoles 
MPS mononuclear phagocyte system 
MRI magnetic resonance imaging 
MS mass spectrometry 
mV millivolts 
Mw molecular weight 
NHS N-hydroxysuccinimide 
NMR nuclear magnetic resonance 
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NOTA 1,4,7-Triazacyclonane-1,4,7-triacetic acid 
NP nanoparticle 
OCT optical coherence tomography 
PBS phosphate buffered saline 
PBS (-) phosphate buffered saline without magnesium or calcium 
PEG polyethylene glycol 
PET positron emission tomography 
ppm parts per million 
q quartet 
q hydration state 
QD quantum dots 
r1 longitudinal relaxivity constant 
R1 longitudinal relaxation rate 
r2 transverse relaxivity constant  
R2 transverse relaxation rate 
RF Flory radius 
RT room temperature 
S0 singlet ground state 
S1 singlet triplet state 
SAP square antiprismatic 
scFv single chain variable fragment 
SDS-PAGE sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
SPECT single-photon emission computed tomography 
SPION superparamagnetic iron oxide nanoparticle 
SQUID superconducting quantum interference device 
t triplet 
T1 spin-lattice/longitudinal relaxation 
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T2 spin-spin/transverse relaxation 
t½ circulation half-time 
tBu tert-butyl 
TBDMS tert-butyl dimethyl silyl 
TEM transmission electron microscopy 
TGA thermogravimetric analysis 
THF tetrahydrofuran 
Ts tosyl 
TSAP twisted square antiprismatic 
US ultrasound 
UV-Vis ultraviolet-visible 
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1 Introduction 
This chapter introduces the reader firstly to molecular imaging and a general overview of 
nanoparticles, especially for use in the medical and imaging field. This leads to a brief explanation of 
magnetic resonance imaging and the contrast agents in use, specifically iron oxide nanoparticles, 
which will be the focus within this project. Some background into how the surface of the 
nanoparticles is functionalised is also described in this chapter but will be discussed in further detail 
in Chapter 3. Dual modal imaging is also briefly described here as one of the targets in this project is 
to design a dual modal MRI/PET imaging agent utilising Ga-68 as the PET moiety. A specific 
application of the nanoparticles is in the imaging of plaque and this is introduced at the end of this 
chapter, with a more detailed discussion in Chapter 5. 
 
1.1 Molecular Imaging 
The combination of information and expertise from various scientific disciplines, including chemistry, 
physics, engineering, biology, as well as many others, has brought about an innovative technology, 
known as molecular imaging. Historically, the traditional method of in vivo imaging was to simply 
image anatomy, and detect structural anomalies to detect diseases.1 Molecular imaging differs from 
traditional imaging by using probes that can interact with a particular target or pathway in the body 
and allowing any abnormalities in these systems to be detected. This will in turn allow for the earlier 
detection, diagnosis and potential treatment of the disease.2–4 Research into non-invasive in vivo 
imaging technology has received an abundance of attention over the last decade or so in order to 
bring about better understanding of the cellular and molecular processes of diseases in the human 
body. Different imaging modalities exist, among them are magnetic resonance imaging (MRI), 
positron emission tomography (PET), single photon emission computed tomography (SPECT), optical 
and ultrasound imaging.5 PET and SPECT imaging rely on radionuclides to produce an image which 
exposes the patient to radiation. In all the imaging techniques, the interaction of tissue with various 
forms of energy is what is exploited to produce an image of the body. These imaging modalities 
differ from each other in the following main aspects, a) spatial resolution, b) depth penetration, c) 
type of energy used to obtain the image, and d) sensitivity – the ability to detect the probe relative 
to the background. This is tabulated below (Table 1.1). 
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Imaging Modality Type of energy used Spatial 
resolution 
Depth 
penetration 
Sensitivity 
Positron emission tomography 
(PET) 
high energy γ rays 1 – 2 mm no limit pM 
Single photon  emission computed 
tomography (SPECT) 
low energy γ rays 1 – 2 mm no limit pM 
Magnetic resonance imaging (MRI) radiowaves 25 – 100 μm no limit mM 
Optical imaging visible to NIR light 2 – 4 mm ≈ 1 cm nM - pM 
Ultrasound high-frequency sound 50 – 500 μm mm to cm - 
Computed tomography (CT) X-rays 50 – 200 μm no limit - 
Table 1.1 General characteristics of the main imaging modalities (modified from ref
5
) 
 
Each imaging modality has its own advantages for a specific application but each also has its own 
drawbacks; for example, MRI gives high resolution images but is not very sensitive, while PET has 
high sensitivity but poor resolution. Therefore, a combination of two or even more imaging 
modalities could improve the quality of the image obtained when they are synergistically combined. 
Many examples of dual- or multi-modality imaging agents already exist in the literature but this is 
not exhaustive and more work can be done to synthesise these contrast agents for various 
applications. This will be discussed further in Section 1.4 of this chapter. 
Nanoparticles have been in existence for centuries, being produced by volcanic eruptions, 
weathering or microbial processes.6 Organic compounds such as proteins, viruses and 
polysaccharides, or inorganic ones such as metals, iron oxides, and aluminosilicates are all naturally 
occurring nanoparticles.7 The field of nanomaterials has expanded in recent years to include those 
which are produced in a modern synthetic laboratory and there is a wide range of nanoparticle 
systems that are being developed and that are in use in the imaging and medical field today. One of 
the criteria for this application is that these nanoparticles have to be between 1 and 1000 nm in 
diameter. Together with the excellent properties of nanoparticles such as the high surface area to 
mass ratio, and relative ease of functionalising the nanoparticles to either introduce new properties 
or modify existing ones, nanoparticles have the potential of bringing significant advances in the 
prevention, diagnosis and treatment of diseases. Nanoparticles are currently being exploited in a 
wide variety of applications, including imaging, drug delivery, photothermal therapy, and biosensors. 
The use of nanomaterials in the medical field for the diagnosis and treatment of disease has been 
termed nanomedicine.8 Nanoparticle systems which include polymeric and magnetic nanoparticles, 
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liposomes, micelles, dendrimers and carbon nanotubes have all been investigated for biomedical 
use.9,10 
Contrast agents have been utilised to enhance image quality and improve the visibility of features 
that would otherwise be difficult to detect.11 Nanoparticles have been used as contrast agents in 
various imaging modalities. This is made either by loading the contrast agent onto a nanocarrier, or 
having the nanoparticle act as the contrast agent themselves. One of the more well-known examples 
of the latter is the use of iron oxide nanoparticles as a contrast agent in magnetic resonance imaging 
(MRI).12 Gold nanoparticles as an X-ray contrast agent,13 quantum dots in fluorescence imaging,14 
microbubbles loaded with nanoparticles on the surface for use as ultrasound contrast agent,15 and 
radiolabelled nanoparticles for combined PET and CT imaging,16 are some other examples where 
nanoparticle systems have been utilised as contrast agents.  
 
1.2 Magnetic Resonance Imaging (MRI)  
MRI is a non-invasive imaging technique that uses the behaviour of proton spins in the body under 
an external magnetic field to produce an image of the internal organs and tissues.17 The contrast in 
the images produced is the result of different spin relaxation rates (spin-lattice relaxation, T1 and 
spin-spin relaxation, T2) of water molecules in different tissues.
18  
MRI uses the principle of nuclear magnetic resonance (NMR) to image nuclei in the body; the most 
frequently used being the hydrogen nucleus as water is abundant in the body. Protons have a 
magnetic moment that is proportional to their angular momentum, and the constant of 
proportionality is given by the gyromagnetic ratio γ. When protons are placed in a magnetic field, 
they change their energy states and their spins are separated into two energy levels (called the 
Zeeman effect, Figure 1.1) - the higher energy level being the spins aligning anti-parallel to the 
magnetic field, and the lower energy level being the spins aligning parallel to the magnetic field 
which is the preferred state. The spins cancel each other out which results in no net magnetisation.   
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Figure 1.1 Energy levels of spins states for the hydrogen nucleus where E is the energy, B0 is the magnetic field, 
γ is the gyromagnetic ratio, m is the spin quantum number, h is Planck’s constant and  is the frequency at 
which resonant transitions occur. 
 
The net magnetisation can be defined as a vector in the Z-axis, with the protons precessing around 
the direction of the external magnetic field B0 at the Larmor frequency. There are more spins aligned 
with B0 than there are in the other direction and so the vector is represented in the positive z-
direction (Figure 1.2). 
 
Figure 1.2 Protons precess around the applied magnetic field, resulting in a net magnetisation vector in the z-
axis. 
 
As the protons are resting in an external magnetic field with no external stimuli to induce changes in 
the spin states, a signal related to the relaxation of the spin states cannot be obtained. Therefore for 
a signal to be measured, there needs to be a change in energy from the equilibrium state. This is 
achieved via a radiofrequency pulse which when applied causes the net magnetisation vector to 
change direction as energy is absorbed, either 90o or 180o to the Z-axis.  
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When the radiofrequency pulse is switched off, the magnetisation vector relaxes back to the ground 
state. This can occur in two ways as shown in Figure 1.3: i) spin-lattice relaxation (which has a time 
constant T1) whereby the vector realigns back to its original position in the Z-axis, and ii) spin-spin 
relaxation (which has a time constant T2) where the magnetisation in the X-Y plane returns to its net 
value of zero until the signal decays with time. The magnetisation and decay of the induced signal 
over time is called free induction decay (FID). 
 
Figure 1.3 Spin-lattice (T1) and spin-spin (T2) relaxation processes which occur after the RF pulse is switched 
off. 
 
Once the electrical signals are recorded, computer software parameters can manipulate the 
information to ascertain the position of the nuclei in the body in order to obtain a contrasted image. 
An advantage of MRI over other imaging modalities is its ability to produce high quality images with 
high spatial resolution in the millimetre range.19 There is also no need to use ionising radiation unlike 
X-rays and CT scanning.19 However, MRI has very low sensitivity compared to PET and SPECT which 
can impair the amount of contrast in the images.20 To overcome this, exogenous substances or 
contrast agents have been developed that can increase the relaxation rate of local water protons.  
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1.2.1 Contrast agents for MRI 
As MRI signal intensity is a result of proton relaxation rates (both the longitudinal, 1/T1 and 
transverse rates, 1/T2), increasing 1/T1 should brighten the image while increasing 1/T2 should 
darken the image. Contrast agents are able to alter the relaxation rate of protons in the body which 
improves the MRI signal intensity. The most commonly used MRI contrast agents in a clinical setting 
contain paramagnetic gadolinium (T1 contrast agents), which brighten the image in the regions 
where the agent accumulates.21,22  
 
Figure 1.4 Examples of clinically-approved contrast agents containing Gd bound by DOTA and DTPA chelators. 
 
Gadolinium contrast agents utilise gadolinium (III) which has 7 unpaired electrons. Free Gd3+ is highly 
toxic – it is similar in size to Ca2+ which is abundant in the body and therefore competes with Ca2+ for 
calcium-binding enzymes and calcium channels, disrupting biological processes.23,24 It, therefore, has 
to be strongly coordinated to a chelator in order to be used in vivo. However, the complex still needs 
to have one or more vacant coordination sites to allow a water molecule to bind. The most common 
chelators have been acyclic DTPA (diethylene triamine pentaacetic acid) and macrocylic DOTA 
(1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid), or derivatives of them (Figure 1.4), 
which allow for water coordination. The much shorter distance between the bound water molecule 
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and Gd(III) ion allows the protons to experience a much stronger paramagnetic effect compared to 
the non-coordinated water molecules which results in enhanced relaxivity and greater image 
contrast. 
Superparamagnetic iron oxide nanoparticles (SPION) have also found use in molecular and cellular 
imaging as T2 contrast agents, which conversely results in a darkened image.
25 SPIONs have a higher 
relaxation value and are removed more slowly by the renal system compared to gadolinium-
containing contrast agents. They are currently being investigated as an attractive choice for 
molecular imaging.26–28 There are a few clinically approved iron oxide nanoparticles, such as Feridex 
and Resovist, for use as MRI contrast agents, however they are much less popular than the T1 
agents, and have been discontinued. SPIONs have primarily been used to image the liver, spleen and 
lymph nodes as this is where they accumulate, but are rapidly removed from circulation by the 
mononuclear phagocyte system (MPS).29 Target-specific applications require a long blood residence 
time therefore SPIONs have to be coated with functionalised coatings such as polyethylene glycol 
(PEG) or dextran to enhance their biocompatibility in order to be used in this application.30 The goal 
is then to functionalise the nanoparticle surfaces to enable targeting for molecular imaging and cell 
tracking, however this is not trivial.  
 
1.2.2 Iron oxide nanoparticles as MRI contrast agents 
Magnetic iron oxide nanoparticles exist in many forms in nature, but the three most common ones 
are magnetite (Fe3O4), maghemite (γ-Fe2O3) and hematite (α-Fe2O3).
31 However, magnetite and 
maghemite are focused on for the purposes of imaging as hematite is only weakly ferromagnetic.32 
Magnetite has a higher proportion of Fe2+ therefore it can potentially oxidise to maghemite in air or 
at low pH in the absence of oxygen if the nanoparticles are bare.33 Both have spinel structures, 
however magnetite has a higher saturation magnetisation than maghemite particles of the same 
size.33,34 The magnetic properties of the iron oxide nanoparticles are strongly dependant on the 
crystallinity of the material and this can change depending on the method of synthesis.35,36 In order 
to utilise iron oxide nanoparticles as MRI contrast agents, the particles need to have good relaxivities 
which is achieved by having a highly crystalline core.37,38 
Iron oxide nanoparticles as contrast agents are made up of an iron oxide core, and capped with a 
passivating layer which is usually a stealth layer of polymers (PEG or dextran) for biocompatibility 
and to prevent aggregation. These can be functionalised for further attachment of an optical moiety, 
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a radioligand, biological molecules such as antibodies, or even drugs - for use as dual-modal imaging 
agents, disease-specific target or therapeutics respectively (Figure 1.5). 
 
Figure 1.5 Simplified representation of general iron oxide nanoparticle structure. 
 
Nanoparticles have been separated into three different classes according to their size: i) micrometer-
sized paramagnetic iron oxide (MPIO, up to several micrometers), ii) superparamagnetic iron oxide 
(SPIO, up to hundreds of nanometers), iii) ultrasmall superparamagnetic iron oxide (USPIO, less than 
50 nm).39 The ideal size for in vivo delivery of nanoparticles is 10-100 nm although this is dependent 
on the application.40 Smaller nanoparticles are removed too quickly by the kidneys while larger 
nanoparticles are isolated by the MPS. 
There are numerous chemical methods that can be used to synthesise superparamagnetic 
nanoparticles. These include co-precipitation, thermal decomposition, microemulsions, sol-gel 
syntheses and hydrothermal reactions among others.41–43 The difficulty faced in synthesising these 
nanoparticles is in obtaining a monodisperse population of appropriate size.  
The simplest and most common method of synthesising magnetic nanoparticles is by the classical 
literature method of co-precipitation.44–48 This involves ageing stoichiometric amounts of ferrous and 
ferric salts in aqueous media to produce the iron oxides. This occurs in two stages; nucleation and 
growth.49–52 A disadvantage of the co-precipitation method is that particle size control is limited as 
the control of the crystal growth is due to kinetic factors. The nanoparticles produced by this 
method have a large size distribution due to the nucleation and growth steps occurring 
simultaneously. Nucleation to produce the seed crystals occurs rapidly when the reaction solution 
reaches supersaturation, and then simultaneous slow growth of the crystals on the surface of the 
seeds occurs.38 This results in particles of varying sizes. Hence, to produce narrowly dispersed iron 
oxide nanoparticles, the process of nucleation should be separated from growth.53  
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Narrowly dispersed nanoparticles with a good size control can be achieved by the high-temperature 
decomposition of iron organic precursors such as Fe(CO)5, Fe(acac)3 or Fe(Cup)3 [Cup = Cupferron - 
N-nitroso-N-phenyl hydroxylamine] in the presence of organic solvents and surfactants.54 The 
products of this type of synthesis have been shown to deliver higher relaxivities due to improved 
crystallinity.38 The co-precipitation and thermal decomposition methods are the two most commonly 
used to prepare iron oxide nanoparticles for biomedical applications.55  
To prevent aggregation of the nanoparticles, the iron oxide cores have to be capped with a 
stabilising agent.29 These can be monomeric (carboxylates, phosphates), inorganic (silica, gold) or 
polymeric (PEG, dextran). The capping moieties are not usually covalently-bound to the iron oxide 
core. For example, hydrogen bonding between the hydroxyl groups of dextran and the surface of the 
iron oxide has been postulated.30 This means that the capping layer may be easily stripped in vivo, 
resulting in aggregation and/or clearance from the body. The commonly used molecules to stabilise 
SPIONs in the literature have been surfactants such as oleic acid and alkane phosphonic acids.56 
These molecules are amphiphilic and result in highly stable nanoparticles that are dispersible in 
organic solvents. But this is not ideal as these SPIONs require further functionalisation to impart 
water solubility before use in biological applications. Polymeric coatings such as dextran are ideal 
molecules as they impart biocompatibility to the iron oxide nanoparticles.57 This enables the SPIONs 
to be used in biological systems and remain stable in water at neutral pH and physiological salinity. 
The polymer coating can also allow further functionalisation of the SPION surface with drugs, 
fluorescent compounds or even PET/SPECT reporters for therapeutic and bimodal imaging purposes. 
 
1.3 Functionalisation of nanoparticle surfaces 
1.3.1 Capping agents as stabilisers 
As previously mentioned, there are different capping agents that have been used in the literature – 
monomeric, inorganic and polymeric. Monomeric stabilisers utilise functional groups such as 
carboxylates and phosphates to bind to the surface of the iron oxide core. These molecules are 
usually citric acid or other organic acids which bind to the iron oxide core via the oxygen atoms of 
the acids. Inorganic materials such as silica and gold provide a binding site on the nanoparticle 
surface for biological ligands. For example, with a silica surface, the silanol groups on the surface 
allow reaction of specific ligands to the particles, via hydrolysis and condensation of an 
organosilane.58,59  
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Natural and synthetic polymeric capping agents such as dextran and polyvinyl alcohol (PVA) have 
been the most widely used as they are biocompatible and biodegradable.60 However, they are not 
covalently linked to the iron oxide core and may be easily stripped in vivo, therefore inducing 
aggregation.61  
An alternative direct method of functionalising the nanoparticle surface has been developed by 
Herranz et al, and involves synthesising oleic-acid capped SPIONs by the high temperature 
decomposition route but then oxidising the double bond of the oleic acid to form azelaic acid which 
has a higher water solubility.62 The terminal carboxylic acid group was then reacted with amines in 
water to show that the nanoparticles can be functionalised further in aqueous medium (Scheme 1.1). 
 
Scheme 1.1 Synthesis of hydrophilic nanoparticles by oxidation of the double bond in the oleic acid using 
potassium permanganate (KMnO4) and benzyltrimethyl-ammonium chloride (BTACl). 
 
Silica and gold are the two more exploited materials to be used as coatings for iron oxide 
nanoparticles. Silica is advantageous as it is relatively inert which improves chemical stability.63,64 The 
silica surface is usually deposited by three main methods, a) the Stöber process, b) emulsion 
method, and c) from a silicic acid solution. Gold coating is also highly useful as gold-thiol interactions 
can be utilised to further functionalise the nanoparticle surface. Gold surfaces have been deposited 
on iron oxide nanoparticles by literature protocols such as the thermal decomposition of gold 
compounds over a pre-made iron oxide nanoparticle,65,66 or by a reverse-micelle approach.67 Coating 
of iron oxide nanoparticles will be further discussed in Chapter 2. 
Surfactants such as oleic acid chains are good at stabilising the iron oxide nanoparticles in organic 
solvents but their coordinating bonds are labile.29 Exchanging carboxylic acid anchors for a molecule 
containing a phosphonate group that can more strongly coordinate to the iron on the surface of the 
core will greatly improve the stability of the nanoparticles over a larger pH and temperature 
range.34,68–71  
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Figure 1.6 Simplified diagram of 99mTc-containing bisphosphonate iron oxide conjugate for dual modality 
SPECT-MR imaging. 
 
Daou et al have carried out studies on the phosphonate interaction with iron oxide nanoparticles 
and have also shown that nanoparticles with phosphonates exhibit higher magnetisation.68–70 A 
recent paper by Torres et al  have also successfully shown that 99mTc-containing bisphosphonate 
ligands can directly bind to the iron oxide core of dextran coated nanoparticles  (Figure 1.6).72 Other 
recent papers by Motte et al have also used bisphosphonates as capping agents for SPIONs.73 This 
will be expanded upon in Chapter 2. 
 
1.3.2 Surface modification for functionality  
Nanoparticles that have not been functionalised with a targeting moiety will be taken up by 
macrophages in the body and this has so far limited their use to imaging organs such as the liver, 
spleen and lymph nodes. Targeting moieties such as antibodies, proteins or peptides can be 
bioconjugated via mediators (such as NHS ester) to form a covalent link between them.  
Surface modification using covalent linkages is usually used to attach components which will remain 
a part of the contrast agent. These are typically radioligands and fluorophores, as opposed to drugs. 
The conjugation of radioligands and fluorophores to MRI contrast agents to give dual-modality 
imaging agents will be discussed further below. 
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1.3.3 Site-targeted contrast agents for imaging of diseases 
Early contrast agents in clinical use were not specifically designed to recognise specific targets such 
as receptors or cell markers. These contrast agents were still termed “tissue-specific” due to their 
accumulation in tissues and organs via phagocytosis or endocytosis, ending up in the liver, kidneys 
(via MPS) or lymph nodes.74,75 Other contrast agents which were not quite tissue-specific, but had 
long blood residence times due to either their high molecular weights or by binding to serum 
albumin, were called blood pool contrast agents.76,77  
In order for highly specific targets to be recognised and induce a different signal intensity to that of 
non-targeted tissue, contrast agents require conjugation to a ligand for selective receptor binding.78 
This can be an antibody, peptide, protein or other biological molecule to act as a targeting agent 
towards receptors in a diseased organ or cells in order to image a specific disease or pathway. A 
large proportion of targeted contrast agents in the literature has been for MRI, ultrasound and 
optical or fluorescence imaging, as much of the initial work to create these targeted contrast agents 
was to simply conjugate the relevant probe with an antibody. In the case of MRI, this was initially 
achieved by the direct conjugation of an antibody to the Gd chelate. However, this method is 
challenging due to the low sensitivity of MRI which makes the target detection difficult.79  
Several different conjugation techniques have been developed to overcome this. One way to do this 
is by employing a two-step avidin-biotin conjugation. The HER-2/neu receptor is a known marker in 
breast cancer cells and Artemov et al demonstrated targeted imaging by pre-labelling the receptor 
with biotin conjugated anti-HER-2/neu antibodies.80 The gadolinium contrast agent complexed to 
avidin specifically binds to the biotin-antibodies generating a positive T1 contrasted MRI image. 
Others have used lipid or micelle based nanoparticles carrying high payloads of Gd chelates 
embedded in the lipid membrane.81 Increasing the relaxivity of Gd-based contrast agents to obtain 
larger signal intensity, or utilising iron oxide nanoparticles to generate a negative contrast, have also 
been successful approaches. Zhao et al have used specific phosphate binding proteins which target 
apoptotic cells conjugated to SPIO to image cell death and have shown in vivo that tumours treated 
with chemotherapy showed a shift in MR signal.82 This would be a useful way to monitor cancer 
response to therapy.   
Other imaging modalities besides MRI have also seen attempts to produce targeted contrast agents. 
Microbubbles have been labelled with various antibodies and peptides for the ultrasound imaging of 
specific diseases or events. Conjugation of a microbubble to a P-selectin specific ligand or antibody 
has been shown by Klibanov et al to effectively image inflammation.83 Tumour angiogenesis has also 
been successfully imaged with selective uptake of microbubbles conjugated to integrin-binding 
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Knottin peptides.84 Price et al and Song et al have both separately shown that targeted microbubbles 
can be used for drug delivery, with destruction of the bubbles at the intended specific site releasing 
the drug.85,86 Fluorescence-based targeted contrast agents for tumour imaging have also been 
demonstrated. Conjugation of a tumour receptor-specific peptide to a dye resulted in tumour 
retention compared to negligible uptake by non-tumour-specific dyes.87,88 
 
1.4 Dual- or Multi-modality Imaging 
No single imaging modality is faultless – each has its limits and because of this, combining two or 
more imaging agents within one probe is becoming increasingly explored. Of the various 
combinations of imaging modalities, MRI/optical imaging has been the most well-developed, 
especially the functionalisation of gadolinium chelates with fluorophores or even quantum dots.89 
Other modalities that have been combined are PET/optical, SPECT/optical and MRI/PET. 
Even though multimodality imaging has been used clinically to obtain a greater understanding of 
disease processes, different agents have been used for each modality. Dual-modal imaging cannot 
simply be addressed by adding two separate classes of contrast agents together as each can have 
different pharmacokinetic properties. Therefore, a multi-functional probe that can be detected by 
two or more imaging modalities simultaneously would be extremely beneficial.90 
Multimodality imaging was initially carried out by using two separate probes and acquiring two 
separate images, then overlapping/fusing the images to obtain a more in-depth picture of the 
disease and its processes. This is termed software fusion. However, this is not always ideal as this 
method requires two separate machines and therefore moving the patient into a different position. 
Coupled with the involuntary movement of the organs, images obtained (especially MR images) can 
result in artefacts and cause difficulties when fusing images. To overcome this, a single probe which 
incorporates two or more imaging modalities and the ability to acquire the images using a single 
machine/instrument allows the patient to remain in the same/similar position while the image is 
acquired.91–93   
In the early 1990s, Hasegawa et al at the University of San Francisco, pioneered a CT scanner that 
was placed in tandem with a SPECT camera.94 Their success led to the eventual commercial scanners 
by GE Healthcare (SPECT/CT) and Siemens Molecular Imaging (PET/CT in 1998).  
A combined scanner would facilitate seamless production of fused images, and improve acquisition 
times. It also offers more accurate images which provide an advantage during surgery, which 
Chapter 1: Introduction 
 
33 
 
requires accurate localisation of the image (for example guided biopsies where sampling error can 
be reduced). Ultimately, it should offer the simplicity and convenience that fusion software cannot. 
A combined PET/CT scanner also gives the additional benefit of providing low-noise attenuation 
correction with the prospect of improved PET scan quality and quantitative accuracy. Combined 
scanners have an advantage in therapy as they allow for more efficient therapy planning and 
accurate monitoring of the therapy administered compared to just using a single imaging 
modality.95,96 
With a combined scanner, the image can be obtained using two separate contrast agents, a dual-
modal probe, or even with just one contrast agent. 
The advantages of using a single dual-modal probe over two separate contrast agents are: 
a) A single probe helps to ensure the same pharmacokinetics throughout. 
b) Allows for complementary anatomic, functional and molecular information to be obtained. 
c) The body’s clearance mechanism is not put under additional stress to remove the probes 
(compared to using two separate probes). 
d) Dual-imaging probe gives the assurance that the signal obtained by both modalities comes 
from the same molecule. 
 
The main disadvantages of dual-modal imaging are that the concentration of the different contrast 
agents to be used can vary by 3 orders of magnitude.95 It may not be as simple as coupling two 
separate modalities together (especially for MRI which is not sensitive and therefore requires a large 
amount of contrast agent, but PET which is very sensitive needs only a small amount of the 
radionuclide). Also, the dual-modal instruments, especially for PET/MRI have been difficult to design 
and combine due to the interference between the separate components (for example, the magnets 
for the MRI can interfere with the photodetector on PET). This results in acquisition of images that 
are difficult to align. 
Although combined scanners are likely to improve the accuracy of image fusion, some inaccuracies 
still exist, for example, related to respiratory chest movement differences between fast CT and 
slower PET acquisitions. As the PET and CT scans are not acquired simultaneously, the risk of patient 
movement between scans will still remain. 
Optical/PET (SPECT) has also been looked into due to the high detection sensitivity of both imaging 
modalities. Optical imaging’s depth penetration is limited by the energy being absorbed and 
scattered by tissue. PET/SPECT on the other hand, is not limited by tissue depth. When combined, 
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the optical data provides high-throughput imaging of molecular and functional events while the 
nuclear imaging provides quantitative data. Also, optical imaging is relatively low cost and flexible 
enough to be integrated into existing PET or SPECT systems. A fused PET/optical image would 
provide the information on where the probe has been localised (by PET), while the optical data 
would report the probe activity.  
Following on from the success of PET/CT scanners, the combination of PET with MRI was a logical 
progression and can offer several advantages, the greatest of which is that it would theoretically 
provide the “perfect” spatial combination of molecular/functional PET and anatomic/functional 
MRI.20 Compared with PET/CT, PET/MRI has the added advantage of greatly reducing radiation 
exposure (both PET and CT use radiation). However, a combined PET/MRI scanner faces a technical 
challenge in terms of space constraints. Also, PET detectors use photomultiplier tubes to acquire the 
images which are affected by the magnets of the MRI component.  
Another advantage of MRI/PET over CT/PET is that MRI/PET images can be acquired simultaneously 
while CT/PET images are taken sequentially, lengthening scan times. CT/PET also require two 
different breathing protocols, which causes artefacts and therefore affect the accuracy of the images 
and attenuation correction. MRI also has several other advantages over CT – MRI has excellent soft-
tissue contrast and does not use ionising radiation. 
One of the more popular combinations of dual-modal imaging is to combine MRI and optical 
imaging, with small molecules being the simplest concept but challenging to synthesise.95 There are 
various examples of MRI/optical probes of different combinations of signalling components in the 
literature. The majority of these have incorporated Gd-chelates and have primarily been 
synthesised by manipulating the chelate structures to include an organic fluorophore. For example, 
fluorescein covalently attached to Gd-DO3A has been shown to be an effective dual-modality probe 
(Figure 1.7).97 The fluorescein moiety was attached via the reaction of fluorescein isothiocyanate to 
an amino group on the macrocycle. Other organic fluorophores such as rhodamine have also been 
investigated.98  
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Figure 1.7 Structure of Gd-DO3A-ethylthioreido-fluorescein. 
 
Another example of an MRI/optical probe features gadolinium-functionalised quantum dots on 
dye-doped silica.99 Quantum dots have been known to have solubility and toxicity issues which may 
prove problematic. This can be overcome by introducing passivating ligands before use in vitro. 
However, the silica shells are inert and can hold a large amount of Gd ions which enhances the 
relaxivity.  
Aside from gadolinium chelates, iron oxide nanoparticles have also been functionalised with optical 
agents. Similar to the functionalisation of gadolinium chelates by simple conjugation with 
fluorescent moieties, iron oxides can be modified for MRI/optical imaging by coupling to 
fluorophores such as rhodamine,100,101 indolequinones,102 dansyl103 and Cy5.5.104–106 These examples 
have all shown bimodal imaging capabilities. There are many examples of core/shell structures as a 
means to introduce optical probes onto iron oxide nanoparticles, however not all have been shown 
to act as a dual modal MRI/optical probe in a biological setting. One of the more popular methods 
to form these core/shell systems is to coat the iron oxide core with a silica shell and subsequently 
trap the fluorophore such as rhodamine or terbium complexes, within the silica shell,107,108 or to 
deposit the optical moiety such as a quantum dot as another layer onto the silica shell.109 Quantum 
dots can also be directly grown around the iron oxide core,110 and this method has also been used 
to coat iron oxides with inorganic luminescent shells such as LaF3CeTb, and Y2O3:Eu.
111,112 However, 
the core/shell structures usually have large sizes, making them less suitable for use in biological 
imaging despite having both magnetic and optical capabilities. Therefore, simple conjugation of 
organic dyes have remained the more attractive way of forming dual modal MRI/optical agents, 
especially with Cy5.5 due to the desirable wavelength emission of Cy5.5 for biological applications 
(675 λex/694 λem).  
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1.4.1 PET/MR imaging 
With respect to this project, dual-modal MRI/PET imaging is an area of exciting development. PET is 
a technique that can be used to detect chemical changes in the body before the disease symptoms 
become apparent.113–115 Radioisotopes with a short half-life such as 11C and 18F are less suited for 
PET/MRI dual-modality probes due to the time restrictions on the synthesis and purification of the 
probes as well as their compatibility with long-lived biological molecules. Isotopes such as 64Cu, 68Ga 
and 124I have longer half-lives that make them more ideal for PET/MRI systems. 
There have not been many examples of dual-modal MRI/PET imaging agents, simply due to the 
difficulties in combining an MRI and PET probe together and overcoming the question of 
concentration (as previously discussed). Nanoparticles have been the predominant MRI contrast 
agent used in the development of this field as they are the perfect scaffold to integrate different 
imaging modalities onto a single platform.116 64Cu has been more widely chosen as the radioisotope 
to be investigated due to its well-established coordination chemistry which allows for a more varied 
approach to chelation enabling further linkages to nanoparticles, other imaging agents, peptides and 
other biological molecules.117  
Examples of dual modal MRI/PET probes from the literature include work by Glaus et al, who have 
shown that their SPIO core coated with micelles composed of functionalised PEGylated lipids, and 
modified with DOTA for 64Cu labelling have dual imaging capabilities.118 These have been different to 
previous probes where the particles were coated with more traditional polymer and carbohydrate 
based molecules (Figure 1.8) such as those by Lee et al 119 and Nahrendorf et al.120 Lee et al have 
further shown that their system, which includes conjugation to an RGD peptide that targets tumours 
results in a tumour-specific probe. Nahrendorf et al went further and conjugated a fluorophore 
which gave a trimodal probe. They also showed that these probes can be used for the imaging of 
atherosclerotic plaque from their biodistribution results and PET/CT scans which show accumulation 
of the probe in the arteries of the diseased mice, corroborated by in vivo MRI and ex vivo 
fluorescence imaging. 
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Figure 1.8 Left: Micelle-coated 
64
Cu-conjugated IONP as synthesised by Glaus et al, image adapted from ref 
118
. 
Right: Nahrendorf’s IONP (B) coated with dextran (D) and labelled with a fluorophore (C) and 
64
Cu (A), image 
adapted from ref 
120
. 
 
There have been even fewer examples of iron oxide nanoparticles conjugated to 68Ga for use in 
MRI/PET imaging. Gallium-68 has several advantages over copper-64 and so would be an ideal 
radioisotope to label dual MRI/PET probes. Gallium-68 is produced by a readily available generator 
as opposed to the cyclotron-produced copper-64, and the positron efficiency of 68Ga (89 %) is much 
higher than 64Cu (17.4 %).121 
An example of 68Ga conjugated to silica nanoparticle with cobalt ferrite core is shown below (Figure 
1.9).122 The triple modality MRI/PET/NIRF probe consists of 50 nm sized silica nanoparticles with 
amino and PEG coating and a NIRF dye encapsulating a cobalt ferrite core. The 68Ga-NOTA complex 
was chelated to the amine surface. However, this probe has not been functionalised to be target-
specific. Another example by Stelter et al used the same principle but incorporated a transfection 
agent for cell labelling.123   
 
Figure 1.9 Diagram showing the synthesis of PET/MRI/fluorescent triple modality molecular probe based on 
silica nanoparticles with cobalt ferrite core. TEOS - tetraethyl orthosilicate; NOTA - 1,4,7-triazacyclonane-1,4,7-
triacetic acid [Image from ref 
122
]. 
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The use of DOTA and NOTA ligands to chelate metal ions has been extensively researched therefore 
these would seem logical ligands to use for binding Ga(III). Although NOTA has a slightly higher log K 
value for Ga (30.1)124 than DOTA (21.3)125, NOTA has not yet been approved for clinical use. Within 
this project, the PET moiety (gallium-DOTA) will be attempted to be conjugated to the nanoparticle 
via the copper-free azide-alkyne cycloaddition reaction. The dual-modal contrast agent would be 
assembled in vivo as the large size of a single pre-combined nanoparticle MRI/PET probe would slow 
down in vivo movement, diminishing radioactivity before reaching its target. Pre-targeting using a 
magnetic nanoparticle followed by the injection of the radio-labelled molecule at the correct time 
will ensure radioactivity remains sufficiently high. Therefore, a pre-targeting concept whereby the 
magnetic nanoparticle is first injected, followed by the injection of the radio-labelled molecule at the 
correct time will be attempted to ensure radioactivity remains sufficiently high. This will be 
discussed further in Chapter 3.  
 
1.5 Applications specific to this project 
Iron oxide nanoparticles are currently being extensively researched for use in target-specific 
applications. These include cancer imaging and inflammation in atherosclerosis, among others, and 
have already been briefly introduced in previous sections.126–128 Nanoparticles are optimal for 
targeted imaging because of their large surface area capable of conjugating biological molecules 
such as antibodies and proteins. In theory, it would be possible to image any disease state, or an 
event, as long as the specific target (receptor or cell marker) to be imaged is known. In the body, this 
amounts to a large collection of diseases, receptors and cell markers, and hence antibodies, peptides 
and proteins that can be conjugated to contrast agents.  
An immediate application of the nanoparticles synthesised in this project is in cardiovascular plaque 
imaging and was carried out in collaboration with the Bioengineering Department at Imperial 
College London. Cardiovascular disease (CVD) is one of the leading causes of deaths in the UK. The 
causes of CVD are varied, although atherosclerosis and hypertension are two of the more common 
ones. Atherosclerosis is a condition where the walls of the arteries harden and the lumen narrows, 
due to the formation of atherosclerotic plaque. Atherosclerotic plaque has been shown to play a 
significant role towards the development of acute coronary syndrome (ACS). Post-mortem 
examinations of patients who have suffered heart attacks indicate that the plaques become 
vulnerable in ACS leading to blood clots and eventually heart attacks.129 The main factor that 
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contributes to plaque progression and vulnerable plaque formation is inflammation which is 
regulated by a chemokine network. By imaging the key proteins during vulnerable plaque formation, 
it is hoped that at-risk patients can be diagnosed earlier.  
 
1.5.1 Atherosclerosis 
Atherosclerosis is a vascular disease where the artery wall thickens (stenosis) and hardens due to the 
presence of atheromatous plaque. Atherosclerosis was initially thought to be predominantly caused 
by high concentrations of lipids in the artery wall. However, even after lifestyle and diet changes, 
and the use of pharmaceutical drugs to control cholesterol concentrations, it remains one of the 
leading causes of death in many industrialised countries.130,131 Therefore, the composition and 
morphology of plaque in the arteries are more important factors than luminal stenosis when 
determining whether a cardiovascular event will occur.132,133 It is now widely accepted that 
atherosclerosis is a disease that is a result of inflammation.134–138  
There are two types of plaque (illustrated in Figure 1.10): a) stable plaque, which has a small and hard 
fatty core with a thick fibrous cap, and where the atheroma grows to eventually restrict blood flow 
due to reduction in the lumen diameter; and b) unstable (or vulnerable) plaque, consisting of a 
larger and soft fatty core with a thin fibrous cap, which is susceptible to rupture. When a vulnerable 
plaque ruptures, a clot can form elsewhere in the body that can either slow or stop blood flow, 
leading to tissue death. The two most commonly recognised situations where a clot from vulnerable 
plaque disruption results in tissue death, is a heart attack (artery blockage in the heart) and stroke 
(artery blockage in the brain).  
 
Figure 1.10 Simplified illustration of stable and vulnerable plaque. Stable plaques have a small, hard lipid core 
with a thick fibrous cap, while vulnerable plaques have a larger lipid core, with a thin and fragile fibrous cap.
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The process for the formation of plaque in the arteries is not fully understood, but the general 
consensus is that plaque is formed as a result of inflammatory processes in the endothelial cells of 
the artery wall due to the presence of irritants. The presence of these irritants arises from factors 
such as diabetes, smoking, a high fat diet, hypertension, and even some bacterial infections, which 
results in foreign materials such as free radicals and lipids in the blood stream. 
Arteries are made up of three layers, the intima, media and externa. The intima layer further 
consists of a layer of cells called the endothelium, supported by an internal elastic lamina, which 
help to maintain the smoothness of the inside of the arterial wall, thus keeping a good flow of blood. 
As people age, endothelial dysfunction (or damage) is aggravated by any one or a combination of the 
following: elevated low density lipoprotein (LDL) levels; infections from microorganisms such as the 
herpes virus; genetic mutation; free radicals from hypertension, diabetes, or smoking.140–142 This 
allows the endothelium to be more permeable to LDL, thus starting the atherosclerotic process. 
Macrophages are dispatched to the site of inflammation, and upon recognition of the LDLs as 
exogenous, they internalise them and turn into foam cells.143  
When this inflammatory response fails to remove the irritants, the inflammation can continue 
indefinitely. As the inflammatory response repeats itself, more macrophages and T-cells migrate to 
and accumulate within the plaque.144,145 At the same time, a high concentration of LDL in the blood 
stream results in the LDL accumulating in the intima to form fatty streaks. The smooth muscle cells 
of the tunica media start migrating to the intima, forming a fibrous cap over the fatty streak. The 
combination of the fatty core and the fibrous cap is known as an atherosclerotic plaque. The artery 
wall can compensate for the presence of the lesion for some time, so that the lumen remains 
unchanged. This is known as “remodelling”.146 Eventually, the artery wall becomes so severely 
damaged that it cannot compensate for the large size of the plaque, which now obtrudes far into the 
lumen, and obstructs blood flow. As the disease progresses, macrophages, endothelial cells and 
smooth muscle cells within the plaque die from apoptosis or necrosis.147 This results in a large lipid-
necrotic core and a thinner fibrous cap that is more fragile and prone to rupture.148 
 
1.5.2 Vulnerable Plaque 
The deviation to form vulnerable plaque has been found to be directly correlated to a vast number 
of macrophages at the site of inflammation. When the foam cells and other components of the 
plaque die, various chemical factors are triggered and released which sustain the inflammatory 
process, thus increasing the numbers of macrophages even more. These macrophages have been 
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known to produce proteinases and free radicals that can degrade tissue as well as prevent the 
formation of stable fibrous cap, leading to wall damage and plaque rupture.149–151 The total amount 
of macrophages that is found within the plaque has been correlated to an increased risk of plaque 
rupture.143 
Even with the advances in medical treatments for cardiovascular disease, a large number of patients 
who appear healthy die suddenly without any prior symptoms.152,153 A large proportion of these 
sudden deaths have been attributed to the presence of vulnerable plaque. Vulnerable plaque differs 
from stable plaque and has been defined by several groups to generally have a thin fibrous cap that 
is <65 μm thick and a large lipid core that is infiltrated by macrophages.154 It is more difficult to 
detect by traditional imaging methods due to these differences in composition and morphology 
between the stable and vulnerable plaque. 
 
1.5.3 Imaging of vulnerable plaque 
In order to prevent the worst-case scenarios of heart attacks and strokes when a vulnerable plaque 
ruptures, earlier diagnosis of vulnerable plaque in high-risk patients (such as those with a family 
history of heart disease) is required. Commonly used methods to image plaque are by ultrasound 
(US), optical coherence tomography (OCT), computed tomography (CT) and conventional 
angiography. These methods typically detect atherosclerosis by evaluating the physical 
characteristics of the arterial walls, especially the considerable narrowing of the lumen.132 However, 
these conventional techniques have low resolutions and do not allow for the accurate determination 
of the presence of thin fibrous caps to distinguish between stable and vulnerable plaque and 
therefore are less than reliable for imaging vulnerable plaque.139  
Several methods for imaging atherosclerosis and vulnerable plaque have been reported in the 
literature, mostly on small animal models for practical purposes. Atherosclerosis is a chronic 
inflammatory disease, where the inflammatory cells such as macrophages play a significant role at 
every stage of the disease. Many examples in the literature have used these markers in the 
inflammatory processes, as well as other biological targets such as apoptosis,155–157 to image 
atherosclerosis, most commonly with radioisotope imaging. A relatively straightforward method is to 
use radiolabelled LDL to visualise their accumulation in plaque,158–160 as well as tracking monocytes 
(precursors to macrophages) labelled with 111In-oxine, a clinically approved radiotracer.161 A less 
direct method that has been shown to successfully image plaque in mice, is by imaging a specific 
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receptor, LOX-1 that binds to oxidised LDL.162,163 Macrophages in plaque have also been imaged by 
following the uptake of 18F-FDG, as macrophages have a high metabolic rate.164 
So far, the methods to image plaque involve the use of radiotracers, and although they may 
determine the presence of the relevant criteria for vulnerable plaque, PET/SPECT imaging does not 
provide complementary local tissue confirmation of the vulnerable plaque. MR imaging is better 
suited to imaging plaque, and vulnerable plaque in particular, as the excellent soft-tissue contrast 
allows for composition and morphology of plaque vulnerability, not just luminal stenosis.165 After the 
discovery that SPIONs were spontaneously taken up by macrophages in plaque, first in rabbits,166–169 
and then later in humans,170 MR imaging of plaque using nanoparticles as contrast agents began to 
develop in earnest. By attaching targeting moieties to nanoparticles,171,172 which enable even more 
selective uptake by macrophages in plaque, MRI offers a very promising method for in vivo targeted 
imaging of plaque. However, even with MR imaging (with and without the use of contrast agents), 
not all the vulnerable plaque criteria can be evaluated at the same time by one single MR technique. 
Therefore, combined imaging will be required in order to assess multiple plaque features for a truly 
useful clinical evaluation. 
 
1.6 Aims 
Magnetic iron oxide nanoparticles as MRI contrast agents have been researched extensively. 
However, the formation of a single dual-modal MRI/PET contrast agent incorporating iron oxide 
nanoparticles has been less heavily explored, and is therefore an area that would be interesting to 
investigate. An application of the dual-modal MRI/PET probe would be to image vulnerable plaque, 
by targeting a cytokine protein that is expressed in the endothelial cells of the arteries.  
Taking all of this into consideration, the aims of this project are briefly outlined below: 
1. To synthesise iron oxide nanoparticle with a high magnetisation, high crystallinity and low 
size dispersion. Different synthesis methods will be explored and the nanoparticles from 
each method characterised. 
2. To coat the nanoparticle surface with a suitable ligand that will render the resultant 
nanoparticle water-soluble, and examine their stability at physiological conditions. 
3. Functionalise the nanoparticles with suitably reactive functional groups to allow the surface 
to be decorated further with: 
a. PEG molecules for biocompatibility; 
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b. Alkyne for copper-free alkyne-azide cycloaddition reaction to assemble a dual-modal 
MRI/PET imaging agent in vivo. 
4. Study the physical characteristics of the functionalised nanoparticles. 
5. Conjugate the nanoparticles to an antibody to enable the targeting and imaging of 
vulnerable plaque in atherosclerosis.  
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2 Magnetic nanoparticle preparation and ligand exchanges  
2.1 Introduction 
This chapter discusses the various methods of iron oxide nanoparticle synthesis and their 
characterisation. As previously mentioned in Chapter 1, there are multiple ways to synthesise iron 
oxide nanoparticles. Several methods were attempted to synthesise the core nanoparticles to 
determine the method that best produces nanoparticles with a narrow polydispersity, and high 
crystallinity. The bulk nanoparticles synthesised here were via the high temperature thermal 
decomposition of an iron precursor, and are not soluble in polar solvents, so exchanging the initial 
coating for a different ligand which will allow the resultant nanoparticles to be resuspended in 
water, or DMSO/ethanol/methanol (which can be diluted with water) would be most ideal. The 
ligands chosen for exchange were based on functional groups that have been shown to have a 
strong affinity for the nanoparticle surface. Carboxylate anchors (the most commonly used chemical 
group) were not compared as there are already plentiful examples in the literature.1 Furthermore, as 
the bulk core nanoparticles are synthesised with oleic acid which has a carboxylate unit as the 
anchor, it was thought best to replace the oleic acid with a ligand that has a stronger binding affinity 
for the nanoparticle surface, instead of replacing a carboxylate for another carboxylate. Phosphates 
and bisphosphonates2,3 were then the first choice as nanoparticle coating groups. Another type of 
functional group, sulfonates, was also investigated as an anchor for ligands to cap the nanoparticles. 
Only a few examples in the literature utilise sulfonates as capping ligands for iron oxide 
nanoparticles, especially for small molecules containing the sulfonate group. One example of such a 
ligand system is described by Portet et al.4 However, the resultant nanoparticles were not stable in 
water for very long.  
Within this chapter, the different methods explored to synthesise the core nanoparticles will be 
described, alongside an explanation of the results of the ligands exchanges carried out. 
 
2.2 Synthesis of bulk core iron oxide nanoparticles 
As previously discussed in the introduction chapter, there are many literature preparations of iron 
oxide nanoparticles. Co-precipitation of iron salts in a basic medium is the most common method of 
nanoparticle preparation in the literature, and was one of the methods attempted here. Other 
methods of syntheses attempted were the hydrothermal synthesis method and the high 
temperature thermal decomposition of iron salts. Several methods were attempted in order to 
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determine which method was most favourable and which produced nanoparticles with a narrow size 
distribution and high crystallinity.  
 
2.2.1 Hydrothermal syntheses 
The first method to be attempted was the hydrothermal method of synthesis.5,6 This is usually 
carried out by heating an iron salt at a relatively high temperature and pressure in a Parr reactor. 
Two protocols were attempted using two different iron salts, with one having a citric acid coating to 
stabilise the nanoparticles, and another using n-decylamine (Scheme 2.1).  
 
Scheme 2.1 The hydrothermal synthesis of iron oxide nanoparticles via iron salts such as FeCl2 and FeSO4.  
 
The citrate-coated nanoparticles has a better appearance in solution compared to the decylamine 
stabilised nanoparticles and were therefore imaged by transmission electron microscopy (TEM). As 
seen in Figure 2.1, the citrate-coated nanoparticles are unfortunately highly aggregated, with the 
organic ligand coating forming a layer around several nanoparticle cores. Therefore the 
hydrothermal method of synthesis proved difficult to obtain reproducible nanoparticles with the 
desired characteristics. 
 
Figure 2.1 TEM image of highly aggregated citrate coated NP from the hydrothermal reaction of FeCl2. 
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2.2.2 Co-precipitation of iron salts 
The co-precipitation method involves combining a mixture of aqueous Fe2+/Fe3+ salts in the presence 
of a base such as NH4OH at either room temperature or slightly elevated temperature. This method 
is advantageous as it allows for large-scale production of iron oxide nanoparticles, up to 40 g.7 
Between pH 8 and 14, and at a stoichiometric ratio of 2:1 (Fe3+/Fe2+) in a non-oxidising environment, 
the thermodynamics of the reaction indicates that complete precipitation of Fe3O4 (magnetite) 
should occur (Scheme 2.2). 1 
 
Scheme 2.2 Reaction scheme for the co-precipitation of iron to form Fe3O4. 
 
Fe3O4 however, is not very stable and is sensitive to oxidation, transforming into γ-Fe2O3 
(maghemite) in the presence of oxygen. This can be prevented by protecting the surface of the 
nanoparticle through the addition of a capping ligand (such as citrate, or polymers such as dextran or 
polyvinyl alcohol).  
In this work, a literature co-precipitation method was attempted.8 FeCl2 and FeCl3 were stirred 
together in degassed deionised water under nitrogen. Under mild heating, aqueous ammonia was 
added and the nanoparticles precipitated immediately. The nanoparticles were isolated by a magnet 
and resuspended in ethanol. Citric acid was also added in another attempt but this gave the same 
results as the bare nanoparticles. The bare and citrate coated nanoparticles were both a cloudy 
suspension. TEM images of the nanoparticles (Figure 2.2) show that the shape of the particles are not 
consistently spherical, and form aggregates. This was as expected as the nanoparticles in solution 
were not homogenous.  
 
Figure 2.2 TEM images of iron oxide nanoparticles obtained via the co-precipitation of iron salts. The particles 
were highly aggregated, and were inconsistent in shape. 
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2.2.3 Silica shell coated iron oxide core 
Silica is one of the preferred inorganic coatings for iron oxide nanoparticles as it has a high 
biostability, low toxicity, and the exposed silanol groups on the surface would allow for further 
versatile functionalisation, for example with amine groups.9 It was hoped that the availability of 
amine groups would then allow for straightforward chemistry for building a water-soluble surface, 
especially through the use of peptide coupling reactions with carboxylic acids to form stable amide 
bonds. There are several protocols in the literature to produce a silica shell coated iron oxide 
nanoparticle.8,10 
Typical methods for synthesising a core-shell iron oxide-silica nanoparticle usually involve the 
synthesis of the magnetic core, followed by layering on a surface of silica. The silica shell is usually 
deposited via either the Stöber method or a microemulsion process.11–15 The Stöber method has 
primarily been used for the preparation of silica nanoparticles and involves stirring a solution of 
tetraethyl orthosilicate in water, and a low MW alcohol such as ethanol, and ammonia. Varying the 
type of alcohol and the reaction volumes will produce silica particles of varying sizes. In the case of 
silica nanoparticle synthesis, the Stöber method produces particles with a less than ideal size 
distribution. When this process is applied to the formation of silica shells in core-shell systems, it 
usually results in a multi-core assembly with a non-uniform thickness of the silica surrounding 
several cores.13 An alternative to the Stöber method that has had success in the literature is an 
inverse microemulsion or water-in-oil microemulsion system.16–19 These systems employ a surfactant 
to lower the interfacial tension between the water component and the oil component, resulting in 
the formation of a stable single-phase system.20 Like the Stöber method, the microemulsion system 
has also been used to form core-shell iron oxide-silica nanoparticles.21–23 As with the silica 
nanoparticles, when the microemulsion method is used to produce the core-shell nanoparticles, it 
results in multi-cored nanoparticles which increases the overall size and hence reduces the stability 
of the particles in solution.22  
A literature preparation of a core-shell iron oxide-silica nanoparticle which aimed to eliminate the 
multi-core problem was attempted.10 The iron oxide nanoparticles were synthesised via the co-
precipitation method above and used immediately after for the deposition of the silica shell. The 
silica coating appeared to have been successful as two distinct structures were observed in the TEM 
image (Figure 2.3, below). However, the nanoparticles were in a multicore assembly with the silica 
shell surrounding several cores. This was repeated several times with the same results each time. 
The synthesis of single core-shell systems may be more complicated than suggested by literature 
and therefore this route was not carried forward. 
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Figure 2.3 TEM image of the silica-coated iron oxide nanoparticles. The darker spots are the iron oxide 
nanoparticles and the lighter areas surrounding the nanoparticles are the silica shell.  
 
2.2.4 High temperature thermal decomposition 
Nanoparticle preparation via the high temperature thermal decomposition of iron (Scheme 2.2) gives 
a very narrow size dispersion and high crystallinity, both of which are important for a good contrast 
agent with high relaxivity properties.24 The protocol followed was one from literature and was 
chosen due to the simplicity and convenience of carrying out the reaction in an organic solution 
whilst being able to tune the size of the nanoparticles with ease, simply by varying the reaction 
conditions or by seed-mediated growth.24  
 
Scheme 2.2 Scheme showing the synthesis of iron oxide nanoparticles via the high temperature decomposition 
of Fe(acac)3. 
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The synthesis of 6 nm nanoparticles involved heating the reaction mixture to 200 °C for 2 hours, then 
at 300 °C for 1 hour. Over this time, the mixture turned black suggesting the formation of 
nanoparticles. Once cooled, addition of ethanol precipitated the nanoparticles. Isolation by 
centrifugation or by a magnet, resulted in a black pellet which could be resuspended in a non-polar 
solvent. The nanoparticles were washed by repeated addition of methanol, ethanol and acetone to 
precipitate the particles out of a solution in hexane followed by centrifugation or magnetic sorting. 
Final addition of hexane resuspended the nanoparticles for storage in the freezer. 
Characterisation of the oleic acid-capped nanoparticles was by TEM, infrared spectroscopy (IR), X-ray 
diffraction (XRD), and superconducting quantum interference device (SQUID). Analytical data for 
XRD and magnetic measurements (SQUID) were obtained with assistance from PDRAs in the Long 
group, Nazila Kamaly and Juan Gallo.  
The IR spectrum was obtained neat on an attenuated total reflectance (ATR) plate. The spectrum 
confirmed the presence of the oleic acid ligands on the surface of the nanoparticles through the C=O 
stretches which appear around 1500 cm-1 (Figure 2.4). This stretch indicates that the carboxylic 
groups are bound to the nanoparticle surface as the infrared stretch has shifted slightly from that of 
free carboxylic acids (1700 cm-1). 
4000 3500 3000 2500 2000 1500 1000
%
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Figure 2.4 Infrared spectrum of bulk oleic acid coated iron oxide nanoparticles (neat, ATR plate). 
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TEM micrographs (Figure 2.5 A, B) showed a narrow distribution of spherical NPs, with the average 
size of approximately 6.1 nm (based on 500 measurements, Figure 2.5 E). Using TEM, a selected area 
electron diffraction (SAED) pattern was obtained and the composition of magnetite was confirmed 
based on measured lattice spacings from the rings in the diffraction pattern, which compared to 
known lattice spacings for bulk Fe3O4 along with their respective hkl indexes (Figure 2.5 C). XRD 
obtained on solid Fe3O4 NPs shows several peaks corresponding to the interplanar spacings 111, 220, 
311, 400, 511 and 400 comparable to standard peaks (JCPDS, 01-075-0449, Inorganic Crystal 
Structure Database), confirming the correct reflection peaks for the inverse cubic spinel Fe3O4 
structure (Figure 2.5 D). In addition, energy-dispersive X-ray spectroscopy (EDXS) of a sample of the 
nanoparticles confirmed the presence of iron (Figure 2.5 F). 
 
Figure 2.5 A: TEM micrograph of as-prepared Fe3O4 nanoparticles (oleic acid capped) (scale bar = 20 nm); B: 
enlarged area from A; C: SAED showing lattice ring patterns; D: XRD diffractogram with indexed peak positions 
and relative intensities; E: Size distribution diagram of as prepared Fe3O4 nanoparticles; F: EDXS spectra of a 
sample of Fe3O4 nanoparticles. Red lines indicate Fe peaks; black lines show Cu and Si peaks coming from the 
sample holder. 
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The magnetic properties of the sample were measured by superconducting quantum interference 
device (SQUID). The normalised saturation (Ms) magnetisation for the Fe3O4 NPs was measured to be 
68 emu/g (Figure 2.6) which is comparable to similar sized IONPs (30-60 emu/g).25,26 Zerofield cooled 
(ZFC) and field cooled (FC) magnetisation data measured with a field of 100 Oe in the temperature 
range 0-400 K were obtained (Figure 2.6). In the ZFC measurement, with increasing temperature 
more particles re-orientate their magnetisation with the external field and the total magnetisation 
increases. This reaches a maximum at the blocking temperature (Tb) of 34 K, indicating magnetic 
interactions between the NPs are present (Figure 2.6). These results show that the synthesised IONPs 
exhibit superparamagnetic behaviour at room temperature with no hysteresis. 
 
 
Figure 2.6 Magnetic measurements of Fe3O4 nanoparticles. A and B, room (red) and low temperature (5 K) 
(blue) magnetisation hysteresis. C, zero field cooled (ZFC) and field cooled (FC) magnetization measurements 
of the same sample. 
 
2.2.5 Conclusion 
The nanoparticles synthesised via the high temperature thermal decomposition of iron 
acetylacetonate produced particles with a good size distribution, well-controlled sizes, and 
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nanoparticles with a high crystallinity. This is highly advantageous over the other above mentioned 
methods of nanoparticle preparation (hydrothermal and co-precipitation). The nanoparticles 
synthesised by co-precipitation were highly aggregated which is undesirable. A disadvantage of the 
thermal decomposition method is that the nanoparticles are only soluble in apolar solvents thus 
requiring a ligand exchange step to further functionalise the nanoparticles. Nevertheless, the quality 
of the nanoparticles synthesised via thermal decomposition outweighs this added synthetic step and 
therefore all the bulk core nanoparticles synthesised for further functionalisation were synthesised 
via the high temperature thermal decomposition method. 
 
2.3 Ligand exchange with small molecules 
Naked iron oxide nanoparticles form agglomerates due to the lack of stabilising surface ligands. It is 
therefore essential to coat the nanoparticles with capping agents such as small molecules, polymers, 
or inorganic shells such as gold and silica. As previously described in chapter 1 (introduction), there 
are various capping agents already used in the literature.1 In the previous section, work on the 
synthesis of silica shell coated iron oxide nanoparticles was attempted but this was not trivial for 
forming single core-shell systems. It was determined that the best method to synthesise the bulk 
core nanoparticles was via the high temperature thermal decomposition method and these particles 
are only soluble in non-polar solvents. In order to disperse the nanoparticles in polar solvents, it is 
necessary to replace the oleic acid/oleylamine coating. During the course of this PhD, the focus was 
primarily on small molecules such as phosphates, bisphosphonates and sulfonates, as these groups 
have been shown to have a stronger affinity for the nanoparticle surface than carboxylates.1–3 
Several bisphosphonate ligands were investigated, and as a comparison, a phosphate ligand was 
synthesised based on previous work within the group. As an alternative, sulfonate-type ligands were 
investigated as capping ligands for the nanoparticles. Sulfonates are rarely mentioned as anchoring 
units in the literature and this will be discussed below. 
 
2.3.1 Sulfonates 
Sulfonates have not been widely used as an anchoring group for capping ligands on nanoparticles 
and few examples exist in the literature. This could be because there are not many small molecule 
sulfonate ligands commercially and readily available, and it has not yet been shown to be as good an 
anchor as carboxylates and phosphates. One example in the literature where a sulfonate has been 
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incorporated with nanoparticles is a poly(sodium-4-styrene)sulfonate-iron oxide nanocomposite 
(Figure 2.7).27 This magnetic suspension has been shown to have tunable low-field relaxivities, and 
was synthesised in a one-step co-precipitation procedure.  
 
Figure 2.7 One-step synthesis of poly(sodium-4-styrene)sulfonate-iron oxide nanocomposite. Image from 
ref 27. 
 
In another example, dodecylsulfonate, a surfactant, has also been shown to stabilise iron oxide 
nanoparticles.28 Rafailovich et al have synthesised in one-step via sonolysis of the iron precursor and 
the surfactant. The infrared spectra confirmed the bonding of the sulfonic acid groups to the 
nanoparticle surfaces by ionic bonding, which was possible due to the direct reaction of the 
surfactant with the iron precursor. One example of a small molecule sulfonate ligand coating 
nanoparticles via ligand exchange is by Portet et al where he used a disulfonic acid.4 Sulfonate 3 
(Figure 2.8, S3) was the disulfonic acid Portet used and he found that the resultant nanoparticle was 
stable for greater than 4 weeks.4 This was the starting point for the sulfonate ligands chosen to be 
investigated. The other sulfonates were chosen to have the same core naphthalene, but with some 
modifications. One modification was to compare a monosulfonic acid with the disulfonic acid, in 
order to determine if two sulfonate groups improve the stability compared to having just one 
sulfonate (Figure 2.8, S4). The other was to have only the amine group, with no extra hydroxyl group 
in the molecule (Figure 2.8, S2). After the ligand exchange, NP-sulfonate 1 is given the notation NP-
S1, NP-sulfonate 2 as NP-S2 and so forth. 
 
Figure 2.8 Structures of the sulfonate ligands which were used to coat the nanoparticles. 
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a) Ligand exchange with sulfonates 
 
Scheme 2.3 Ligand exchanges of bulk nanoparticles with sulfonate ligands (S1 to S4) to give NPS1 – NPS4. 
 
The ligand exchanges were carried out via a DMSO/toluene mixture (for NP-S1), or basic H2O/THF 
mixture (S2, S3 and S4) (Scheme 2.3). The DMSO/toluene system proved difficult to purify for NP-S2, 
NP-S3 and NP-S4 as removal of excess sulfonate ligand was difficult during workup therefore the 
basic H2O/THF system was utilised. The ligands were dissolved in either DMSO or basic water, while 
the nanoparticles were suspended in toluene or THF. The mixtures were stirred for two days, at the 
end of which they were centrifuged and the supernatant was decanted off. In the case of the 
DMSO/toluene exchange for NP-S1, the black pellet was washed with DMSO to remove free ligand, 
and then magnetic separation was used to isolate the nanoparticles. In the case of the H2O/THF 
exchange to give NP-S2, NP-S3 and NP-S4, the black pellet was washed with basic water (with 
sonication) to remove any free ligand, then the magnetic particles were separated from the 
supernatant by a magnet. After the respective washings to remove any free ligands, all the 
nanoparticles were re-suspended in DMSO, and treated with a few drops of 1 M HCl, and sonicated. 
Precipitation with acetone or THF, followed by magnetic separation resulted in nanoparticles that 
were soluble in DMSO. 
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All the nanoparticles coated in the sulfonates were dispersible in DMSO, but not directly in water. 
The naphthalene backbone is quite hydrophobic which may explain the lack of solubility of the 
resultant nanoparticles. S3 and S4 however, have an extra OH group which could allow for hydrogen 
bonding and therefore may have aided in the better solubility of the NP-S3 and NP-S4. In terms of 
stability of the nanoparticles, NP-S1, NP-S3 and NP-S4 were stable for several days in a solution of 
DMSO. NP-S2 resulted in nanoparticles that settled after several days. In a more dilute solution 
(approximately 85 μg/mL NP) of DMSO however, this instability was less obvious, with precipitation 
of the nanoparticles taking weeks instead of days (Figure 2.9).  
 
Figure 2.9 From left to right: diluted solutions (approximately 85 μg/mL NP) of NP-S1, NP-S2, NP-S3, NP-S4 in 
DMSO. Left – solution of the nanoparticles at t = 0h. Right – solution of the nanoparticles after 2 weeks. 
 
b) Characterisation of sulfonate coated nanoparticles 
The sulfonate coated nanoparticles were characterised by TEM, IR, thermogravimetric analysis (TGA) 
and dynamic light scattering (DLS). Rhodamine coupling to the amine group on the surface was also 
carried out to determine the number of free amine groups available on the surface. 
All the sulfonate ligands had almost identical infrared spectra, as the structures of the ligands are 
very similar. Hence, after ligand exchange, the nanoparticles coated with the ligands also had very 
similar spectra to each other (see Figure 2.10 for IR spectrum of NP-S1). The sulfonate stretch, ν(S=O), 
for the ligand appears as sharp peaks around 1000 – 1200 cm-1. The NP-sulfonate has a broad stretch 
in a similar region, and is indicative that the ligand exchange was successful.  
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Figure 2.10 Infrared spectrum of NP-S1 (top curve, neat, ATR plate) compared with the infrared spectrum of 
the S1 (bottom curve, neat, ATR plate). The red box indicates region of the spectrum that contain stretches 
from the sulfonate functional group. 
 
DLS measurements 
The sulfonate coated nanoparticles were analysed by DLS measurements, in DMSO, with a glass 
cuvette, and their sizes tabulated below (Table 2.1). The sizes of the ligands are relatively small when 
considering typical bond lengths of approximately 1 – 2 nm, which would mean that on a core of 
6 nm, the sulfonate coated nanoparticles should be roughly 10 nm (actual size). In a solvent, this size 
is expected to increase due to interaction between the nanoparticle and solvent. For NP-S1, NP-S2 
and NP-S3, hydrodynamic diameters were 19.5 nm, 15.2 nm and 14.4 nm respectively and were as 
expected. 
Nanoparticle Hydrodynamic diameter (nm) 
NP-S1 19.5 ± 3.1 
NP-S2 15.2 ± 5.6  
NP-S3 14.4 ± 2.3 
NP-S4 82.9 ± 153.5*  
Table 2.1 Hydrodynamic diameters of the nanoparticles coated with the sulfonate ligands. *inconsistent 
results obtained for this sample. 
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DLS measurements for NP-S4 gave inconsistent results however, even after repeat measurements, 
with very small sizes for some (< 10 nm) as well as very large sizes for others (> 100 nm). This could 
be due to the sample beginning to degrade, resulting in a mixture of aggregates and bare particles.  
When a nanoparticle is surrounded by media, the solvent molecules interact with the particle’s 
surface, and this influences the behaviour of the nanoparticles. The surface-solvent interaction 
forms an additional layer around the nanoparticle, and this is the hydrodynamic diameter. DLS 
measurements are also affected by the solvent the particles are in, as different solvents have 
different properties, such as viscosity. Therefore the outcome of the measurement will be different 
in DMSO compared to in water or other solvents. DLS measurements are also not accurate for 
ultrasmall nanoparticles such as these as the laser beam which hits the nanoparticles may be larger 
in diameter than the nanoparticles themselves, resulting in a large scatter of light and therefore 
introducing large errors. 
 
TEM images: 
The sulfonate coated nanoparticles were imaged by TEM and all showed similar particle morphology 
and size dispersion. A small drop of a dilute solution of the nanoparticle sample was deposited on a 
holey carbon copper grid. Figure 2.11 below shows the TEM image for NP-S1. The nanoparticles are 
spherical in shape, retaining the same structure as the oleic acid capped nanoparticles prior to ligand 
exchange. There is also minimal aggregation as the particles are well dispersed on the TEM grid. 
Average size of the core was calculated to be 6.2 nm, based on 150 measurements.  
 
Figure 2.11 TEM image of NP-S1. The nanoparticles appear to be well dispersed, with minimal aggregation, 
and have an average size of approximately 6.2 nm. 
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TGA and rhodamine coupling: 
TGA is a technique where the mass of a sample is monitored as it is heated in a controlled 
environment. A typical TGA run for the nanoparticles involves heating a concentrated solution of the 
sample in water (about 30 μL). A solid sample of the nanoparticle was difficult to obtain (drying of 
the sample leads to a sticky residue and therefore is difficult to handle and transfer between vessels 
and TGA pan). The program was then set to hold the temperature of the furnace at 120 °C for 30 min 
to drive off the solvent, leaving approximately 1 – 2 mg of dry nanoparticle sample. The temperature 
was then increased to 800 °C at a rate of 10 °C/min. At this stage, the mass loss as the sample is 
heated should correspond to the mass of ligands surrounding the nanoparticle. A curve of this 
section can then be plotted against temperature or time, and the initial mass lost due to solvent can 
be disregarded (Figure 2.12).  
 
Figure 2.12 TGA curve showing the loss of mass from the sample of NP-S1 (after solvent loss) against 
temperature. 
 
From the TGA curve, the difference in mass after the loss of water when the sample is heated can 
then be used to calculate the number of ligands that coat the surface of one particle.29 The total 
mass of ligands lost can be found by subtracting the end mass (mass of NP core only) from the 
starting mass (mass of NP core + ligands).  
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Assuming the NP is a sphere, the volume of the NP, VNP, can be calculated: 
𝑉𝑁𝑃 =
4
3
𝜋𝑟3 = 1.13 × 10−19cm3 
(where r = 3 nm on average based on the diameter of the core obtained from TEM images). 
To find the MW of the nanoparticle core (no ligands), the mass of 1 particle can be calculated from 
the density, dNP (magnetite density: 5.15 g/cm3)30 and volume, VNP (calculated) of the NP. The 
relationship between the mass of 1 particle to Avogadro’s number gives the MW of the core. 
𝑀𝑎𝑠𝑠 𝑜𝑓 1 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =  𝑑𝑁𝑃 ×  𝑉𝑁𝑃 = 5.82 × 10
−19g 
𝑀𝑊 = 𝑚𝑎𝑠𝑠 𝑜𝑓 1 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 × 𝐴𝑣𝑜𝑔𝑎𝑑𝑟𝑜
′𝑠 𝑛𝑢𝑚𝑏𝑒𝑟 
= 350752.16 Da 
 
The number of moles of the core can then be calculated, knowing the mass of the core (mass at end 
of run, from TGA curve); 
𝑛(𝑐𝑜𝑟𝑒) =
𝑚(𝑐𝑜𝑟𝑒)
𝑀𝑊(𝑐𝑜𝑟𝑒)
 
= 1.47 × 10−9mol 
The number of moles of ligands per nanoparticle can also be calculated, knowing the total mass of 
ligands lost from the TGA curve, and the MW of the ligand (271.08, known). 
𝑛(𝑙𝑖𝑔𝑎𝑛𝑑) = 1.79 × 10−7mol 
From the number of moles of ligands per nanoparticle, and the number of moles of the core, the 
number of ligands per nanoparticle can be calculated from the relationship between the two.  
𝑛𝑜. 𝑜𝑓 𝑙𝑖𝑔𝑎𝑛𝑑𝑠 𝑝𝑒𝑟 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =
𝑛(𝑙𝑖𝑔𝑎𝑛𝑑)
𝑛(𝑐𝑜𝑟𝑒)
 
= 121 ligands 
TGA of each nanoparticle sample was run three times, and the average of the combined runs 
calculated to obtain the average number of ligands per sample (Table 2.2). For these sulfonates, TGA 
measurements have not been carried out before in the literature. Based on the structure of the 
ligands, it would be expected that the binding of the ligands to the nanoparticle surface would be 
similar and thus the number of ligands on the surface would also be similar to each other. This is in 
agreement with the experimental results as a small range in the average number of ligands was 
determined (between 93.5 and 110.9). 
 
Chapter 2: Magnetic nanoparticle preparation and ligand exchanges 
 
67 
 
 
Nanoparticle Average number of ligands Number of free amine groups 
NP-S1 95.1 ± 40.1 130.56 ± 4.51 
NP-S2 110.9 ± 28.8 130.08 ± 27.43 
NP-S3 93.5 ± 12.6   124.55 ± 29.26 
NP-S4 98.2 ± 17.0 145.02 ± 26.85 
Table 2.2 Average number of ligands on nanoparticle surface calculated from TGA measurements, and average 
number of free amine groups available on the surface of sulfonate coated nanoparticles determined by 
indirect rhodamine quantification assay. 
 
To determine the number of free amines on the nanoparticle surface, a known quantity of the 
sulfonate-coated nanoparticles were reacted with a known equivalence of 5(6)-carboxy-X-
rhodamine N-succinimidyl ester (rhodamine-NHS) (Scheme 2.4). The amount of unreacted dye in the 
washing was then measured by UV-Vis spectroscopy and correlated to a calibration curve. The 
amount of reacted dye can then be calculated and related back to the number of amine groups that 
reacted. 
 
Scheme 2.4 Reaction between terminal amine group on NP and 5(6)-carboxy-X-rhodamine N-succinimidyl 
ester (rhodamine-NHS). 
 
In a typical experiment, 0.5 mg of nanoparticles were reacted with 300 eq of rhodamine-NHS in 
DMSO. At the end of the reaction, the nanoparticles were precipitated out with THF and the 
supernatant was kept and then evaporated to remove the THF. The residue from the evaporated 
supernatant was dissolved in a known volume of water, and UV-Vis of an aliquot was recorded. 
Calculations revealed that there were between 130 and 145 amine groups available on average for 
NP-(S1 to S4) (Table 2.2). These values are similar to the number of ligands determined from the TGA 
data, within the error values obtained. 
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2.3.2 Phosphate 
Following on from work by Dr Juan Gallo, PDRA in the Long group, a monophosphate-PEG6-amine 
was synthesised. The commercial PEG (HO-PEG-azide) used by Dr Gallo for phosphorylation is not 
economically viable for large scale preparation, therefore a synthetic route to the desired compound 
from the less expensive hexaethylene glycol was explored (Scheme 2.5). (Current prices from Sigma-
Aldrich, August 2014: £277.61/mmol of HO-(PEG)7-azide (≥95 %), £1.59/mmol of hexaethylene glycol 
(97 %)). 
 
a) Synthesis of phosphate-PEG-amine ligand 
 
Scheme 2.5 Reaction scheme for the synthesis of monophosphate-PEG6-amine. Reagents and conditions: a) 
TsCl, Ag2O, DCM, 0 °C. b) NaN3, MeCN, 60 °C. c) POCl3, NEt3, DCM, 0°C. d) SiHEt3, Pd/C, MeOH, RT. 
 
The reaction towards the novel phosphate-PEG-amine ligand (4), starts with the mono-protection of 
hexaethylene glycol using tosyl chloride. Substitution of the tosyl group with azide followed by 
phosphorylation of the terminal alcohol and subsequent reduction of the azide to the amine gave 4 
in good yields. 
In a 2003 paper by Hii et al,31 it was shown that mono-protection with a tosyl group can be 
introduced to a symmetrical diol in the presence of silver(I) oxide and potassium iodide. A similar 
protection protocol using benzyl bromide and silver oxide to monoprotect symmetrical diols with 
high selectivity was presented in a paper by Bouzide and Sauve.32 They proposed that the selectivity 
of the monobenzylation of the diol occurs due to the complexation of the oxygen atoms of the 
alcohol groups with the silver atom thus increasing the lability of the alcohol protons, especially the 
proton that is not involved in intramolecular hydrogen bonding (complex I, Figure 2.13). However, 
when there are more oxygen atoms in the molecule, such as in PEG, the additional oxygen atoms 
Chapter 2: Magnetic nanoparticle preparation and ligand exchanges 
 
69 
 
also complex to the silver atom (complex II, Figure 2.13) which further improves the selectivity of the 
monoprotection. Bouzide and Sauve have proven this by comparing the poorer selectivity observed 
using aliphatic diols with oligoethylene glycols.32 This mechanism would also explain the selectivity 
with the tosyl reaction. The reaction to form 1 gave a 70 % yield after purification by column 
chromatography. Characterisation by 1H NMR, mass spectrometry and elemental analysis confirmed 
the successful synthesis of the compound and were in accordance with the literature.31 
 
Figure 2.13 Complex I shows the complexation of the silver atom to the oxygen atoms in aliphatic diols. 
Complex II shows the chelation of the silver atom to the other oxygen atoms in oligoethylene glycols. 
 
Subsequent reactions to substitute the Ts group with an azide (2), then phosphorylation of the 
untouched OH group (3) were carried out based on known organic synthetic reactions; tosyl groups 
are known to be excellent leaving groups for substitution with azides,33,34 and the introduction of a 
phosphate group was a modification of a literature method.35 Both reactions were successful and 
were relatively simple to purify, requiring only an aqueous workup. Characterisation by 1H NMR, 
31P{1H} NMR (for 3), mass spectrometry and elemental analysis confirmed the synthesis of 2 and 3. 
The reduction of the azide to an amine group (4) was carried out using triethylsilane (TES) and Pd/C 
to generate H2 gas in situ, a modification of a literature method.36 This reaction occurs via a catalytic 
transfer of hydrogen where H2 gas is replaced by a hydrogen donor with Pd/C as catalyst. Mandal 
et al36 have shown that TES/Pd-C is a convenient method of hydrogenation – reactions are often 
completed in 10 minutes or less with excess TES and 10 – 20 % Pd/C in MeOH and require only room 
temperature conditions. The reaction proceeded well to give 4 in 85 % yield, with characterisation 
by 1H NMR, 31P{1H} NMR and high resolution mass spectrometry.  
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b) Ligand exchange of bulk oleic acid capped nanoparticles with phosphate ligand 
 
Scheme 2.6 Ligand exchange of bulk nanoparticles with ligand 4 to give NP1. 
 
Ligand exchange of the nanoparticles with the monodentate ligand 4 was carried out via a single 
solvent system (Scheme 2.6), following the protocol for similar type ligands in the literature.35 Both 
the nanoparticles and the ligand were dissolved in chloroform, then stirred for 2 days. At the end of 
this time, the reaction mixture was concentrated and the nanoparticles precipitated out with 
hexane, isolated by a magnet and the supernatant decanted. The particles were resuspended in 
DCM and again washed with hexane. This was repeated a total of three times. Finally the particles 
were suspended in ethanol. This solubility in a polar solvent suggests a successful ligand exchange.  
The nanoparticles appeared to be stable in solution for over three months (Figure 2.14). 
 
Figure 2.14 A sample of NP1 in ethanol showing a clear solution with no precipitation or aggregation of the 
nanoparticles, after 3 months. 
 
c) Characterisation of phosphate-capped nanoparticles (NP1) 
Characterisation of the resultant nanoparticles was carried out by TEM imaging, TGA, DLS and IR 
spectroscopy. The infrared spectrum (Figure 2.15) shows a sharp stretch around 1100 cm-1 which is 
highly indicative of a phosphate P=O stretch, confirming the successful ligand exchange. 
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Figure 2.15 Infrared spectra of 4 (top) and NP1 (bottom), both were run neat on ATR plate. The NP1 spectrum 
retains a peak around 1100 cm-1, indicative of a P=O stretch. 
 
Comparison of the IR spectra of the ligand 4 and the nanoparticle NP1 show that both have the P=O 
stretch around 1100 cm-1. The P=O stretch in the nanoparticle was slightly broader than that of the 
free ligand due to binding of the phosphate to the nanoparticle surface, reducing the ability of the 
P=O to stretch as freely. 
A 7 μL diluted solution of NP1 in ethanol was deposited on a holey carbon copper grid and imaged 
by TEM. TEM image of NP1 (Figure 2.16) shows that the particles were still highly mono-dispersed 
after the ligand exchange, and the average size of the iron oxide core was 7.2 nm, similar to that of 
the bulk oleic acid capped nanoparticles. The particles were spherical in shape and showed minimal 
aggregation. 
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Figure 2.16 Left: TEM image of NP1. Right: Size distribution of the nanoparticles showing that the average core 
size was 7.2 nm. 
 
TGA and rhodamine coupling: 
After TGA analysis and similar calculations for NP-(S1-S4) applied to NP1, it was calculated that there 
were 1800 ligands on the surface of the nanoparticle. When compared to literature values of 
approximately 150 ligands for similar phosphate-type ligands (1.24 ligands/nm2),35 it suggests that 
the value of 1800 ligands for a 6 nm nanoparticle is incorrect. One explanation for this could be that 
the washing method in the workup was not ideal resulting in unbound ligand remaining and this 
would contribute to the high mass that was lost during the TGA. 
Like the sulfonate coated nanoparticles, NP1 samples were reacted with rhodamine-NHS to 
determine the number of free amines on the surface of the nanoparticle. From the calculations, the 
number of amine groups reacted was 239. This number is still higher than the expected number of 
ligands that should coat the nanoparticle surface (approximately 150), therefore confirming that 
there may still be free ligand in the sample that has not been completely removed during the 
washing step of the purification procedure. This is in agreement with the TGA results. Due to time 
constraints, further experimentation with workup procedures or the use of a different solvent 
system for the ligand exchange was not able to be carried out. 
 
DLS measurements: 
The average hydrodynamic diameter of NP1 was 34.9 ± 6.2 nm in ethanol. Based on standard bond 
lengths, the size of the ligand is relatively small, at about 3 – 5 nm, and thus the expected 
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hydrodynamic size of the resultant nanoparticle would be approximately 15 – 20 nm, taking into 
account the hydration sphere around the nanoparticle. The recorded value however, is slightly 
higher than this. As previously discussed in the DLS measurements of sulfonate coated 
nanoparticles, hydrodynamic size measurements in DLS are affected by different solvents and their 
properties. This could explain why the hydrodynamic size is larger than expected, as the solvent 
sphere around the nanoparticle would change in different solvents. Another possibility in this case 
could be excess ligand remaining after workup, resulting in several ligand layers around the surface 
of the core (Figure 2.17). This would explain the unexpected values obtained in the TGA and 
rhodamine coupling reaction. 
 
 
Figure 2.17 Excess ligand after workup that could result in a second layer on the nanoparticle surface. 
 
2.3.3 Bisphosphonates 
The primary focus of the ligand exchanges in this project has been on bisphosphonate ligands (BP) as 
there is precedent in the literature for bisphosphonate ligands being stronger capping ligands for 
nanoparticles compared to carboxylate and phosphate ligands.2,3,37,38 To begin with, there is a wide 
range of commercially available bisphosphonate ligands, as they have been known to feature in 
bone drugs for the past 40 years. Hydroxyapatite is a modified calcium apatite mineral found in 
bone. The discovery that endogenous pyrophosphate was involved in the formation and dissolution 
of hydroxyapatite crystals led to the development of pyrophosphate analogues. These analogues 
were to be more stable and hydrolysis-resistant molecules that could prevent loss of bone mineral. 
This led to the identification of bisphosphonates where the P-C-P backbone replaced the labile P-O-P 
moiety in pyrophosphates and resulted in a large number of commercially available 
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bisphosphonates.39–41 Examples of some commercially available bisphosphonates are presented in 
Figure 2.18.  
 
Figure 2.18 Examples of current BPs used in a clinical setting. 
 
The general structure of bisphosphonates compared to pyrophosphate can be summarised below 
(Figure 2.19). The P-C-P moiety in the bisphosphonate was identified as being responsible for the 
strong affinity to hydroxyapatite, and the distance between the two phosphate oxygens was found 
to be ideal for Ca2+ binding.42 The replacement of the central oxygen for a carbon allowed for the 
introduction and subsequent variation of R1 and R2 groups, which can alter the bisphosphonate 
affinity for bone, as well as their biological activity. The R1 substituent has been found to play an 
important role in bone affinity. When R1 is an OH group, participation of the hydroxyl group in Ca2+ 
hydroxyapatite binding results in a ‘tridentate’ mode of binding thus enhancing binding activity.43 
Therefore, having an OH group at the R1 position is favoured.  
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Figure 2.19 General structure of a bisphosphonate showing the functional properties of the separate moieties. 
 
Modifications to the R2 side chain also had an effect on hydroxyapatite affinity. Introduction of 
nitrogen-containing groups means the bisphosphonate has a high pKa value which remains 
protonated at physiological pH, resulting in an overall positive charge on the bisphosphonate-
hydroxyapatite surface.44 The opposite is observed when there are no nitrogen moieties resulting in 
repulsion between the bisphosphonate and hydroxyapatite, thus a lower affinity. The development 
of bisphosphonates can be divided into three phases: the non-nitrogen-containing, (alkyl) nitrogen-
containing, and heterocyclic nitrogen-containing. Introduction of alkyl amines at the R2 position 
enhanced the potency of bisphosphonates.45 However, the distance of the nitrogen atom from the 
P-C-P backbone is also important with regards to potency. Lengthening of the alkyl chain from 
pamidronate to alendronate (Figure 2.18) saw an increase in potency, but increasing the chain 
beyond alendronate reduced it.46 The introduction of heterocyclic nitrogen-containing rings, such as 
in zolendronate increased potency further.  
Bisphosphonates have also been known to have a high affinity for other metals. Before its discovery 
as a bone drug, they were used as anticorrosive, anti-scaling and complexing agents.47 There have 
been many examples in the literature where bisphosphonates form complexes with various metals. 
These include Ba(II),48,49 Sr(II),48,49 Mg(II),48,49 Al(III),50 Fe(III),50 Cu(II),51,52 Zn(II),53 Ni(II),54 Co(II),54 
UO2(II)55 and lanthanides such as Nd(III)56 and Gd(III).57  Phosphonic acids and bisphosphonates have 
also been known to bind strongly to metal oxide surfaces, including TiO2,58–62 ZrO2,58,59,63 Al2O3,58,62,64 
SiO2,60,62 Fe2O3/Fe3O4,4,65–68 as well as rare earth metal oxides M2O3 where M = Eu, Er, Yb, and Gd.66 
All these examples have shown that the bisphosphonate ligand is versatile as a ligand. From these 
examples, a few different bisphosphonates were investigated as coating ligands for iron oxide 
nanoparticles. Even though amine groups have primarily been chosen as the R2 group in the 
commercial bisphosphonates due to the improved potency of the drug, it was decided to also 
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attempt the synthesis of an alkyne and thiol version in order to allow for further versatile 
functionalisation via ‘click chemistry’ in the case of the alkyne, or maleimides with the thiol. It was 
hoped that the P-C-P moiety would be sufficient for the binding activity required for BP-metal oxide 
interaction. For the purposes of nanoparticle coating in this project, the distance between the 
terminal functional group and the P-C-P backbone was not taken into consideration. 
 
a) Alkyne and thiol BP 
The alkyne BP and thiol BP chosen as the initial BP ligands were synthesised according to 
literature.69–71 Following a literature survey of bisphosphonate synthesis, it was decided to 
synthesise a vinylidene bisphosphonate as the starting point towards the alkyne and thiol BP as it 
would provide the flexibility of synthesising other BPs via the same precursor, with modifications to 
the synthetic procedures that will be used to produce the initial alkyne and thiol BP. Several 
literature papers use the vinylidene BP as a precursor to other BPs.69,70,72–74  
The vinylidene BP was synthesised over two steps following a literature method, starting with 
tetraethyl methylenebisphosphonate. This was reacted with diethylamine and paraformaldehyde to 
form a methoxymethylated intermediate 5 (Scheme 2.7). The intermediate was heated to reflux with 
a catalytic amount of p-toluenesulfonic acid monohydrate to give the vinylidene bisphosphonate 
ester 6 with the elimination of methanol.70 The initial synthesis of 6 proved problematic as the 
reaction is driven by the elimination of methanol and in order to do this, the methanol produced has 
to be removed as the reaction progresses. This was accomplished in the literature via a Dean-Stark 
reflux. Another method using a Soxhlet apparatus was attempted, and proved to be a better method 
possibly due to the presence of CaH2 in the Soxhlet chamber to remove methanol. Both 5 and 6 were 
characterised by 1H and 31P{1H} NMR, and were in accordance with the literature. 
 
Scheme 2.7 Synthesis of vinylidene bisphosphonate ester 6, intermediate towards the synthesis of thiol and 
alkyne bisphosphonic acid. Reagents and conditions: a) HNEt2, (HCOH)n, MeOH, reflux. b) TsOH.H2O, toluene, 
reflux. 
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The next stage of the synthesis was to convert the phosphonate ester to the free acid 7 (Scheme 2.8). 
The majority of literature procedures use bromotrimethylsilane.75,76 The work-up involves removing 
the organic solvent under vacuum and then extracting the residue into water and neutralising with 
40 % aqueous tetrabutylammonium hydroxide to pH 4. This gives 7 as the tetrabutylammonium salt 
instead of the free acid. The solution was dried at 50 – 60 oC under vacuum. Characterisation was by 
1H and 31P{1H} NMR and was in accordance with the literature.  
 
Scheme 2.8 Hydrolysis of the phosphonate ester 6 into the free acid 7, with BrSiMe3 in DCM at RT. 
 
 
Thiol BP 
The thiol BP 8a was initially synthesised by the nucleophilic addition of 1,3-propane-dithiol (Scheme 
2.9), in accordance with the literature.70 However, this method proved problematic as the 1-butanol 
used in the reaction was difficult to remove, as observed when characterised by 1H NMR 
spectroscopy.  
 
Scheme 2.9 Synthesis of thiol BP via 1,3-propane-dithiol (8a top) and cystamine (8b bottom). 
 
In another method outlined by Alferiev et al, 7 was reacted with cystamine instead.71 This gives a 
disulfide intermediate which was reduced with tris(2-carboxyethyl)phosphine (TCEP) to give 8b, 
which was characterised by 1H and 31P{1H} NMR and was in accordance with the literature. 
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8b was soluble in water and ligand exchange with the bulk nanoparticles was attempted using 
several different solvent systems. Initially, a biphasic hexane/water system containing the 
nanoparticles in hexane and the ligand in water was shaken using a shaker to mix. This resulted in 
the nanoparticles being formed in an emulsion-like layer between the water and hexane layers. The 
nanoparticles were separated from the solution for purification by a magnet and the supernatant 
was decanted. Unreacted ligand was subsequently removed by washing with water and acetone. 
The resulting nanoparticles were a suspension in water that unfortunately settled within 1-3 hours 
after isolation. A single phase solvent system was attempted next, with the ligand in water at basic 
conditions, and the nanoparticles in THF. After the ligand exchange, the resultant nanoparticles were 
washed with acetone and ethanol but the final product was still not well dispersed in water. Infrared 
spectroscopy of the nanoparticles recorded a P=O stretch at 1039 cm-1 which suggested that a 
successful ligand exchange had occurred. However, thiols themselves are not very water soluble due 
to poor hydrogen bonding and once on the nanoparticles, the ligands would have lost the water 
solubilising bisphosphonate group to surface binding thus rendering the nanoparticles poorly soluble 
in water.  
 
Alkyne BP 
The alkyne BP was synthesised via the reaction between vinylidene bisphosphonate ester 6 and 
sodium acetylenide, according to literature (Scheme 2.10).69 Aqueous workup yielded 9 which was 
then reacted on with bromotrimethylsilane to reduce the esters to the free acid 10. Both species 
were characterised by 1H and 31P{1H} NMR and were in accordance with the literature. 
 
Scheme 2.10 Synthesis of alkyne BP. Reagents and conditions: a) sodium acetylenide, THF, -20 °C then RT. b) 
BrSiMe3, DCM, 0 °C then RT. 
 
Ligand exchange between 10 and bulk nanoparticles using the same method as that for 8b was 
attempted. As with 8b, the infrared spectrum of the nanoparticles was similar with a P=O stretch 
observed. However, the resultant nanoparticles were also not water soluble, likely due to the same 
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reasoning that the loss of the phosphonate group to metal oxide binding renders the nanoparticles 
insoluble in water. 
 
b) Sodium alendronate 
Due to the solubility difficulties encountered with the alkyne and thiol BP capped nanoparticles, a 
commercially available bisphosphonate ligand was then utilised. Sodium alendronate was chosen 
due to its water solubility, availability of a terminal amine group for further functionalisation, and 
was economically more attractive compared to the other alkyl amine BPs such as pamidronate. 
(Current prices from TCI-UK, August 2014: £1.38/mmol of sodium alendronate trihydrate (97 %), 
£97.37/mmol of disodium pamidronate hydrate). 
 
Scheme 2.11 Ligand exchange reaction between bulk nanoparticles and sodium alendronate ligand. 
 
Ligand exchange of the oleic acid-capped nanoparticles with sodium alendronate was carried out in 
one phase in a miscible two solvent system of THF and water to give NP2 (Scheme 2.11). In a typical 
experiment, a large excess of sodium alendronate (approximately 60 mg) was dissolved in water 
with the addition of 1M KOH to the solution to completely solvate the white solid alendronate and 
bring the solution to pH 9/10. Sodium alendronate is acidic and highly acidic conditions will degrade 
the iron oxide nanoparticles so it is essential that the solution is kept at a slightly basic pH. 
Approximately 1.5 mL of bulk oleic acid capped nanoparticles (from a 20 mL stock solution in 
hexane) dispersed in THF was then added and the mixture of the ligand and the nanoparticles stirred 
at room temperature for two days. After this, the nanoparticles were isolated by a magnet, the 
residue resuspended in water and precipitated with acetone followed by centrifugation. This 
washing step was repeated twice and finally the nanoparticles were resuspended in water, and 
stored with a few drops of 1 M KOH such that the nanoparticle solution is at pH 8/9. 
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Characterisation of bisphosphonate capped nanoparticles NP2: 
Characterisation of the alendronate-capped nanoparticles NP2 was done by IR, DLS, TEM and TGA. 
TEM images (Figure 2.20) shows negligible difference in size and morphology of the nanoparticle core 
before and after ligand exchange. The size of the core stays roughly the same, with only the 
nanoparticles arrangement on the grids changing due to the type of solvent they were suspended in 
before placement on the grids. Substitution of the oleic acid ligand with the alendronate would have 
no drastic effect on the core of the nanoparticles, which is what the TEM images capture.  
 
Figure 2.20 TEM images of the nanoparticles before (left) and after (right) ligand exchange with sodium 
alendronate. 
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Figure 2.21 Infrared spectrum of the nanoparticles before and after the ligand exchange with sodium 
alendronate (neat, ATR plate). Top – sodium alendronate ligand, middle – oleic acid capped nanoparticles, 
bottom – alendronate capped nanoparticles NP2. 
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The nanoparticles were also characterised by infrared spectroscopy, run neat on an ATR plate (Figure 
2.21). Functional groups with a strong stretching frequency, such as C-O in the carboxylic group of 
oleic acid, and the phosphonate resonance of the alendronate will have characteristic stretches. The 
IR of the alendronate capped nanoparticles show a strong P=O stretch at approximately 1100 cm-1 
which was not present in the oleic acid capped particles. 
From DLS measurements, the nanoparticles were found to have a hydrodynamic diameter average 
of 20.2 ± 5.2 nm and a charge of -25 mV in water at pH 7.4. Taking into consideration typical bond 
lengths for C-C, C-N and C-P bonds, the approximate size of the ligand would be around 1 nm. 
Coupled with the average core diameter of 6 – 7 nm, the approximate size of NP2 should be in the 
region of 10 nm, and with the shell of water should theoretically give a total hydrodynamic diameter 
of approximately 20 nm. This is in agreement with the observed hydrodynamic diameter measured 
by DLS. Multiple layers of alendronate ligand as shown in Figure 2.22 was found to not be present as 
the hydrodynamic diameter measured by DLS did not change with more washing steps. 
 
Figure 2.22 Diagram showing multiple layers of alendronate ligand on the NP core. 
 
The negative surface charge of -25 mV in water at pH 7.4 is unexpected. The amine group on the 
alendronate has a pKa of 12.2,77 so at approximately pH 7 in water, the amine group should be 
protonated giving a positive charge. However the OH group which has a pKa of less than 7 would still 
be deprotonated at pH 7. Surface charge of NP2 was also measured at different pH to determine if 
acidic pH would protonate the amine and hydroxyl groups, resulting in a positive charge. This was 
indeed the case, as at highly acidic pH (around 2-3), the surface charge of the nanoparticles was 
+18.5 while at highly basic pH (around pH 10-11), the surface charge was -28.4. This confirms that 
the results obtained at pH 7 are as they should be.  
Chapter 2: Magnetic nanoparticle preparation and ligand exchanges 
 
82 
 
TGA and rhodamine coupling: 
TGA measurements were repeated three times for each batch of nanoparticles, and three different 
batches of nanoparticles were measured, for a total of nine readings (Table 2.3). This was to ensure 
the reproducibility of the data between different batches of NP2 synthesised at different times. The 
average number of ligands overall was 116. 
 
 
 
 
 
 
 
Table 2.3 Table detailing the average number of ligands determined for each batch of NP-alendronate 
 
The ligands on NP2 were lost over a range of temperature, between 200 and 450 °C. According to 
literature, there are approximately 1.6 bisphosphonate ligand molecules per nm2 of iron oxide 
nanoparticles for a nanoparticle core of approximately 6 nm diameter.4 For these particles, this 
equates to about 180 bisphosphonate ligands on the surface. This theoretical value is not far from 
the average measured number of alendronic acid ligands (average 115 ± 30) which coat NP2. 
Rhodamine coupling to NP2 was performed similarly as before where 300 equivalents of 
rhodamine-NHS was reacted with 1 mg of NP2 in water. After 3.5 h, the mixture was centrifuged and 
the supernatant’s UV-Vis spectrum was measured. After repeating the rhodamine coupling six times, 
the absorbance at 554 nm (λmax) correlated to an average of 145 amine groups reacted. These data 
suggest that the rhodamine coupling data correlates well with the number of ligands determined by 
TGA.  
 
2.3.4 Further stability measurements 
To assess stability of the nanoparticles at different physiological conditions, the nanoparticles NP1 
and NP2 were suspended in various media. Both NP1 (ethanol stock, diluted with water) and NP2 (in 
water) were assessed in different concentrations of NaCl solution as well as in water at different pH. 
The sulfonate coated nanoparticles were not assessed in this way as they were already not very 
stable in the DMSO solution. In addition as the nanoparticles would eventually be used in vivo, the 
toxicity of the iron oxide nanoparticles in blood was investigated. This measurement to determine 
NP-alendronate (NP2) sample Average no. of ligands 
Batch 1 123.02 ± 39.78 
Batch 2 108.42 ± 33.14 
Batch 3 115.59 ± 33.99 
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possible toxicity of nanoparticles towards blood cells is important in order to maintain red blood cell 
integrity after administration of the nanoparticles.78 All the nanoparticles after ligand exchange 
(NP1, NP2 and sulfonate coated) were diluted with PBS and incubated with blood.  
 
a) In H2O at different pH over time 
There are different pH conditions in different cells and regions of the body. To determine the 
stability of the particles at different pH, the nanoparticles were observed after addition to water at 
different pH, in the range from highly acidic (pH 1) to highly basic (pH 13). 100 μL of NP1 and NP2 
were suspended in water at different pH (between 1 and 13, 1 mL each). Their stability in the 
respective pH was recorded at different time points (Figure 2.23). 
 
Figure 2.23 Nanoparticles in water at varying pH (from L to R: pH 1, 3, 5, 7, 9, 11, 13). a) at t = 0 h; b) t = 6 h; c) 
t = 24 h. Top set NP1, bottom set NP2. 
 
Overall, NP1 was more stable at lower pH range, compared to NP2, over a 24 hour period. The 
nanoparticles NP1 were stable between pH 3 and 9, while NP2 were stable between pH 5 and 11. 
This slight difference in range could be due to the different pKa’s of the ligands on NP1 and NP2 
which affects the stability of the particles as the functional groups are protonated and deprotonated 
in the respective pH.  Instability at the lower acidic pH is as expected, as iron oxide nanoparticles 
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begin to be digested in a highly acidic environment. Instability at the higher basic pH is most likely 
due to charge repulsion between the particles, as the surface groups are deprotonated. 
 
b) In NaCl solution  
As the traditional method of delivering nanoparticles to a patient is via a saline solution, the stability 
of the nanoparticles in salt solutions of varying concentration was observed. Normal saline is 0.9 % 
NaCl solution, so an upper limit of 1.2 % was used. 100 μL of nanoparticles NP1 and NP2 were added 
to 0.5 mL of NaCl solutions of varying concentration between 0 % and 1.2 % NaCl. In Figure 2.24, the 
nanoparticles are seen to have precipitated out of solution after 1 h.  
 
 
Figure 2.24 Stability of nanoparticles in NaCl solution, from L to R 0 % solution, 0.3 %, 0.6 %, 0.9 % and 1.2 %. 
Top NP1, bottom NP2 (alendronate). 
 
However, this is a relatively high concentration of nanoparticles for the volume of salt solution. A 
typical dose for a human is 0.56 mg Fe/kg of body weight diluted in 100 mL of saline. This would 
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equate to 0.034 mg and is lower than the concentrations used here (0.15 mg Fe) which would not be 
used in vivo. Nevertheless, the nanoparticles are still stable in the salt solutions for a short period of 
time and would be stable in the time period used in a clinical setting. 
 
c) Toxicity in blood 
As an application of the iron oxide nanoparticles is to act as imaging contrast agents in the body, it 
was necessary to determine the toxicity of the nanoparticles in blood. The assay used here is based 
on literature protocol.79 A known concentration of the nanoparticles was incubated with whole 
blood for 90 min at 37 °C in a shaker. Then, the samples were centrifuged at 600 g for 5 min, the 
pellet discarded and the supernatant incubated at room temperature for a further 30 min to allow 
haemoglobin oxidation. Finally, the absorbance of the samples was recorded at 560 nm. If a high 
signal at this wavelength is observed, it indicates that the red blood cells have burst and the sample 
is toxic to blood. Water is used here as a positive control, where a definite UV-Vis signal would be 
expected due to movement of water by osmosis into the red blood cells causing lysis.  
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Figure 2.25 Graph showing the uptake of nanoparticles by red blood cells in blood. 
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Phosphate buffered saline (PBS), having a comparable solute concentration to red blood cells should 
not cause a large amount of cells to burst and therefore the absorbance in UV-Vis measurement 
would correlate to a non-toxic effect on red blood cells. From the graph in Figure 2.25, all the 
nanoparticle samples do not appear to be toxic as their UV-Vis signals at 560 nm are all below that of 
water, and are comparable to that of the PBS sample. 
 
2.3.5 Conclusion 
Based on the above results, the most stable of the nanoparticles synthesised is NP2, the alendronate 
coated nanoparticles. The NP1 particles were also stable in solution, with no signs of aggregation or 
precipitation, after several months. The sulfonate-coated nanoparticles (NP-S1 to NP-S4) were 
soluble in DMSO but were less stable in solution, as precipitation of the nanoparticles occurred after 
about one week. As the size of the ligands coating the nanoparticles in each of the species were 
approximately the same, the hydrodynamic diameters of the resultant nanoparticles were expected 
to be similar to each other. However sizes were not directly comparable due to the different nature 
of the solvent the nanoparticles were suspended in during DLS. TGA measurements for NP2 and the 
sulfonate coated nanoparticles correlated well with the rhodamine coupling data obtained, but this 
was not the case for NP1. Removal of excess ligand is important during work up to ensure that only 
bound ligand remains on the nanoparticle surface, but this can be difficult to achieve as the solubility 
of the nanoparticle and ligand have a significant effect on the success of the work up procedure. 
The stability of the nanoparticles in physiological conditions was also investigated, where NP1 and 
NP2 were found to be not very stable in the presence of high salt concentration. This was attributed 
to the high concentration used in the saline incubation. All the nanoparticles were shown to be non-
toxic to red blood cells.  
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2.4 Experimental 
General procedures and characterisation techniques 
The synthesis of the core nanoparticles was carried out under nitrogen, while the ligand exchanges 
were performed under ambient conditions. Nanocrystals were characterised by low and high 
resolution TEM on a JEOL JEM 2000F microscope. Magnetic data from the nanoparticles were 
recorded with a QD magnetometer MPMS-7T. Thermogravimetric analysis (TGA) was carried out on 
a Perkin Elmer Pyris 1 TGA instrument. UV-Vis spectra were recorded on a Perkin-Elmer Lambda 25 
UV-Vis system. FT-IR spectra were acquired on a Perkin-Elmer Spectra 100 FT-IR spectrometer, neat 
on ATR plates. Z-measurements were obtained on a Beckman Coulter Delsa™ Nano. 1H, 13C{1H} and 
31P{1H} NMR spectra were obtained on a Bruker DRX400 MHz spectrometer. Mass spectrometry was 
carried out by Mr. J. Barton (2010 – 2012) and Dr. L. Haigh (2012 onwards) at the Department of 
Chemistry, Imperial College London. Microanalyses were carried out by Mr. S. Boyer, London 
Metropolitan University.  
Syntheses of the ligands were carried out under nitrogen unless stated otherwise. All reagents were 
purchased from Sigma-Aldrich or TCI-UK (sodium alendronate and sulfonates 2, 3 and 4), and were 
used as received without further purification. Dry solvents were obtained from the Imperial College 
Chemistry Department dry solvent towers, which dried the solvents over alumina beads. All other 
solvents were analytical grade and were obtained from VWR. Water was puriﬁed by the PURITE 
system. 
 
2.4.1 Synthesis of bulk iron oxide nanoparticles 
a) Fe3O4 nanoparticles via the hydrothermal method 5,6 
a) FeCl2.4H2O (0.05 g, 0.25 mmol) was dissolved in distilled water (8 mL). Under vigorous stirring, 
ammonia solution (1 mL) was added which turned the mixture black. The mixture was stirred for a 
further 10 minutes before citric acid (0.10 g, 0.52 mmol) was added. The total reaction mixture was 
placed in a Parr reactor and sealed, then heated in an oven at 134 °C for 3 h. After cooling, the 
mixture was centrifuged, supernatant decanted and the black precipitate dried to give a black 
powder. 
b) A 0.1 M FeSO4.6H2O aqueous solution (2.5 mL, 1 eq) and n-decylamine (0.17 mL, 1.0 mmol, 4 eq) 
were added to a Parr reactor, sealed and heated in an oven at 200 °C for 10 min. The reaction was 
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stopped by quenching the reactor in a water bath at room temperature. The reactor was rinsed with 
ethanol then water and the solid nanoparticles were collected by 5 cycles of centrifugation-
decantation.  
 
b) Fe3O4 nanoparticles via co-precipitation 8 
FeCl3.6H2O (1.17 g, 4.33 mmol) and FeCl2.4H2O (0.43 g, 2.16 mmol) were dissolved in deionised 
water (40 mL) that was purged with nitrogen gas for 1 h. The mixture was stirred vigorously under 
nitrogen at 90 °C. Aqueous ammonia (1.5 mL) was added to the iron solution which resulted in a 
colour change from orange to black immediately. The as-formed nanoparticles were isolated using a 
magnet and washed 3 times with deionised water, and 3 times with ethanol.  The nanoparticles 
were dispersed in ethanol (40 mL), and 20 mL of this solution was used in the following reaction. The 
remainder had the ethanol decanted and the nanoparticles dried. 
 
c) Fe3O4 via high temperature thermal decompositions 24 
Fe(acac)3 (2 mmol), 1,2-hexadecanediol (10 mmol), oleic acid (6 mmol), oleylamine (6 mmol), and 
benzyl ether (20 mL) were placed in a round bottomed flask under nitrogen, and stirred. The mixture 
was heated to 200 °C for 2 h, then heated to reflux (approx 300 °C) for 1 h. The mixture was a black-
coloured solution after heating and was left to cool to room temperature. Under ambient 
conditions, ethanol (40 mL) was added to the reaction mixture until a black precipitate formed and 
this was separated by centrifugation. The black product was redispersed in hexane (approx 30 mL) 
and the mixture centrifuged to remove undispersed particles. The hexane layer was precipitated 
with ethanol, centrifuged then redispersed into hexane (in a typical synthesis, the final solution was 
made up to approximately 20 mL hexane). 
 
2.4.2 Silica coated nanoparticles 10 
This reaction was carried out in a non-glass vessel: To the 20 mL of the above solution of 
nanoparticles in ethanol, was added ultrapure water (5 mL), and aqueous ammonia (0.25 mL). The 
mixture was sonicated for 5 min. Then, tetraethylorthosilicate (TEOS, 0.5 mL) was added to the 
reaction mixture, and sonicated for a further 5 min. The reaction mixture was stirred for 4 h, then 
magnetic separation was carried out to separate the nanoparticles which were washed with ethanol 
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and DMF three times. The isolated nanoparticles were immersed in 1 M HCl for 20 min to dissolve 
any uncoated IONPs. After separating the silica coated NPs from the HCl solution, the coated NPs 
were washed again with ethanol then dried under vacuum.  
 
2.4.3 Synthesis of phosphate-PEG6-amine ligand 
A mathematical shorthand is used to denote the positions of oxygen atoms in the elongated PEG 
chains, in this case 17-tosyloxy-3n153-pentaoxaheptadecan-1-ol represents 17-tosyloxy-3,6,9,12,15-
pentaoxaheptadecan-1-ol. 
a) Synthesis of 17-tosyloxy-3n153-pentaoxaheptadecan-1-ol (1) 31 
 
1 was synthesised according to a literature method.31 To a chilled (0 °C) solution of hexaethylene 
glycol (5.00 g, 17.7 mmol, 1.0 eq) in DCM (50 mL), were added Ag2O (6.15 g, 26.6  mmol, 1.5 eq), TsCl 
(3.70 g, 19.5 mmol, 1.1 eq), and KI (0.59 g, 3.54 mmol, 0.2 eq). After stirring for 30 min, the silver 
salts were removed by filtration through a pad of celite, which was washed thoroughly with EtOAc. 
The combined filtrated was concentrated, and the residue purified by silica column chromatography 
with DCM/acetone (3:2) as eluent, Rf 0.35. The product was obtained as a colourless oil (5.37 g, 12.3 
mmol, 70 % yield). 1H NMR (400 MHz, CDCl3): δ 2.45 (3H, s, Me H’s on Ts), 2.68 (1H, br s, OH), 3.58 – 
3.71 (22H, m, CH2-CH2-O), 4.14 (2H, t, 3JH-H = 4.6 Hz, -CH2-O-Ts), 7.34 (2H, d, 3JH-H = 7.8 Hz, Ts ring H), 
7.79 (2H, d, 3JH-H = 7.8 Hz, Ts ring H). 13C{1H} NMR (100 MHz, CDCl3): δ 144.8, 133.0, 130.0, 128.0, 
72.5, 70.7, 70.6, 70.5, 70.3, 69.3, 68.7, 61.7, 21.6. ESI-HRMS calc. for C19H32O9SNa 459.1665 found 
(m/z): 459.1656 [M + Na]+. Anal. Calc. for C19H32O9S: C, 52.28; H, 7.39. Found: C, 52.10; H, 7.50. 
 
b) Synthesis of 17-azido-3n153-pentaoxaheptadecan-1-ol (2) 33,34 
 
2 was synthesised via a modification of literature methods.33,34 17-Tosyloxy-3n153-
pentaoxaheptadecan-1-ol (1.00 g, 2.29 mmol) was dissolved in dry acetonitrile (20 mL) under 
nitrogen. Sodium azide (0.74 g, 11.46 mmol) was added in one portion and the mixture heated at 
60 °C overnight. Once cooled, the reaction mixture was filtered over celite and washed with more 
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MeCN and EtOAc. The combined filtrates were evaporated to give 2 as a pale yellow oil (0.69 g, 2.25 
mmol, 98 % yield). 1H NMR (400 MHz, CDCl3): δ 2.83 (1H, br s, OH), 3.41 (2H, t, 3JH-H = 5.15 Hz, -CH2-
N3), 3.62 – 3.73 (22H, m, CH2-CH2-O). 13C{1H} NMR (100 MHz, CDCl3): δ 72.5, 70.7, 70.6, 70.5, 70.3, 
70.0, 61.7, 50.6. ESI-HRMS calc. for C12H26N3O6 308.1822 found (m/z): 308.1823 [M + H]+. IR (ν/cm-1): 
2102 (N≡N). Anal. Calc. for C12H25N3O6: C, 46.89; H, 8.20; N, 13.67. Found: C, 46.90; H, 8.10; N, 13.52. 
 
c) Synthesis of phosphate-PEG-azide (3) 35 
 
3 was synthesised following a similar phosphorylation reaction in the literature.35 17-Azido-3n-
pentaoxaheptadecan-1-ol (1.00 g, 3.25 mmol) and triethylamine (0.36 g, 3.58 mmol) was dissolved in 
dry THF (20 mL). The mixture was cooled to 0 °C and POCl3 (0.55 g, 0.33 mL, 3.58 mmol) was added 
dropwise. The reaction mixture was stirred for 3 h at room temperature, then quenched with H2O. 
After checking that the solution had a pH < 2, the product was extracted into CHCl3 (3 x 15 mL). The 
combined organic extracts were dried over MgSO4 and solvent evaporated to give a colourless oil 
(0.55 g, 1.42 mmol, 44 % yield). 1H NMR (400 MHz, CDCl3): δ 3.41 (2H, t, 3JH-H = 6.50 Hz, -CH2-N3), 3.60 
– 3.80 (22H, m, CH2-CH2-O), 9.17 (s, -PO(OH)2). 13C {1H} NMR (100 MHz, CDCl3): δ 70.6, 70.5, 70.4, 
70.0, 50.7. 31P{1H} NMR (162 MHz, CDCl3): δ 1.32. ESI-HRMS calc. for C12H27N3O9P 388.1485 found 
(m/z): 388.1478 [M + H]+. IR (ν/cm-1): 2113 (N≡N), 1115 (P=O). Anal. Calc. for C12H26N3O9P: C, 37.21; 
H, 6.77; N, 10.85. Found: C, 37.35; H, 6.85; N, 10.69. 
 
d) Synthesis of phosphate-PEG-amine (4) 36 
 
4 was synthesised following the reduction of an azide to an amine via similar literature protocols.36 
Phosphate-PEG-azide (0.50 g, 1.29 mmol) was dissolved in methanol (3.87 mL) and stirred with 10 % 
Pd-C (10 % by weight). Neat triethylsilane (1.50 g, 12.9 mmol) was added dropwise and the reaction 
mixture left to stir at room temperature for 6 h. At the end of the reaction, the mixture was filtered 
over celite, and washed through with methanol. The solvent was evaporated to give the product as a 
pale yellow oil which was dried overnight under vacuum (0.39 g, 1.08 mmol, 85 % yield). 1H NMR 
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(400 MHz, CDCl3): δ 3.24 (2H, t, 3JH-H = 5.15 Hz, -CH2-NH2), 3.50 – 3.90 (22H, m, -CH2-CH2-O), 8.13 (s, -
PO(OH)2 or NH2). 13C{1H} NMR (100 MHz, CDCl3): δ 70.6, 70.4, 70.2, 70.0, 67.3. 31P{1H} NMR (162 
MHz, CDCl3): δ 0.6. ESI-HRMS calc. for C12H29NO9P 362.1580 found (m/z): 362.1595 [M + H]+. IR 
(ν/cm-1): 1115 (P=O). Anal. Calc. for C12H28NO9P: C, 39.89; H, 7.81; N, 3.88. Found: C, 37.38; H, 8.34; 
N, 3.45. *values are slightly awry due to possible salt contamination. 
 
2.4.4 Synthesis of alkyne and thiol bisphosphonates 
a) Methylmethoxy intermediate (5) 70 
 
5 was synthesised according to a literature method.70 Diethylamine (0.29 g, 4.00 mmol) and 
paraformaldehyde (0.61 g, 20.0 mmol) were dissolved in dry methanol (12 ml) and warmed until 
clear. Tetraethylmethylene bisphosphonate (1.16 g, 1.00 ml, 4.00 mmol) was added and the mixture 
heated to reflux for 24 h. The methanol was removed under vacuum, toluene (15 ml) added and 
then concentrated. This was repeated four times to ensure all the methanol was removed. The 
methylmethoxy intermediate was isolated as a colourless oil (1.00 g, 3.00 mmol, 75 % yield). 1H NMR 
(400 MHz, CDCl3): δ 4.18 (8H, m), 3.88 (2H, td, 3JH-H = 5.60 and 16.0 Hz), 3.37 (3H, s), 2.69 (1H, tt, 3JH-H 
= 5.30 and 24.0 Hz), 1.32 (12H, t, 3JH-H = 7.00 Hz). 31P{1H} NMR (162 MHz, CDCl3): δ 21.2.  
 
b) Vinylidene bisphosphonate ester (6) 70 
 
6 was synthesised according to a literature method.70 The methylmethoxy intermediate (1.00 g, 3.00 
mmol) was diluted with toluene (25 mL) and p-toluenesulfonic acid monohydrate (0.1 g) added. The 
reaction was heated to reflux over CaH2 in a Soxhlet attachment for 14 h, then cooled and toluene 
removed. DCM (25 mL) was added and washed with water (3 x 15 mL). The combined organic layers 
were dried over MgSO4, filtered and solvent removed under vacuum to yield a light yellow oil (0.86 
g, 2.87 mmol, 96 % yield). 1H NMR (400 MHz, CDCl3): δ 7.01 (2H, dd, 3JH-H = 33.8 and 37.7 Hz), 4.17 
(8H, m), 1.37 (12H, t, 3JH-H = 7.03 Hz). 31P{1H} NMR (162 MHz, CDCl3): δ 13.1.  
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c) Conversion of phosphonate ester to free acid (7) 75,76 
 
7 was synthesised according to a literature method.75,76 Vinylidene bisphosphonate ester (0.50 g, 
1.67 mmol) was dissolved in DCM (10 mL) and reacted with BrSi(CH3)3 (2.4 mL, 18.3 mmol) which 
was added dropwise at 0 oC. The mixture was then stirred at room temperature for 48 h. DCM was 
evaporated off and the free acid extracted into water (2 mL) and neutralised with 40 % aqueous 
tetrabutylammonium hydroxide to pH 4. The solution was dried in vacuo at 50 – 60 oC and again 
under the same conditions with 1-butanol (4 mL) to give a thick sticky mass which still contained 
butanol after drying under vacuum for 2 days (1.20 g crude yield. Assuming 100 % conversion and 
from NMR integration, 0.30 g of this was the free acid). 1H NMR (400 MHz, D2O): δ 6.50 (2H, dd, 3JH-H 
= 33.4 and 36.7 Hz). 31P{1H} NMR (162 MHz, D2O): δ 9.2. 
 
d) Synthesis of thiol bisphosphonate via 1,3-propane-dithiol (8a) 70 
 
Alkene bisphosphonic acid 7 (0.30 g, 1.60 mmol) was dissolved in 1-butanol (2 mL) then 1,3-propane-
dithiol (0.86 mL, 8.00 mmol) added. The mixture was heated to reflux under nitrogen for 2.5 h. After 
the mixture was cooled, water (25 mL) was added then washed with hexane (3 x 15 mL). The 
aqueous layer was concentrated under vacuum to give a yellow oil 8a. Again, a large amount of 
butanol was still present after drying under vacuum (1.00 g crude yield. Assuming 100 % conversion 
and from NMR integration, 0.05 g of this was the free acid, 0.17 mmol, 10 % yield). 1H NMR 
(400 MHz, D2O): δ 2.90 (2H, td, 3JH-H = 6.50 and 15.5 Hz), 2.60 (2H, t, 3JH-H = 7.19 Hz), 2.52 (2H, t, 3JH-H 
= 6.89 Hz), 2.27 (1H, tt, 3JH-H = 6.60 and 19.9 Hz), 1.79 (2H, p, 3JH-H = 7.02 Hz). 31P{1H} NMR (162 MHz, 
D2O): δ 18.8. 
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e) Synthesis of thiol bisphosphonate via cystamine (8b) 71  
 
Preparation of cystamine base: Cystamine dihydrochloride (10.00 g, 0.044 mol) was dissolved in 
water (13 mL). To this was added Et2O (50 mL) and THF (20 mL). The mixture was cooled to 0 °C, and 
the temperature maintained during the slow addition of 40 % NaOH solution (60 mL, 0.622 mol). The 
layers were separated and the aqueous layer extracted with Et2O (20 mL), and THF (15 mL). The 
combined organic layers were dried over solid NaOH at 4 °C, and then filtered. The residue was 
washed with Et2O (20 mL) and THF (10 mL), and the combined filtrate dried in vacuo to give the 
crude product as a pale yellow residue (6.86 g). The crude residue was purified by vacuum 
distillation (0.05 mm Hg, b.p. 85 – 90 °C) to give the cystamine base as a thick colourless syrup 
(3.62 g, 0.024 mol, 54 %). The free base decomposes at room temperature and should be stored 
at -20 °C. 1H NMR (400 MHz, CDCl3): δ 1.24 (4H, br s), 2.73 (4H, t, 3JH-H = 6.30 Hz), 2.98 (4H, t, 3JH-H = 
6.30 Hz). 
Alkene bisphosphonic acid 7 (0.25 g, 1.329 mmol) was added to cystamine base (0.20 g, 1.329 mmol) 
in water. The mixture was dried over a steam bath until a clear syrup was obtained. The resultant 
syrup was heated at 100 oC for 5 h at which point the mixture turned a dark brown colour. After 
cooling, the residue was dissolved in water (10 mL) and acetic acid (0.15 mL, 2.66 mmol) was added. 
The reaction was protected with nitrogen gas and cooled to 15 oC. Tris(2-carboxyethyl)phosphine 
(0.50 g, 2.00 mmol) was added in two portions and stirred at room temperature for 2 h. The mixture 
was filtered by cannula, the filtrate diluted with water and concentrated to half the volume under 
reduced pressure. This was then passed through an ion-exchange resin in H-form, and eluted with 
water until neutral. The water was removed under vacuum to give a yellow syrup of 8b (0.31 g, 1.17 
mmol, 88 % yield). 1H NMR (400 MHz, D2O): δ 2.48 (1H, tt, 3JH-H = 7.00 Hz and 2JP-H = 20.0 Hz), 2.80 
(2H, t, 3JH-H = 6.00 Hz), 3.24 (2H, t, 3JH-H = 6.00 Hz), 3.42 (2H, td, 3JH-H = 7.00 Hz and 3JP-H = 14.00 Hz). 
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f) Synthesis of alkyne bisphosphonate (10) 69 
 
Alkene bisphosphonate ester 6 (0.25 g, 0.833 mmol) was dissolved in dry THF (2.50 mL). A slurry of 
sodium acetylenide in xylene (0.23 mL, 18 % solution) was added dropwise at -15 oC. The reaction 
mixture was allowed to warm to room temperature and stirred for 48 h. After this time, ether (5 mL) 
and 1M HCl (5 mL) was added to the reaction mixture. The organic layer was washed with 1M HCl (5 
mL), brine (2 x 5 mL) and dried over magnesium sulphate. The solvent was removed under reduced 
pressure to give a yellow oil 9 (0.21 g, 0.627 mmol, 75 % yield). 1H NMR (400 MHz, CDCl3): δ 1.39 
(12H, t, 3JH-H = 7 Hz), 2.09 (1H, s), 2.50 – 2.90 (3H, m), 4.10 – 4.30 (8H, m). 31P{1H} NMR (162 MHz, 
CDCl3): δ 21.4.  
Alkyne bisphosphonate ester 9 (0.10 g, 0.306 mmol) was dissolved in dry DCM (3 mL). The mixture 
was cooled in an ice bath and BrSiMe3 (0.28 mL, 2.15 mmol) was added dropwise. The reaction 
mixture was allowed to warm to room temperature and stirred for 48 h. The solvent was removed in 
vacuo, dissolved in water (2 mL) and neutralised with 40 % tetrabutylammonium hydroxide to pH 4. 
The solution was dried in vacuo at 60 oC to give a sticky white solid with oily residues 10 (0.24 g, 
0.205 mmol, 67 % yield). 1H NMR (400 MHz, D2O): δ 1.98 (1H, s), 2.39 – 2.73 (3H, m). 31P{1H} NMR 
(162MHz, D2O): δ 18.0. 
 
2.4.5 Ligand exchanges 
a) Sulfonate 1 (NP-S1) 
7-Amino-1,3-naphthalenedisulfonic acid monopotassium salt monohydrate (50 mg) was dissolved in 
DMSO (5 mL). To this, bulk oleic acid-capped nanoparticles (2 mL from 20 mL hexane stock) which 
were precipitated out of hexane and resuspended in toluene (2 mL), were added. The reaction 
mixture was stirred for 2 days after which time the mixture was centrifuged. The supernatant was 
decanted and the pellet taken up in basic H2O to remove any remaining ligand. The nanoparticles 
were separated by a magnet and the supernatant again decanted. DMSO was added and the 
solution treated with 1 M HCl, quickly sonicated and acetone added to precipitate the particles. It 
was important to ensure that this acid step took no more than 1 – 2 minutes to prevent the 
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digestion of the nanoparticles. Separation of the nanoparticles by magnet yielded a black solid that 
was resuspended in DMSO. 
 
b) Sulfonate 2 (NP-S2) 
6-Amino-2-naphthalenesulfonic acid monohydrate (50 mg) was dissolved in water (5 mL) and the pH 
adjusted to 9/10 with 1 M KOH. To this, bulk oleic acid-capped nanoparticles (2 mL from 20 mL 
hexane stock) which were precipitated out of hexane and resuspended in THF (2 mL), were added. 
The reaction mixture was stirred for 2 days after which time the mixture was centrifuged. The 
supernatant was decanted and the pellet taken up in basic H2O to remove any remaining ligand. The 
nanoparticles were separated by a magnet and the supernatant again decanted. DMSO was added 
and the solution treated with 1 M HCl, quickly sonicated and acetone added to precipitate the 
particles. It was important to ensure that this acid step took no more than 1 – 2 minutes to prevent 
the digestion of the nanoparticles. Separation of the nanoparticles by magnet yielded a black solid 
that was resuspended in DMSO. 
 
c) Sulfonate 3 (NP-S3) 
This ligand exchange followed the same method as for NP-S2 above but with sodium 4-amino-5-
hydroxy-2,7-naphthalene disulfonate hydrate as the ligand. Workup was as before. 
 
d) Sulfonate 4 (NP-S4) 
This ligand exchange followed the same method as for NP-S2 and NP-S3 above but with 6-amino-4-
hydroxy-2-naphthalenesulfonic acid as the ligand. Workup was as before. 
 
e) Monodentate phosphate-PEG6-amine (NP1) 
 
Bulk oleic acid-capped nanoparticles (2 mL from 20 mL stock) were precipitated out of hexane and 
redissolved in chloroform (2 mL). Monophosphate-PEG6-amine (100 mg) was dissolved in chloroform 
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(4 mL). The two solutions were combined and stirred at room temperature in a sealed vial for 3 days. 
Following this, some of the solvent was evaporated to leave a concentrated nanoparticle solution 
that was precipitated with hexane. The black solid was isolated by a magnet, resuspended in DCM 
and again precipitated with hexane. This was repeated 3 times in total before the nanoparticles 
were suspended in ethanol.  
 
f) Bidentate bisphosphonate alendronate (NP2) 
 
Bulk oleic acid-capped nanoparticles (2 mL from 20 mL stock) were precipitated out of hexane and 
redissolved in THF (2 mL). Sodium alendronate trihydrate (50 mg) was dissolved in water (5 mL) and 
the pH adjusted to 9 with 1 M KOH. The THF solution of the nanoparticles was added to the ligand 
solution, and stirred for 2 days. Then, the stirrer bar was removed and the nanoparticles isolated by 
a magnet. The supernatant was decanted and the black solid suspended in water. Acetone was 
added to wash out any remaining ligand and this was repeated a further two times. Finally, the 
nanoparticles were resuspended in water (approximately 5 mL for this scale of reaction) and the pH 
checked to ensure it was around 8 (adjusted accordingly with KOH solution). 
 
2.4.6 Determination of iron concentration in nanoparticle samples by the Ferrozine 
assay 
Prior to any coupling reactions with the nanoparticles, the iron concentration in a sample of 
nanoparticles was determined by a modified protocol of the original Ferrozine assay as described by 
Stookey.80 The Ferrozine assay detailed below is based on a literature protocol by Viollier et al. 81 
The ferrozine reagent (monosodium salt hydrate of 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p’-
disulfonic acid) reacts with Fe2+ to form a stable purple complex species. This purple colour can be 
measured by UV-Vis spectroscopy, where the maximum absorbance is recorded at 562 nm. This 
method of determining iron concentration is used for all nanoparticles in solution and carried out 
prior to all coupling reactions on the relevant nanoparticles. As an example, typical iron 
concentration for alendronate coated nanoparticles is approximately 0.5 mg/mL. 
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Iron calibration standards between 0 – 50 μg/mL Fe(III) were prepared from a 1 mg/mL Fe(III) stock 
solution of FeCl3 in deionised water. The following solutions were prepared for use in the assay: 
a) Reducing agent solution was a 1.4 M hydroxylamine hydrochloride solution in 2 M HCl.  
b) Ferrozine solution was 0.01 M Ferrozine in a 0.1 M ammonium acetate solution. 
c) Final buffer was a 10 M ammonium acetate solution adjusted to pH 9.5 with NH4OH 
solution. 
10 μL of iron sample (calibration standard or NP sample) was diluted with deionised water (90 μL) 
and with 0.5 M HCl (900 μL) to bring the total volume to 1000 μL. The nanoparticle solutions were 
heated for 45 min at 70 °C to digest the nanoparticles. An aliquot of the heated solution (100 μL) was 
diluted with deionised water (750 μL) and the reducing agent solution (150 μL). The mixture was 
allowed to react for 30 min to complete the reduction of Fe(III). Ferrozine solution (100 μL) was 
added to the mixture, followed by the final buffer (150 μL). The absorbance of the solution at 
562 nm was then recorded. 
 
2.4.7 Protocols for further stability measurements 
Experiment using healthy volunteers was approved by the local research ethics committee (P/00/029 
East London and The City Local Research Ethics Committee 1). Informed written consent was 
provided according to the Declaration of Helsinki. Blood was collected into 3.2% sodium citrate and 
diluted 1:1 in RPMI-1640 before separation through a double-density gradient using Histopaque® 
1077 and 1119 (Sigma-Aldrich). 
 
a) In H2O at different pH’s 
Water at different pH’s (pH 1, 3, 5, 7, 9, 11, 13) were prepared by adjusting the pH of ultrapure 
water (5 mL) with 0.5 M HCl or 0.5 M KOH, and monitoring with a pH meter. 100 μL of prepared NP1 
(100 μL ethanol stock diluted with 100 μL H2O to give a concentration of 0.75 mg/mL Fe) and NP2 
(1.0 mg/mL Fe in water) were added to vials containing 1 mL of the water at different pH. The 
stabilities of the particles were visually observed over time. 
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b) In NaCl solutions 
NaCl solutions (10 mL each) of varying concentrations were prepared (0 %, 0.3 %, 0.6 %, 0.9 % and 
1.2 % w/v) by dissolving NaCl (12.0 g) in water (10 mL) for a 1.2 % stock solution and diluting 
accordingly. 100 μL of prepared NP1 (100 μL ethanol stock diluted with 100 μL H2O to give a 
concentration of 0.75 mg/mL Fe) and NP2 (1.0 mg/mL Fe in water) were added to vials containing 1 
mL of the water at different pH. The stabilities of the particles were visually observed over time.  
 
c) Toxicity in blood 
Whole blood (750 μL) were incubated for 90 min at 37 °C in an orbital shaker with 10 mM PBS buffer 
(250 μL) solutions of the nanoparticles at 2 different concentrations (10 μg and 50 μg of each NP 
sample). Then the samples were centrifuged at 600 g for 5 mins, the pellet was discarded and the 
supernatant was incubated at room temperature for 30 more min to allow haemoglobin oxidation. 
Finally the absorbance of the samples was recorded at 560 nm.   
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3 Further functionalisation of the nanoparticles 
3.1 Introduction 
This chapter discusses the functionalisation of NP2 (alendronate coated nanoparticles) with PEG for 
improving water-solubility and for biocompatibility. The main focus was to synthesise a dual-modal 
MRI/PET imaging agent incorporating iron oxide nanoparticles for the MRI moiety, and Ga-68 as the 
PET moiety.  
With the nanoparticle surface coated with sodium alendronate (NP2), the surface of the 
nanoparticles was further functionalised by coating the nanoparticles with i) polyethylene glycol 
(PEG) to enhance blood lifetime, ii) a targeting moiety, in this case an antibody for plaque imaging, 
and, iii) a strained alkyne for copper-free click reaction with a Ga-68 moiety to give a dual-modal 
MRI/PET imaging agent. The terminal functional group at each step is typically a chemical group that 
can be reacted further by moderately simple chemistry. The use of peptide coupling chemistry using 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to react amines and carboxylic acids together 
is exploited. In this case, the amine functional group was the terminal reactive group on the 
nanoparticle surface with the carboxylic acid group on each of the PEG, the strained alkyne and the 
targeting moiety.  
The dual-modal MRI/PET imaging agent can be assembled in two ways. The first would be to carry 
out the cycloaddition reaction between the azide and alkyne to form a single probe prior to 
injection. This method can be further broken down into two routes, with the azide-DOTA moiety 
being radiolabelled with the Ga-68 either before or after the cycloaddition reaction. Both routes 
have disadvantages; gallium chelation typically requires elevated temperatures and an acidic 
environment, both of which affect nanoparticle stability and thus radiolabelling after the 
cycloaddition reaction would not be ideal. However, radiolabelling before the cycloaddition reaction 
prior to injection into the patient would result in diminished radioactivity, which is also less than 
ideal. Another disadvantage of having a single pre-combined nanoparticle MRI/PET probe is the large 
size that would slow down in vivo movement, diminishing radioactivity before reaching its target. 
Therefore, an alternative route would be to carry out the cycloaddition reaction in vivo, with the 
administration of the two contrast agents separately. Pre-targeting using a magnetic nanoparticle 
followed by the injection of the radio-labelled molecule at the correct time will ensure radioactivity 
remains sufficiently high. The functionalisation of the nanoparticles begins with PEGylation, followed 
by the strained alkyne and the targeting moiety (Scheme 3.1), followed by the copper-free 
cycloaddition reaction in vivo. 
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Scheme 3.1 General synthetic scheme for the decoration of nanoparticle surface with PEG, strained alkyne and 
targeting moiety, followed by reaction between the alkyne (on NP) and azide (on PET moiety) in vivo. 
 
Herein, the synthesis and characterisation of the nanoparticles during the PEGylation and coupling 
of the strained alkyne will be discussed. Prior to using radioactive gallium, model copper-free click 
reactions with the lanthanide complexes to confirm the success of the click reactions were carried 
out.  
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3.2 PEGylation of nanoparticles 
Nanoparticles are highly advantageous for use as imaging and therapy agents as they are able to 
carry high payloads, have high stability, and are able to carry out multiple, simultaneous applications 
as a result of their high surface area to volume ratio.1 Despite these advantages, nanoparticle use in 
medicine has been hampered by several factors, the most significant of which is the ability of the 
particles to remain in the body long enough to reach the targeted site of action. Nanoparticles are 
readily cleared from the body by a variety of mechanisms, one of which is elimination by phagocytes 
in the mononuclear phagocyte system (MPS).2 Plasma proteins attach to the nanoparticles and are 
recognised as foreign material by phagocytes in the blood and other tissues. The nanoparticles are 
engulfed and sent to the liver and spleen for excretion. The nanoparticles can accumulate in the MPS 
and there have been concerns of toxicity if the nanoparticle aggregates are trapped in the lungs or 
elsewhere due to capillary obstruction.3 
Polyethylene glycol (PEG) has been used extensively in the literature to coat nanoparticle surfaces 
and is undeniably one of the most popular methods to improve blood lifetimes and introduce stealth 
properties.3–6 PEG is a coiled, hydrophilic polymer consisting of repeating ethylene ether units which 
can be attached onto the surface of nanoparticles. The addition of PEG to the nanoparticle surface 
has been shown to reduce MPS uptake and increase blood circulation time, compared to uncoated 
nanoparticles.7 
Circulation half-time (t½) is the time period over which more than 50 % of the injected nanoparticles 
remain in the blood stream, similar to that of the half-life of a drug.8 In order for nanoparticles to be 
effective at its application, be it imaging or drug delivery, the t½ should be long enough that the 
particles reach their intended target, as well as remaining there in sufficient concentration for a 
certain amount of time before image capture or drug delivery. The ideal t½ is dependent on 
application. 2 – 6 h is optimal in imaging for the injection, accumulation of the particles at targeted 
site, clearance from non-targeted areas and data collection.9 For therapeutic NPs, the ideal t½ is 
longer, usually days, to allow repeated exposure to the affected area.9 To avoid exposure of healthy 
cells to the drug, targeted NPs should allow for the preferential accumulation in diseased cells.  
PEG chains increase the circulation time of nanoparticles by modifying the surface of the 
nanoparticle that interacts with the environment or solvent. In the body, the MPS works by 
circulating macrophages and monocytes to remove foreign material such as bacteria and viruses.10 
Macrophages and bacteria (and viruses) have similar negative surface charges, so to prevent 
repulsion between the two, plasma proteins called opsonins attach to the foreign entities to reduce 
the surface charge before the macrophages engulf them and transport to the liver or spleen for 
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degradation and excretion.11 PEG chains reduce the process of opsonin attachment, thus enabling 
concealment of PEG-coated nanoparticles from the phagocytes and therefore increasing the t½.
11–14  
Besides the interaction between NP and the MPS, NP-NP interactions (leading to aggregation) also 
result in low t½. NPs aggregate due to the stronger interaction between particles than the interaction 
between the nanoparticle and solvent.15 Spherical nanoparticles have a greater tendency to 
aggregate when they have a high surface energy, and this interaction potential is associated with the 
electrostatic repulsion potential and the van der Waals attraction potential.16,17 PEG molecules 
minimise the van der Waals attraction and hence decrease the surface energy, resulting in less 
aggregation.18–20  
The ideal particle size for in vivo applications is between 10 and 100 nm. Particles smaller than 
10 nm have increased chances of renal filtration, while those larger than 100 nm are more likely to 
be taken up by the MPS and will find it more difficult to accumulate in tumour tissue.13 PEGylation of 
nanoparticles can help modify the size of the particles, by varying chain length with the size of the 
nanoparticle core.  
PEGylation of nanoparticles has been extensively covered in the literature, with the NP cores ranging 
from magnetic iron oxide nanoparticles,21 gold NPs,22 and quantum dots (QD)23–25 employed in the 
imaging field. PEGylated gold NPs have also been used in catalysis and optics.26–29 Iron oxide 
nanoparticles however, were one of the first nanoparticles to be used in imaging.30,31 It has been 
shown that PEGylation or dextran coating of iron oxide nanoparticles extends t½ by up to 200 min 
and improves image quality.32–34  
 
3.2.1 Synthesis of PEGylated NP2 
In this project, NP2 (IONP coated with sodium alendronate) are further coated with PEG molecules 
of various lengths, and with various terminal groups. According to literature, in general, larger NPs 
(between 50 and 100 nm) are usually coated with smaller PEG chains (3400 – 10000 MW) as further 
increases to the hydrodynamic diameter can reduce t½.
3 However, the hydrodynamic diameter is 
affected by the arrangement and conformation of the PEG chains on the NP surface which can be 
either mushroom or brush.35,36 This is discussed further in Section 3.2.3. The terminal functional 
group on the PEG chain also influences in vivo behaviour. Different terminal functional groups will 
alter the overall surface charge on the nanoparticle. This in turn, will affect whether the particles are 
detected by opsonins and therefore phagocytic cells. 
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The PEG molecules chosen here were all linear and their MW were approximately 800, 3000 and 
5000 (PEG units 12, 58 and 96 respectively). At these molecular weights, coupled with the size of the 
core (6 nm diameter), it was expected that the hydrodynamic diameter of the PEGylated NP be no 
greater than 50 nm for the highest MW PEG, assuming linearity is maintained. This is based on 
average bond lengths and the average length of a PEG monomer unit (0.35 nm),37,38 where a PEG 
chain with 96 units, is roughly 33 nm.  
In this project, carboxylic acid, amine and hydroxyl terminal groups were investigated. All the PEGs 
have a carboxylate on one end which react with the terminal amine on NP2 (Scheme 3.2). The amine-
terminated PEGs were initially protected with an Fmoc group to prevent reaction with itself. The 
Fmoc group was cleaved after the coupling reaction to free the amine group. The hydroxyl-
terminated PEG was used as obtained. The carboxylate-terminated PEG was produced by reacting 
the amine-PEGylated NP2 with succinic anhydride once on the nanoparticle. 
 
Scheme 3.2 Synthetic scheme showing PEGylation of NP2 
 
As it was determined previously that there are approximately 145 free amine groups on the surface 
of NP2, the PEG molecules were added in 300 equivalents relative to the nanoparticle. This 
equivalence is in a slight excess in order to maximise the yield of the reaction and to maximise the 
number of PEG molecules coating the surface of the nanoparticle. In a typical experiment, the 
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nanoparticles were reacted with 300 equivalents of PEG molecules in the presence of EDC to 
activate the carboxylic acid. After reacting overnight, the mixture was centrifuged and the 
supernatant decanted. For the OH-terminated particles (NP-PEGn-OH; NP3, NP4, NP5), the mixture 
was washed three times by precipitation with acetone, and finally the nanoparticles were 
resuspended in water. For the amine-terminated particles (NP-PEGn-NH2; NP6, NP7, NP8), the black 
pellet was suspended in a piperidine/DMF (20/80) mixture for 15 mins, to remove the Fmoc group 
on the amine. This was repeated three times to finally give the free amine. The carboxylate-
terminated particles (NP-PEGn-COOH; NP9, NP10, NP11) were obtained by reacting NP-PEGn-NH2 
with 300 equivalents of succinic anhydride for 3 hours. At the end of the reaction, the mixture was 
washed three times by precipitation with acetone, and finally the nanoparticles were resuspended in 
water. The OH and COOH terminated nanoparticles were not very soluble in water compared to the 
NH2 particles, resulting in a cloudy suspension.  
 
3.2.2 Characterisation of PEGylated nanoparticles 
The PEGylated nanoparticles were characterised by infrared spectroscopy, run as neat samples on an 
ATR plate. For the NH2 and OH terminated PEG chains, a sharp peak at 1649 cm
-1 was observed 
which corresponds to a C=O amide stretch. The infrared spectrum for NP-PEG96-NH2 (NP8) (MW 
5000) is shown below (Figure 3.1). 
4000 3500 3000 2500 2000 1500 1000
%
 T
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-1
C=O stretch
 
Figure 3.1 Infrared spectrum (neat, ATR plate) of NP-PEG96-NH2 (NP8). 
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The particles were also characterised by DLS measurements to obtain the hydrodynamic size and 
surface charge of the nanoparticles (Table 3.1). All the measurements were carried out at pH 7.4 at 
298 K in water. Assuming the PEG molecules remain relatively straight on the nanoparticle surface, it 
was expected that the higher MW PEG would have a larger hydrodynamic size. A longer PEG chain 
will extend further out from the surface of the nanoparticles than a shorter PEG chain, creating a 
thicker PEG layer, as illustrated in Figure 3.2. This trend is observed for the NH2 and OH functionalised 
PEGs when the MW of the PEG is increased. However the COOH functionalised PEGs gave variable 
size measurements (between 10 and 200 nm over repeats). This could be due to the poor water 
solubility of the particles making sizing measurements of a suspension difficult to obtain. 
Sample Core PEG length Surface group Surface charge (mV) Size (nm) 
NP2 NP2 No PEG NH2 -25 30.0 
NP6 NP2 12 (ca 800 Da) NH2 -14 31.0 
NP7 NP2 58 (ca 3000 Da) NH2 -12 33.3 
NP8 NP2 96 (ca 5000 Da) NH2 -12 39.8 
NP3 NP2 12 (ca 800 Da) OH +3 34.3 
NP4 NP2 58 (ca 3000 Da) OH  +10 58.5 
NP5 NP2 96 (ca 5000 Da) OH  +18 89.4 
NP9 NP2 12 (ca 800 Da) COOH -27 n/a* 
NP10 NP2 58 (ca 3000 Da) COOH -25 n/a* 
NP11 NP2 96 (ca 5000 Da) COOH -25 n/a* 
Table 3.1 DLS data detailing the size and surface charges of the various PEGylated NP2. *Nanoparticles were 
not very soluble in water, measurements of the suspensions gave increasingly larger values suggesting 
aggregation. 
 
 
Figure 3.2 Illustration showing PEGylated nanoparticles with a long (left) and short (right) PEG chain. The 
longer PEG chain extends further out from the surface of the nanoparticles, increasing the thickness of the PEG 
layer. 
 
The different terminal functional groups should also affect the surface charge on the nanoparticles. 
In theory, the terminal amine groups would be protonated at pH 7.4, resulting in a positive surface 
charge. However, an overall negative charge, albeit less negative than NP2 was observed. This was 
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expected due to the negative charges from the OH and phosphonate oxygen atoms on the 
alendronate ligand, countering the positive charge from the amine resulting in an overall smaller 
negative charge (as previously explained in Chapter 2). The COOH terminal groups on the other 
hand, would be deprotonated at pH 7.4, resulting in a negative charge, and therefore an overall 
more negative charge compared to NP2 and this is indeed what is observed. OH groups have a 
higher pKa than carboxylic acids (OH approximately 16 compared to 5 for COOH), so the OH terminal 
group on the PEG would also be deprotonated at pH 7.4 but to a lesser degree than the COOH. 
However, this would still mean that an overall negative surface charge is expected but a slightly 
positive charge is observed instead.  
The amine terminated PEGylated particles were reacted with rhodamine-NHS to determine the 
number of free amines on the surface of the nanoparticle after PEGylation. Assuming that no 
rhodamine reacts with any remaining amines on the alendronate ligand, due to steric hindrance 
from the PEG chains, the results from the rhodamine coupling after PEGylation should give the 
number of amine groups on the surface which are from the PEG molecules only. This can then be 
correlated back to the number of PEG molecules present per nanoparticle. 
Sample No. of amine groups reacted 
NP6 (PEG600) 71 
NP7 (PEG3000) 72 
NP8 (PEG5000) 57 
Table 3.2 Number of amine groups that reacted to rhodamine after PEGylation of NP2. 
 
From the results (Table 3.2), the NP8 (PEG5000) had fewer amine groups that reacted with 
rhodamine compared to the NP6 (PEG600) and NP7 (PEG3000), which suggests that there are fewer 
PEG5000 molecules on the nanoparticle surface. Besides extending further out from the 
nanoparticle surface, a longer PEG molecule would also bind with lower density due to the bulkiness 
of the larger PEG. A longer PEG would also have a more flexible chain than can coil and therefore 
render the terminal NH2 groups less readily accessible for reaction. 
 
3.2.3 Estimation of PEG density and surface conformation 
As mentioned previously, PEG molecules on the surface of a nanoparticle can adopt either a 
mushroom or brush conformation, based on a model by de Gennes.35,36 The polymer conformation 
can be determined by comparing the relative polymer size or Flory radius (RF) of the polymer to the 
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distance between PEG chains on the nanoparticle surface. The Flory radius (RF) can be found using 
the following equation: 
𝑅𝐹 = 𝑎𝑁
3/5 
where a = the length of the monomer unit (which is 0.35 nm for PEG)37,38, and N = number of 
monomer units in the polymer. 
The distance between PEG chains, D, on a nanoparticle surface is related to the density of polymer 
on the nanoparticle surface. If there is a low density of polymers on the surface, the distance 
between the PEG chains will be larger and if this value for D is greater than the RF value, the 
polymers adopt a mushroom conformation. When D is smaller than RF, the polymers adopt a brush 
conformation. This is illustrated in Figure 3.3. 
 
Figure 3.3 Simplified diagram showing the low-density mushroom configurations (A) and high-density brush-
type arrangements (B) of polymers on nanoparticle surface. Image taken from ref 
9
. 
 
The number of amine groups that reacted with rhodamine can be correlated to the number of PEG 
molecules on the surface of the nanoparticle (assuming that little to no rhodamine reacts with any 
free amines from the alendronate). From the rhodamine coupling results, the PEG molecules of MW 
600 and 3000 have similar number of PEG molecules on the surface (71 and 72 respectively) while 
the PEG 5000 has 57 PEG molecules on the surface (Table 3.2). From this and the total surface area of 
the nanoparticle (assuming a sphere), the area that one PEG molecule occupies on the nanoparticle 
surface (APEG) can be determined. 
𝐴𝑃𝐸𝐺 =
𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝐴𝑟𝑒𝑎 (𝑁𝑃)
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝐸𝐺 𝑝𝑒𝑟 𝑁𝑃
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Assuming that the area covered by one PEG chain is a circle, the distance between two PEG 
molecules on the nanoparticle surface (D) is the diameter of this circle. 
𝐷 = 2 × √
𝐴𝑃𝐸𝐺
𝜋
 
Taking into consideration all of these assumptions, equations and rhodamine coupling results in 
mind, the Flory radius (RF), PEG density and distance between each PEG molecule can be calculated 
(Table 3.3). 
Sample PEG units APEG (nm
2
) RF (nm) D (nm) Conformation 
NP6  12 1.59 1.6 1.42 brush 
NP7 58 1.59 4.0 1.42 brush 
NP8 96 1.98 5.4 1.59 brush 
Table 3.3 Summary of values for the surface area of one PEG molecule on the NP (APEG), Flory radius (RF) and 
the distance between each PEG molecule (D), for the different PEG lengths to give the expected PEG 
conformation on the NP surface.  
 
In theory, larger molecular weight PEG molecules on a nanoparticle surface are expected to adopt a 
mushroom conformation due to longer distances between the PEG molecules. However, comparison 
of the D to RF value for PEG5000 indicates that the PEG conformation is brush. This was due to 
increasing PEG molecular weight having a weak effect on the number of PEG surface groups, which 
in turn resulted in a relatively slow increase in D compared to RF. 
 
3.3 Coupling to cyclooctyne for copper-free click reaction in vivo to give a 
dual modal MRI/PET contrast agent 
3.3.1 ‘Click’ reactions 
In 2001, Sharpless, Kolb, and Finn, published a review that described in detail the criteria required 
for a series of reactions to be referred to as ‘Click Chemistry’.39 These criteria state that the reactions 
should be high-yielding, stereospecific, be simple to perform by making use of readily available 
starting materials in environmentally friendly conditions such as water as a solvent, and the 
byproducts should be removable without the need for chromatographic separation.39,40 They also 
described that reactions that fall under the click chemistry group of reactions should have a large 
thermodynamic energy, and these usually involve carbon-heteroatom bond formation. These types 
of reactions that fulfil the click chemistry criteria include the opening of strained rings such as 
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epoxides,41 epoxidation reactions (addition of oxygen to C=C bonds),42 and cycloaddition reactions 
such as Diels-Alder43 and 1,3-dipolar cycloadditions.  
One of the reactions which has seen a large success from the utilisation of click chemistry is the 
Huisgen cyclisation reaction to prepare 1,2,3-triazoles by a 1,3-dipolar cycloaddition between azides 
and alkynes. The original reaction involved reacting both reagents at elevated temperature and 
produced triazoles with a lack of regioselectivity, a 1:1 mixture of the 1,4 and 1,5 regioisomers 
(Scheme 3.3).44 This in itself meant that this cyclisation reaction was not suitable to be regarded as a 
click reaction.  
 
Scheme 3.3 Original reaction between azide and alkyne giving the 1,4 and 1,5 regioisomer in 1:1 mix. 
 
However, it was found that this cyclisation reaction can be catalysed by copper(I) salts to give the 1,4 
regioisomer exclusively.40,45 The copper-catalysed cycloaddition is also carried out in aqueous media 
at room temperature, and is still compatible when other functional groups are present on both 
reagents. The copper(I) source is usually obtained through the reduction of copper(II) sulphate in the 
presence of sodium ascorbate.45 Other catalyst systems have also been reported, these include 
organic-soluble copper(I) complexes such as CuBr.(PPh3)3 and CuI.P(OEt)3,
46 and copper(I) stabilised 
with ligands such as tris-(benzyltriazolylmethyl)amine (TBTA).47 These types of modifications which 
results in the exclusive regioselectivity and experimental simplicity has made this reaction the gold 
standard among the click reactions.48–51 
The triazole moiety has found an abundance of applications in biological and pharmaceutical 
settings, with many examples in the recent literature showcasing the synthesis of triazole-containing 
peptides, oligosaccharides52,53 and natural product analogues.54,55 Through the copper-catalysis of 
the alkyne-azide cyclisation, it has been possible to synthesise new materials in other fields such as 
polymers,56 liquid crystals57,58 and biological macromolecules.59 The alkyne-azide cycloaddition has 
therefore become synonymous as a model click reaction even though Sharpless’ initial description 
covers a variety of syntheses. 
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The copper-catalysed reaction has a postulated mechanism (Scheme 3.4) that involves the initial 
formation of a copper-alkyne complex which lowers the pKa value of the alkyne and the proton on 
the alkyne can then be deprotonated in aqueous medium.44,60 The copper(I) acetylide complex is 
attacked by the azide to form a copper(I) adduct and intramolecular cyclisation results in a copper-
containing 1,2,3-triazole. Protonation regenerates the copper catalyst and the 1,4-regioisomer of the 
triazole.  
 
Scheme 3.4 Postulated mechanism of the copper-catalysed cyclisation between alkyne and azide.
44,60
 
 
Out of the various click reactions, the azide-alkyne cycloaddition has been shown to be the most 
biologically relevant as both the azide and alkyne functionalities are either absent or relatively rare 
in biological systems.61 In order to utilise this highly efficient reaction in vivo, the cycloaddition 
reaction between an alkyne and an azide has to be copper-free as copper is toxic.62 To achieve this, a 
modification where the alkyne is in a strained ring system has been employed by Bertozzi.63–68 Prior 
to Bertozzi, the reaction between cyclooctyne, the smallest of the stable cycloalkynes, and phenyl 
azide, had already been observed by Wittig and Krebs in 1961 to proceed extremely quickly giving 
the triazole as a single product.69 The rate of reaction when the strained alkyne is utilised is 
dramatically higher than unstrained alkynes due to the acetylene bond angle deformation in the 
ring.70,71  
The first generation cyclooctyne synthesised by Bertozzi et al was a substituted cyclooctyne (Figure 
3.4) synthesised according to a modified method originally carried out by Reese and Shaw.72 
However, model reactions of this substituted cyclooctyne with simple azides showed that the 
reaction suffered from slower kinetics compared to the copper-catalysed reactions. Incorporation of 
electron-withdrawing groups on alkynes had been shown previously by Ju et al to improve reaction 
rates for catalyst-free alkyne-azide cycloadditions.73 
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Figure 3.4 Examples of the different cyclooctynes showing the progression in modifications to the compounds. 
 
The Bertozzi group therefore introduced electron-withdrawing fluorine atoms adjacent to the alkyne 
which would lower the LUMO energy of the alkyne and promote reaction with the azide.74 One 
drawback of the original cyclooctynes was the low water-solubility, thereby making it less than ideal 
for biological applications. Removal of the phenyl ring improved the solubility, as well as decreased 
steric bulk around the reactive centre, allowing for improved reaction rates (2nd generation, Figure 
3.4). Further investigations to incorporate two fluorine atoms (DIFO), or with methoxy groups 
(DIMAC, 3rd generation, Figure 3.4) also showed improved kinetics, and no apparent toxicity when 
used in vitro for biomolecule labelling.64,66,75 The nitrogen atom within the ring in the methoxy 
substituted cyclooctyne also improved the solubility brought about by the nitrogen atom disrupting 
the hydrophobicity of the molecule.  
To improve the reaction rates even further, steric interaction in the form of phenyl rings fused on 
either side of the cyclooctyne was added (DIBO, 4th generation). The added rings impart extra strain 
and the cyclooctynes were shown to have vastly increased reaction kinetics.76 This 
dibenzocyclooctyne has been used by El-Sagheer et al to join DNA fragments together and they  
found that the reaction was very fast, completing in 1 minute.77  
A hybrid of the difluoro-substituted cyclooctyne and the fused aryl cyclooctyne was subsequently 
synthesised in the Bertozzi group which possessed even greater kinetic reactivity (DIFBO, 5th 
generation).78 However, all these modifications have also shown to give unwanted side reactions, as 
well as oligomerisation of the molecules in solution. Incorporation of a sulfur atom into the ring 
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(thiaDIFBO, 6th generation) was shown to result in a much more stable molecule that did not 
undergo oligomerisation, but had very low reaction rate. Contraction of the ring as in the 
cycloheptyne TMTH, still gave a stable molecule but with the fastest rate constant for an azide-
alkyne cycloaddition to date.79 Unfortunately, a benzene fused TMTH (akin to DIFBO’s structure) has 
not yet been possible to isolate. 
Cyclooctynes have found a variety of uses, and in a biological setting, have been shown to 
successfully be applied in vitro and in vivo. Site-specific surface functionalisation via the anchoring of 
proteins, fluorescent tags or other biomolecules to glass surfaces and magnetic beads has been 
made possible through the use of the copper-free azide-alkyne reaction.80 Modification of quantum 
dots (QD) to obtain biomolecule-conjugated QDs while maintaining the luminescent properties of 
the QDs has also been achieved by “copper-free click”.81 Feringa et al have shown that 18F can 
radiolabel a peptide called bombesin that targets a receptor overexpressed in tumour cells by 
conjugating bombesin with a cyclooctyne (in this case they used a modified dibenzocyclooctyne). 
The radiolabelled peptide can then be used as a cancer diagnosis and imaging radioligand.82 
Bertozzi’s work has been primarily with glycans. Glycans in cells have been successfully labelled with 
DIFO (3rd gen), and because the alkynes were also conjugated to fluorophores, imaging of the 
glycans being internalised into cells was possible.66 They have also shown that use in a live mouse 
has been promising. Cells in the mouse were metabolically labelled with azides, and conjugation to 
cyclooctynes (DIFO and DIMAC among others) was confirmed by detection of glycoconjugates in the 
isolated cells and other organs ex vivo.75 
Despite the modifications to the cyclooctyne structure to improve reaction rates, most of the 
cyclooctynes have poor water-solubility. The synthetic routes to these cyclooctynes are also highly 
demanding, usually between 7 and 10 steps, and giving low final yields. In this work, the simple 
cyclooctyne (non-fluorinated 2nd gen) was chosen as it can be synthesised in four steps according to 
a literature method. It is methanol-soluble but still stable after dilution with water. The successful 
initial use in vitro and in vivo by Bertozzi et al and others, is promising and shows that this system 
would be ideal for use in this work to produce a dual-modal MRI/PET contrast agent which combines 
together via copper-free alkyne-azide cycloaddition in vivo.  
The idea then is to label the iron oxide nanoparticles with the cyclooctyne, and a suitable biological 
targeting moiety to localise the nanoparticles to a particular location in vivo. Subsequent injection of 
the azide on a 68Ga-DOTA complex (the PET agent), would then see the azide selectively target the 
cyclooctyne on the nanoparticle, resulting in the dual-modal probe forming in vivo (Figure 3.5). 
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Figure 3.5 Simplified schematic of the copper-free click reaction in vivo to form the dual modal MRI/PET probe. 
 
3.3.2 Synthesis of cyclooctyne 
As the majority of the cyclooctynes in literature suffer from poor water-solubility and require 
demanding synthetic preparation procedures, one of the earlier cyclooctynes (13, Scheme 3.5) was 
chosen as it was water-soluble. The cyclooctyne 13 is not commercially available and so was 
synthesised according to literature method.81 
 
Scheme 3.5 Synthesis of 13 from cycloheptene. Reagents and conditions: a) bromoform, 
t
BuOK, anhydrous 
pentane, RT; b) AgClO4, methyl glycolate, anhydrous toluene, RT; c) NaOMe, DMSO, RT. 
 
The synthesis of the strained alkyne was not trivial. As with almost all the literature preparations of 
the cyclooctyne which can take up to 10 synthetic steps, some of these steps are complex and give 
low final yields. This 3 step procedure at first glance appears to be relatively simple. However, large 
loss of yield was encountered at every step after column chromatography, with only about 20 – 
50 mg of pure 13 obtained from 1 g of cycloheptene. Isolation of 13 in the final step was difficult as 
the DMSO used in the reaction was never completely removed during the workup, and co-eluted 
during the column. The yield of pure 13 relative to DMSO was calculated by running a 1H NMR with 
an internal standard. From repeat reactions, an average yield of about 20 % of the total mass 
obtained was pure product. 13 was characterised by NMR, MS and elemental analysis, and was in 
accordance with literature.81 There were initial concerns that the low yield of the reaction was due 
to the level of dryness of the solvents. However, this factor was eliminated with the use of freshly 
distilled methanol which did not improve yields.  
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3.3.3 Functionalisation of nanoparticles with cyclooctyne 13 
The alendronate coated nanoparticles NP2 were functionalised with the cyclooctyne 13 by EDC 
coupling (Scheme 3.6), for subsequent copper-free cycloaddition reaction with the 68Ga-DOTA-azide 
complex.  
 
Scheme 3.6 Synthetic scheme showing the coupling of strained alkyne to NP2 to give NP12. 
 
In a typical reaction, 200 equivalents of strained alkyne were reacted with NP2 in the presence of 
EDC. It was previously determined in Chapter 2 that NP2 has on average 115 ± 30 ligands on the 
surface. To maximise the yield of the alkyne coupling reaction, a slight excess of the ligand 13 was 
reacted with NP2. NP2-alkyne (NP12) was characterised by both infrared spectroscopy and DLS 
measurements.  
To quantify the number of cyclooctyne molecules reacted with NP2, a known quantity of rhodamine 
was reacted with the NP12 particles and the unreacted rhodamine measured and correlated to a 
calibration graph, to determine the number of free amine groups left on the surface of the 
nanoparticle after the alkyne coupling.  
Sample Number of amine groups reacted to rhodamine 
NP2 + alkyne 100 eq 193 ± 86  
NP2 + alkyne 200 eq 171 ± 94  
Table 3.4 Number of amine groups that reacted with rhodamine, after cyclooctyne coupling. 
 
The number of amine groups reacted when rhodamine was added is quite large (Table 3.4), but the 
error in measurements over the repeats is also high. However, some general observations can be 
deduced from these results. For the 100 eq of alkyne added, the amount of rhodamine reacted was 
between 107 and 279 molecules per nanoparticle. For the 200 eq of alkyne added, the amount of 
rhodamine reacted was less, between 74 and 265 molecules. This suggests that there are more 
cyclooctyne molecules per nanoparticle when 200 eq is used, which is as expected. However, using 
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200 eq does not result in 100 % coupling yield for the cyclooctyne. When a much higher equivalence 
of cyclooctyne was used (400 eq or higher), the nanoparticles precipitated out during the reaction, 
usually very quickly (within 30 min) of the cyclooctyne addition. The resultant nanoparticles were no 
longer soluble in water. This suggests that at 400 eq, the coupling yield was much higher, maybe 
even being close to 100 %, but the trade-off is the loss of water-solubility. The loss of water solubility 
made rhodamine coupling quantification for the 400 eq of cyclooctyne addition difficult and no 
reproducible or comparable results were obtained. 
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Figure 3.6 Infrared spectrum of NP12 (below, neat on ATR plate) compared to NP2 (above, neat on ATR plate). 
 
Infrared spectrum of NP12 (Figure 3.6) showed a weak alkyne stretch at around 2100 cm-1 which was 
not present in NP2 prior to the alkyne coupling. Some weak NH amide stretches between 3500 and 
3700 cm-1 are also present, indicative of successful cyclooctyne coupling to NP2. 
There was no significant change in the hydrodynamic diameter of the NP12 compared to NP2, 
remaining at approximately 30 nm. This was as expected as the cyclooctyne is a small molecule and 
so would not significantly change the hydrodynamic diameter of the resultant nanoparticle after 
coupling. The NP12 had a similar surface charge when compared to the NP2, of -25 mV. This result 
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was also as expected, for the same reason there was no change to the hydrodynamic diameter after 
coupling.   
 
3.4 Click reactions with lanthanide azide-DOTA complexes 
3.4.1 Lanthanides – properties and luminescence 
The azide functional group on the PET moiety (Ga-68), was designed to be on a DOTA macrocycle. 
DOTA was preferred over NOTA as DOTA is approved for in vivo use whereas NOTA is not. Prior to 
complexation with radioactive gallium, complexations to non-radioactive gallium as well as selected 
lanthanides were carried out. As both gallium and lanthanides bind similarly well to hard donor 
atoms (N and O on DOTA-type chelates), lanthanides were used to provide confirmation of complex 
formation. 
The lanthanides are a series of elements in the same period between the s- and d-blocks of the 
periodic table, from lanthanum (atomic number 57) to lutetium (atomic number 71). The 4f electron 
shell is filled gradually across the period, but is shielded from the outer 5s and 5p subshells, resulting 
in the f-orbitals being unavailable for bonding. Like the other series in the periodic table, such as the 
halogens, or alkali metals, the lanthanides share many similar characteristics to each other. These 
include having a common oxidation state of +3 in aqueous solutions, the adoption of 8 or 9 
coordinate complexes, a preference for ‘hard’ donor atoms (such as O and N), and paramagnetic 
properties due to having unpaired f-electrons.83 This paramagnetism leads to spectral broadening 
and resonance shifts in the NMR spectrum for the NMR active nuclei on the ligand coordinated to 
the Ln(III) ion, and have thus been used as lanthanide shift reagents to determine macromolecular 
structures such as proteins and nucleic acids.84  
Another characteristic property of lanthanides is their luminescence. Other than La(III), Gd(III) and 
Lu(III), the Ln(III) ions emit in the visible and near IR regions of the electromagnetic spectrum. Gd(III) 
has the largest ground state to excited state energy gap (ΔE) of about 32,000 cm-1 therefore the 
maximum emission wavelength, λmax, occurs in the UV region, which would overlap with the 
emission of organic chromophores that may be present in solution.85 Hence, Gd(III) cannot be used 
in luminescence studies. Analogues using Eu(III) or Tb(III) can be used in place of Gd(III) as they have 
similar ionic radii, chemical properties and also smaller ΔE values of 12,300 cm-1 and 14,800 cm-1 
respectively. This allows structural properties of Eu(III) and Tb(III) complexes to be deduced from 
luminescence and NMR spectroscopic studies and then applied to the Gd(III) analogue with 
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considerable confidence.86 These results for the lanthanides can then be extrapolated for the non-
luminescent gallium analogue.  
There are two types of luminescence, one of which is fluorescence, which involves the emission of 
light from an electronically excited singlet state (S1) to the ground singlet state (S0). Another type of 
luminescence is phosphorescence, which involves the emission from the excited triplet state (T1) to 
the ground singlet state (S0).
85 As there is a change in spin during phosphorescence, this process is 
forbidden by the selection rule ΔS = 0, and therefore is usually slow in comparison to fluorescence. 
Lanthanide luminescence is due to three types of electronic transitions. The first is via ligand-to-
metal and/or metal-to-ligand charge transfer, which are high in energy and therefore rarely 
observed. Secondly, transition of an electron between a 4f and 5d subshell, can result in 
luminescence where the energy is largely dependent on the nature of the interactions between the 
ligand and the Ln(III) 5d orbitals. As this transition occurs between orbitals that have opposing 
symmetries with respect to the centre of inversion, it is allowed according to the Laporte selection 
rule. Finally, although the Laporte rule forbids f-f transitions, interactions between the 4f 
wavefunction and the ligand field or its vibrational states allows this rule to be relaxed and therefore 
give weak and narrow emission bands that are unique to each lanthanide. Although the emission 
wavelengths for these bands are unaffected by the coordination environment as the 4f orbitals are 
not involved in bonding, the intensities of these bands can be affected. The redistribution of the 
electrons within the 4f orbitals can be spread over many energy levels. The nature of the 4f orbitals 
which can be split into (2S+1)L spectroscopic terms by Coulombic interaction arising from 
interelectronic repulsion, where (2S+1) is the spin multiplicity, and L = S, P, D and F when the total 
orbital angular momentum quantum number equals 0, 1, 2 and 3 respectively. These terms are 
further split into J levels by spin-orbit coupling where J is the total angular momentum. These 
splittings are illustrated in Figure 3.7. 
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Figure 3.7 Diagram representing the interactions leading to the splitting of the electronic energy levels of a 
Eu
3+
 ion. Increase in energy is in the upwards direction. Image from ref 
87
. 
 
Direct excitation of the lanthanides is difficult due to the forbidden f-f transitions, and usually results 
in weak luminescence, which is also quenched by nearby OH and NH oscillators. To increase the 
intensity of the lanthanide luminescence, organic chromophores (with higher extinction coefficients 
than lanthanides) are introduced to the ligand, to indirectly excite the lanthanide by acting as an 
antenna, allowing for energy transfer to the lanthanide.88 This energy transfer occurs over several 
steps (Figure 3.8). Firstly, the ligand absorbs energy and electrons are excited into the ligand singlet 
excited state. The large size of the lanthanide ions allows for intersystem crossing (ISC) of the 
electron from the singlet to the triplet excited state of the ligand. As long as this triplet excited state 
is higher than the excited state of the lanthanide ion, energy transfer from the ligand to the 
lanthanide can occur, resulting in increased emission intensity. The efficiency of this energy transfer 
however, is affected by the rate of energy transfer which has a 1/r6 distance-dependence (and r is 
the distance between the organic chromophore and the Ln(III) centre).89 Minimising this distance 
therefore will ensure a more efficient energy transfer and therefore enhanced emission. 
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Figure 3.8 Jabloński diagram demonstrating Eu(III) sensitised emission. Excitation of the organic chromophore 
to its singlet excited state is followed by intersystem crossing (ISC) to the triplet excited state (lines and arrows 
in black). Energy transfer from T1 state to Eu(III) results in emission (red arrows). 
 
Emission from the lanthanide via sensitisation with an organic chromophore also results in a large 
Stokes shift between the chromophore absorption and the Ln(III) emission. For example, aromatic 
groups usually have λex of 250 – 300 nm and λem of 350 – 400 nm, whereas lanthanides such as Eu(III) 
emit in the visible light region, λem of 570 – 720 nm, and so the Eu(III) emission spectrum is red 
shifted (Figure 3.9). Each individual band in a Eu(III) emission spectrum corresponds to the respective 
transitions from 5D0 to 
7FJ (J = 0 – 6), see Table 3.5.  
ΔJ λem range (nm) Intensity 
0 577 – 581 Very weak 
1 585 – 600 Strong 
2 610 – 625 Strong to very strong 
3 640 – 655 Very weak 
4 680 – 710  Medium to strong 
Table 3.5 Wavelength ranges and intensities for Eu(III) ΔJ transitions. 
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Figure 3.9 Typical Eu(III) emission spectrum of a Eu-DO3A species bearing an organic antenna (red line). 
Excitation of the organic chromophore (black line) occurs at much shorter wavelengths resulting in a large 
Stokes shift from the Eu(III) emission in the visible light region. 
 
3.4.2 Synthesis and characterisation of M.L1 complexes and small molecule copper-free 
click to cyclooctyne 
3-Azidopropyl-mono-amide-DOTA (L1) was purchased from Macrocyclics. The Eu, Gd and Ga 
complexes for L1 have been synthesised and discussed in the literature but no detailed synthetic 
procedures were outlined. The complexation reactions to europium, terbium, gadolinium, and 
gallium were carried out in mildly acidic conditions (Scheme 3.7), analogous to those outlined for 
similar complexes.90,91 Besides NMR and MS characterisation of the gallium complex, the 
luminescence of the Eu and Tb complexes serve to provide further evidence of the successful 
complexations.  
 
Scheme 3.7 Complexation of azido-mono-amide-DOTA L1 to M = Eu, Tb, Gd, Ga. 
 
In a typical complexation reaction (for the lanthanides), a slight excess (1.2 eq) of the metal salt was 
added to the DOTA ligand and the pH of the solution adjusted to 5.5. The reaction mixture was left 
to stir overnight. The pH of the solution was raised to about 10 to precipitate any unreacted metal 
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which is filtered off. The filtrate was concentrated and then purified by passing through a sephadex 
G-10 column to remove any salts. The gallium complex was formed by a similar method, but with the 
pH adjusted to 4.5 instead. All other steps remained the same.  
The europium complex Eu.L1 (14) was isolated as a white solid. High resolution ESI-MS gave a 
[M + H]+ peak at m/z = 637.1610 with the correct isotope splitting pattern for a Eu(III) complex. The 
terbium complex Tb.L1 (15) was isolated as a white solid and characterised by high resolution ESI-MS 
with a peak at m/z = 643.1656 [M + H]+. 
 
a) Fluorescence spectroscopy of 14 and 15 (Eu.L1 and Tb.L1) 
Fluorescence spectroscopy of 14 (Figure 3.10) and 15 (Figure 3.11) were recorded. A weak peak at 
395 nm in the excitation spectrum of 14 corresponded to the wavelength required for pseudo direct 
excitation of the Eu(III) ion.  In the range 575 – 710 nm of the emission spectrum, four weak 
emission bands, arising from the 5D0 → 
7FJ (J = 1 – 4), were observed when the complex was excited 
at 395 nm, with a gate time of 5 ms. The most intense of the peaks observed were at ΔJ = 1, ΔJ = 2 
and ΔJ = 4 transitions. The emission spectrum is typical of a Eu(III) emission, but is weak due to the 
absence of a chromophore to act as a sensitiser for the Eu centre. 
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Figure 3.10 Excitation and emission spectrum of Eu.L1 (14) (λex = 395 nm, 100 μM, H2O, 298 K, pH 7.4). 
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The excitation spectrum of 15 showed peaks at 320, 355 and 375 nm, corresponding to the pseudo 
direct excitation of the Tb(III) ion.  The peak at 355 nm had the highest intensity, so this wavelength 
was used to excite the complex and obtain an emission spectrum. In the range 450 – 650 nm, four 
emission bands, arising from the 5D4 → 
7FJ (J = 3 - 6), were observed when the complex was excited 
at 355 nm. The emission spectrum is typical of Tb(III) emission but weak due to the absence of a 
chromophore to act as a sensitiser. 
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Figure 3.11 Excitation and emission spectrum of Tb.L1 (15) (λex = 355 nm, 100 μM, H2O, 298 K, pH 7.4). 
 
Hydration state, q, of the Eu(III) and Tb(III) complexes can also be determined and related back to 
the Gd(III) analogue, which is useful for relaxivity. A higher hydration state will result in better 
relaxivity and therefore more intense MRI signal. The usual way to determine hydration state is by 
growing a crystal of the complex, however this is often very difficult. The crystal structure is also in 
the solid state and is hence a less than exact measure of the hydration state. The luminescence 
lifetimes (τ) of both Eu(III) and Tb(III), in H2O and D2O differ, due to differences in energy transfer 
between the vibrational energy levels of H2O/D2O and the Ln(III) centre (Figure 3.12). 
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Figure 3.12 Vibrational energy levels of H2O and D2O with respect to the ground and excited states of Eu(III) 
and Tb(III). There is good overlap between 
5
D0 excited state of Eu(III) and ν = 3 vibrational level of H2O, 
compared to 
5
D4 excited state of Tb(III) and the same ν = 3 vibrational level of H2O. 
 
There is a faster rate of decay in H2O (kH2O) due to less efficient energy transfer between the Ln(III) 
centre and the energy levels for D2O. Eu(III) is also more sensitive to quenching than Tb(III) and so 
has shorter lifetimes in both H2O and D2O compared to Tb(III). From these differences in lifetimes 
and decay rates, the hydration state, q of each complex can be calculated from the following 
equations.86  
𝑞𝐸𝑢 = 1.2[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.25 − 0.075] 
𝑞𝑇𝑏 = 5[(𝑘𝐻2𝑂 − 𝑘𝐷2𝑂) − 0.06] 
where the 0.25 and 0.06 terms reflect the quenching effect of unbound water molecules, and in the 
case of Eu complexes, the 0.075 term reflects the quenching from a coordinated amide NH group. 
Luminescence decays of both 14 and 15 in H2O and D2O were measured, and the q values calculated 
(Table 3.6). From the lifetime measurements, 14 has a hydration state close to 1 (q of 0.94) meaning 
that the Eu complex forms an eight coordinate complex with the macrocycle and will bind one water 
molecule. The determined hydration state of 15 was lower than for 14 (q of 0.67). This could be due 
to less efficient energy transfer from the Tb(III) centre to the OH and OD oscillators. However, the 
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value is still acceptable and within error, and confirms that the Tb complex is also eight coordinate 
and binds one water molecule. 
Complex τH2O/ms kH2O/ms
-1 τD2O/ms kD2O/ms
-1 q 
14 0.63 1.58 2.13 0.47 0.94 
15  1.95 0.51 3.08 0.32 0.67 
Table 3.6 Lifetimes, rate constants and derived hydration states for 14 and 15. 
 
b) Eu complex 14 – NMR studies 
1H NMR studies of the Eu complex can be used to deduce information regarding the Gd analogue. 
Both Eu and Gd have 1H NMR spectra that have wide chemical shift range, due to the 
paramagnetism of the metal ion. 1H NMR of Gd however cannot be studied to deduce structural 
characterisation due to the extreme line broadening as a result of highly efficient proton 
relaxation.92 This proton relaxation is less efficient with europium and therefore, the spectral lines 
are less broadened. An extended sweep-width 1H NMR spectrum for 14 was recorded and showed 
signals between -20 and +36 ppm and is as expected for Eu-DOTA-type complexes (Figure 3.13).  
 
Figure 3.13 Extended sweep-width 
1
H NMR of 14 (D2O, 400 MHz, 250 to -250 ppm, with Watergate water 
suppression). 
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Previous crystal structure and NMR studies carried out on Ln-DOTA complexes by Botta et al, and 
Roth and Hoeft, have shown that DOTA-type complexes can adopt the structure of one of four 
stereoisomers once chelated.93,94 The metal centre is held between the four coplanar nitrogen atoms 
in the macrocycle, and the four coplanar oxygen atoms of the arms. The macrocycle forms a square 
conformation that is slightly distorted and which defines the geometry of the complex. There are 
two main geometries the complex can adopt, the square-antiprismatic isomer (SAP or “major” M) 
and the twisted-square-antiprismatic isomer (TSAP or “minor” m), depending on the angle of 
distortion. These two isomers can be interconverted by flipping the macrocycle ring, or by rotating 
the arm. The ethylene group conformation around the metal centre can be either a δ or λ 
configuration therefore the macrocycle conformation is either δδδδ or λλλλ. The acetate arms can 
also be arranged into two positions, Δ or Λ. The combination of ring interconversion (δ ↔ λ) and 
arm rotation (Δ ↔ Λ) leads to four stereoisomers, related as two pairs of diastereomers 
(Δ(δδδδ)/Λ(λλλλ), and Δ(λλλλ)/Λ(δδδδ) (Figure 3.14).95 
 
Figure 3.14 The four stereoisomeric complexes of LnDOTA−complexes, related as two enantiomeric pairs. 
These stereoisomers interconvert by ring inversion or arm rotation. Sequential ring inversion and arm rotation 
interconverts enantiomers. Figure taken from ref 
96
. 
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The two different isomers can be distinguished by differences in chemical shifts in the NMR 
spectrum, especially for the axial proton closest to the metal centre. In the SAP isomer, this axial 
proton has a more downfield shift in the range of 30 – 50 ppm, while in the TSAP isomer this same 
proton appears in the range of 15 – 20 ppm.97 In the 1H NMR spectrum of 14 (Figure 3.13), the signals 
observed between +30 and +35 ppm in the spectrum corresponds to the axial protons closest to the 
metal centre, for a complex that is a SAP isomer. Resonances for the TSAP isomer which usually 
occur between 15 and 20 ppm are not present in the NMR of 14. 
 
c) Gadolinium and Gallium complexes 
The Gd complex Gd.L1 (16) was isolated as a white solid and characterised by high resolution mass 
spectrometry. ESI-MS of the complex gave a molecular ion peak at m/z = 642.1655 [M + H]+ with the 
correct isotope pattern for a Gd(III) complex. 
From the hydration state measurements for the Eu(III) and Tb(III) analogues, it can be deduced that 
16 also has a hydration state of 1. 1/T1 measurements were carried out and the r1 relaxivity for 16 
was found to be 4.02 mM-1 s-1, which is comparable to the relaxivity of Gd-DOTA (r1 = 4.20 mM
-1s-1).98 
This value of 4.02 is slightly lower than the 4.20 of Gd-DOTA due to the amide N-H that slows water 
exchange rates. SAP isomers are known to have slower water exchange rates, and the Eu analogue 
of this complex (14) was found to be predominantly in the SAP isomer which means that 16 is most 
likely also present as the SAP isomer, and is another reason for the lower r1 measured.
96,99 
The gallium complex Ga.L1 (17) was isolated as a white solid. High resolution ESI-MS was obtained 
with a molecular ion peak at m/z = 553.1637. 1H NMR of the ligand and complex showed slight 
differences, with the NMR of the complex showing sharper signals for the CH2 macrocycle protons 
(between 3 and 4 ppm) compared to the broadened peaks for the same protons in the NMR of the 
ligand. This sharpening of said signals is a result of the metal holding the ligand in a constrained 
conformation preventing bond rotation on the NMR timescale, and is further proof that the 
complexation was a success. 
 
d) Small molecule cycloaddition reaction of M.L1 complexes to cyclooctyne 
Prior to carrying out the cycloaddition reactions with NP2-alkyne (NP12), the complexes were also 
reacted with the cyclooctyne 13 (Scheme 3.8) as confirmation that the cycloaddition reaction is 
successful. In a typical reaction, the same equivalence of both the cyclooctyne (in the minimum 
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volume of MeOH) and the complex (in water) were added together in a vial and left to shake. The 
resulting complexes were characterised without further purification such as column chromatography 
or aqueous workup.  
 
Scheme 3.8 Cycloaddition reaction between M.L1 and cyclooctyne 13. 
 
The excitation spectrum for both the 18 and 19 (Eu and Tb cyclised complexes respectively) no 
longer had peaks at 395 nm and 355 nm respectively, which corresponds to the pseudo direct 
excitation of the respective Ln(III) centres, and instead both excitation spectra had a peak at 255 nm 
which corresponds to an aromatic group, most likely from the triazole formed during the 
cycloaddition reaction. As a general rule, when aromatic groups are present near the europium or 
terbium ion, they can act as an antennae which enhances the lanthanide based emission by 
harvesting light and transferring the energy to the lanthanide ion.88 The emission spectra of 18 and 
19 showed the same emission spectral lines but at higher intensities when excited at 255 nm. 
Additionally, the emission spectrum of 18 (Figure 3.15) showed more defined spectral lines compared 
to 14 (before cycloaddition reaction), due to the energy transfer from the triazole to the Eu(III) 
centre, resulting in an enhanced emission. 
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Figure 3.15 Excitation and emission spectrum of 18 (λex = 255 nm, 100 μM, H2O, 298 K, pH 7.4). 
 
The complexes were also characterised by high resolution ESI-MS, with each showing their 
respective molecular ion peaks at m/z = [M + H]+ (Table 3.7), confirming the successful click reactions. 
Complex Calc. m/z Found m/z 
18 817.2536 817.2574 
19 825.2590 825.2612 
20 824.1989 824.2003 
21 735.2593 735.2628 
Table 3.7 m/z values for the cyclised complexes 18 - 21. 
 
3.4.3 Copper-free cycloaddition reaction between Ln.L1 to NP-alkyne 
In order to confirm further that the azide-alkyne cycloaddition reaction with the nanoparticles would 
be successful before carrying on with radioactive gallium, it was decided to carry out the 
cycloaddition reactions on the nanoparticles with the lanthanide complexes as well (more 
specifically the europium and terbium complexes), in order to observe the fluorescence, if any, once 
clicked to the nanoparticle (Scheme 3.9).  
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Scheme 3.9 Reactions to couple the alkyne to the nanoparticle followed by copper-free click to Ln-azido-DOTA 
(Ln = Eu, Tb), as well as with L1 (no Ln). 
 
In a typical experiment, 200 equivalents of the complex relative to NP12 were reacted in water for 
two hours. The nanoparticles were purified by three cycles of precipitation with acetone, with the 
nanoparticles finally resuspended in water.  
Emission spectra for NP13 (Eu) showed that there was an unexpected well defined emission from 
the nanoparticles when excited at 395 nm, but not the expected emission from europium metal 
centre (blue curve, Figure 3.16). 
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Figure 3.16 Emission spectra of NP2 (alendronate), NP12 (alkyne), NP13 (Eu), and NP15 (no M). All 
measurements ex = 395 nm, H2O, 0 ms delay, slits 10:10, 1 mg/mL Fe, pH 7, 25
 o
C. 
 
The unexpected emission was further investigated with the nanoparticles at each stage of the 
synthesis (NP2 – alendronate, original surface ligand; and NP12 – alkyne) (Scheme 3.9) to confirm the 
unexpected emission (Figure 3.16). The intensity increases from NP2, to NP12 to NP13 species, 
suggesting an energy transfer from the ligand to the iron oxide nanoparticle, providing a preferred 
energy pathway to that of the europium centre. The emission is weak though as the excitation 
spectrum shows a low intensity peak at 395 nm.  
When excited at 395 nm, NP14 (Tb species) also showed a similar emission, i.e. only the emission 
from the iron oxide nanoparticle (black curve, Figure 3.17). When excited at 375 nm (pseudo direct 
excitation of Tb centre), the emission spectrum of NP14 has a slight resemblance to that of a regular 
Tb complex such as 15 (Tb.L1) (with signals at 490 and 545 nm corresponding to the ΔJ = 2 and ΔJ = 1 
transitions, red curve Figure 3.17). The intensity of these signals are also higher than when excited at 
395 nm, which is as expected as 375 nm is a better wavelength for exciting Tb(III) than 395 nm. The 
emission observed when the nanoparticles are excited at 395 nm suggests that an energy level in the 
nanoparticle is being accessed and is excited more efficiently than the Eu(III) centre at 395 nm. 
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Figure 3.17 Emission spectrum of NP14 (Tb). Red curve ex = 375 nm; black curveex = 395 nm; Both 
measurements in H2O, 0 ms delay, slits 10:10, 1 mg/mL Fe, pH 7, 25
 o
C. 
 
To determine whether the nanoparticles were indeed emitting a weak fluorescence, the experiment 
was repeated both with a control set of nanoparticles (cycloaddition without a metal centre, NP15 
no M), as well as a different ligand on the surface of the nanoparticle (11-aminoundecanoate, NP16, 
provided by Dr Juan Gallo). Again, a similar emission spectrum was observed for both NP15 (green 
curve, Figure 3.16) and NP16 (Figure 3.18), with NP15 still showing an increased emission intensity 
from the precursors. Blanks with water and DMSO were confirmed that the emission was not an 
artefact of the fluorimeter as no emission spectral lines were observed. 
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Figure 3.18 Emission spectrum of NP16 (NP-aminoundecanoate). ex = 395 nm, DMSO, 0 ms delay, slits 10:10, 
1 mg/mL Fe, pH 7, 25
 o
C. 
 
The emission spectrum of NP16 (NP-aminoundecanoate) suggests that a different ligand system 
does not change the spectral outcome of the nanoparticle. These results strongly suggest that there 
is a definite but weak emission from the nanoparticle core. Emission from iron oxide nanoparticles 
however, has not been reported much in the literature with only one known example of 
luminescence observed directly from the nanoparticle reported.100 Fei et al postulated that lattice 
defects on the nanoparticle surface, and the binding of molecules on the nanoparticle surface, cause 
changes in the electronic structure of the entire molecule, resulting in a weak emission from the 
nanoparticle between 400 and 600 nm, depending on the excitation wavelength. Most examples in 
the literature of fluorescent or luminescent nanoparticles involve hybrid or nanocomposite systems, 
with the fluorescent moiety coming from non-iron oxide nanoparticle species. These include hybrid 
luminescent non-iron oxide nanoparticles such as mixed lanthanide oxide nanoparticles (Dy/Eu, 
Ho/Eu and Ho/Tb systems) synthesised by Xu et al and lanthanide conjugated to InP quantum dots 
by Stasiuk et al.101,102 The incorporation of both α-Fe2O3 and quantum dots into silica shells is a 
popular way to form bifunctional nanoparticles with both magnetic and fluorescent properties.103–105 
Another way to synthesise bifunctional luminescent nanoparticles is to conjugate the nanoparticles 
to a fluorescent complex such as the iridium complex functionalised Fe3O4/SiO2 core shell 
nanoparticle system synthesised by Hsiao et al.106 The iridium complex after incorporation onto the 
nanoparticle showed phosphorescent properties. Lanthanide complexes conjugated to iron oxide 
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nanoparticles have been synthesised and studied in the literature, but are fewer in number, despite 
the attractive luminescent properties of lanthanides (long lifetimes and sharp emission bands). Yang 
et al showed that terbium emission is observed after conjugation of terbium to the IONP surface.107 
Similar results were shown by Liu et al and Choi et al where the lanthanide luminescence was 
observed after conjugation to the iron oxide surface.108,109 However, the concentrations of the 
nanoparticle solutions were not always described within the paper, so it is not possible to directly 
compare their results to those obtained here. Nevertheless, the absence of lanthanide emission 
from our studies could be due to one of or a combination of the following: 1) a low concentration of 
lanthanide on the surface of the nanoparticle, 2) absence of an antennae on the Ln complexes to 
enhance Ln emission, and 3) there is an excited energy level within the nanoparticle core that is 
accessible allowing a stronger emission from the nanoparticle core to be observed.  
As the fluorescence spectroscopy of the NP-Ln species (NP13 and NP14) did not definitively confirm 
whether the cycloaddition reaction was a success on the nanoparticle surface, ICP-MS analysis was 
carried out by Dr Stanislav Strekopytov at the Natural History Museum, London to determine the 
concentration of lanthanide in the nanoparticle samples after the reaction. This can be compared to 
the amount of Ln complex added per reaction to give the yield of the cycloaddition reaction (Table 
3.8). The amount of Ln(III) in the respective samples after the reaction was quite low, giving a yield of 
between 10 and 15 %. This could explain why no lanthanide emission is observed on the 
nanoparticles. Nevertheless, the fact that the relevant lanthanides are still present in the respective 
nanoparticle samples after the cycloaddition reaction have shown that the azide-alkyne reaction on 
the nanoparticles were successful. 
Sample Ln Amount of Ln in submitted 
sample (mg) 
Amount added during reaction 
of submitted sample (mg) 
% yield of “click” 
reaction 
NP13 Eu 0.16 1.59 10 
NP14 Tb 0.20 1.61 13 
Table 3.8 Amounts of lanthanide in NP13 and NP14 determined by ICP-MS. 
 
With respect to the reaction in vivo with Ga-68, this low yield should not be detrimental as PET 
imaging is more sensitive and therefore only a small amount of the radioisotope would be required 
to give a significant signal.   
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3.4.4 Synthesis of modified azido-DOTA and the Ln complexes 
To determine if the fluorescence observed after the cycloaddition reaction to the nanoparticles 
could be enhanced if there was a chromophore on the Ln complex, the DOTA ligand was modified to 
incorporate a benzyl group which can act as a weak chromophore for the lanthanide. For indirect 
excitation of Ln(III) to occur, there has to be energy transfer from the sensitising moiety to the 
Ln(III). This energy transfer is more efficient when the energy level of the sensitising moiety is higher 
than that of the Ln(III). In the case of Eu(III), which has a 5D0 excited state energy of 17,277 cm
-1, a 
phenyl group’s triplet excited state is usually between 20,000 and 30,000 cm-1, and therefore 
sensitised emission would be expected.86 
Based on the availability of starting materials for the benzyl moiety, it was decided to utilise a benzyl 
compound, (4-aminomethyl-phenyl)methanol (22). The synthesis of the novel ligand L2 is outlined in 
Scheme 3.10. 4-Aminomethyl-phenyl-methanol is a costly starting material (£325.39/mmol from 
Sigma Aldrich, August 2014), however, it can be synthesised from 4-cyanobenzaldehyde 
(£0.76/mmol from Sigma) via the reduction with LiAlH4 according to a literature protocol.
110,111 This 
reaction gave 22 in moderate yields (60 – 85 %), slightly lower than in literature (96 %). 
Characterisation by 1H and 13C{1H} NMR were comparable to the literature, with EI-MS also 
confirming successful preparation of 22. Protection of the alcohol group with tert-butyl dimethyl silyl 
(TBDMS) to give 23 was carried out, with the protocol based on similar literature methods to protect 
alcohols.112 23 was characterised by 1H and 13C{1H} NMR and ESI-MS and were in accordance with 
literature. Reaction of the amine with chloroacetyl chloride gave a reactive chloroacetyl amide 
species 24 characterised by 1H and 13C{1H} NMR which was assigned by 2D HMQC spectroscopy. 
However, mass spectrometry of 24 did not give the molecular ion, possibly due to the highly reactive 
nature of the chloroacetyl moiety. 
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Scheme 3.10 Synthesis of L2 via (4-aminomethyl-phenyl)methanol. Reagents and conditions: a) LiAlH4, THF, 
reflux. b) TBDMS-Cl, imidazole, DMF, 0 °C. c) chloroacetyl chloride, NEt3, DCM, RT. d) DO3A-
t
Bu, K2CO3, MeCN, 
reflux. e) TFA, DCM, RT. f) TsCl, pyridine, RT. g) NaN3, DMF, 60 °C. 
 
The addition of 24 to DO3A-tBu was based on literature protocols,91 and gave 25, which was 
characterised by 1H NMR and ESI-MS. Deprotection of the TBDMS and tert-butyl groups with 
trifluoroacetic acid (TFA) gave the macrocycle 26 which was water-soluble. 1H NMR of 26 showed 
loss of the tert-butyl signals from the protecting groups and the ESI-MS spectrum showed the 
molecular ion peak at 524.27 [M + H]+.  The reaction to convert the OH to a tosylate group to allow 
for subsequent azide substitution proved difficult due to solubility issues. The macrocycle was not 
soluble in DCM or most other water immiscible organic solvents, so the reaction was carried out in 
pyridine. However, purification was difficult as the pyridine removal was purely by evaporation in 
vacuo and was never fully removed even after extended drying. Characterisation by 1H NMR showed 
traces of pyridine, as well as the product peaks, but also traces of unreacted starting material. 
Attempts at washing away the unreacted starting materials and pyridine with DCM, as well as 
passing the compound down a sephadex column were unsuccessful. The azidation reaction was 
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attempted on crude 27 but this was also unsuccessful as the unreacted azide was not possible to be 
removed with an aqueous work up.  
Due to the difficulties in synthesising L2 via this method, the azide benzyl arm synthesis via 
dibromobenzene was investigated (Scheme 3.11). Conversion of 1,4-bis(bromomethyl)benzene (or 
dibromo xylene) to a diazide species (28) was followed by mono reduction of an azide to an amine 
(29) using literature methods.113 The amine is then reacted with chloroacetyl chloride to form a 
reactive chloro-alkyl amide species (30) that can be attached to DO3A.  
 
Scheme 3.11 Synthetic route towards the modified azido-DOTA target macrocycle via 1,4-
bis(bromomethyl)benzene. Reagents and conditions: a) NaN3, DMF, 60 °C. b) PPh3, 1M HCl/Et2O, RT. c) 
chloroacetyl chloride, NEt3, DCM, RT. d) DO3A-
t
Bu, K2CO3, MeCN, reflux. e) TFA, DCM, RT. 
 
Using a literature method where two equivalents of sodium azide was used, 1,4-
bis(bromomethyl)benzene species was converted to the diazido species (28).114 The reaction was 
high yielding (86 %) and did not require further purification after aqueous workup. Characterisation 
by 1H NMR and ESI-MS was in accordance with literature. The subsequent reaction to convert one of 
the azide groups to an amino group was also carried out according to literature, via the Staudinger 
reaction.113 It involved a two phase reaction with diethyl ether and 1 M HCl, and 1.3 equivalents of 
triphenylphosphine as a reducing agent. As the reduction of one azide was completed, the desired 
product (29) was taken up into the HCl layer. This reaction to give 29 gave moderate yields (38 % 
compared to literature yield of 60 %) but after an aqueous workup, no further purification of the 
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product obtained was required. Purity was confirmed by 1H NMR and ESI-MS as well as elemental 
analysis, and these data were in accordance with literature.  
The next stage was to react 29 with chloroacetyl chloride to give 30, which has not previously been 
reported. The reaction was extremely high yielding (>90 %), needing no further purification after 
workup. The purity of 30 was confirmed by CI-MS and elemental analysis. Finally, 1.5 equivalents of 
30 was reacted with DO3A-tBu in the presence of K2CO3 to give 31. From the 
1H and 13C{1H} NMR 
spectra, the desired product was successfully synthesised. High resolution ESI-MS shows the 
molecular ion peak at 717.4674 [M + H]+, and purity was confirmed by elemental analysis. 
Subsequent deprotection of the tBu groups with TFA gave L2 (32) which was characterised by the 
loss of the tBu signals in the 1H NMR, and high resolution ESI-MS with the molecular ion peak for 
[M+H]+ at m/z = 549.2788. Elemental analysis was attempted but did not give satisfactory values 
most likely due to the presence of salts after the deprotection with TFA. 
Complexation of L2 with Eu and Tb was carried out. In a typical complexation reaction, a slight 
excess (1.2 eq) of the metal salt was added to the DOTA ligand and the pH of the solution adjusted 
to 5.5. The reaction mixture was left to stir overnight. The pH of the solution was raised to around 10 
to precipitate any unreacted metal which was filtered off. The filtrate was concentrated and then 
purified by passing through a sephadex G-10 column to remove any salts.  
 
Scheme 3.12 Complexation of the modified azido-DOTA L2 with M = Eu, Tb, Gd. 
 
a) Characterisation of the Ln.L2 complexes 
The gadolinium complex Gd.L2 (35) was isolated as a pale yellow solid. High resolution ESI-MS gave 
an [M + H]+ peak at m/z = 704.1820 with the correct isotope splitting pattern for a Gd(III) complex. 
Relaxivity for 35 was found to be 4.70 mM-1 s-1, and is comparable to the relaxivity of 16 (Gd.L1) and 
Gd-DOTA.  
The europium complex Eu.L2 (33) was isolated as a pale yellow solid. High resolution ESI-MS gave an 
[M + H]+ peak at m/z = 697.1766 with the correct isotope splitting pattern for a Eu(III) complex. An 
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extended sweep-width 1H NMR of the complex was recorded (Figure 3.19) showing signals between -
20 and +36 ppm and is as expected for Eu-DOTA-type complexes. Like Eu.L1 (14), the SAP isomer was 
again predominantly present.  
 
Figure 3.19 Extended sweep-width 
1
H NMR spectrum of Eu.L2 (D2O, 400 MHz, 250 to -250 ppm). 
 
As with the triazole formed with the cyclised Eu and Tb L1 complexes (18 and 19), the benzyl group 
in L2 is also expected to act as an antenna for the lanthanide emission. The excitation spectrum was 
monitored at λem = 595 nm (ΔJ = 1 transition) and showed an intense indirect sensitisation at λex 
255 nm, with a much weaker peak at λex 395 nm. The emission spectrum of 33 (Figure 3.20) was 
recorded at both excitation wavelengths, 255 nm (excitation of the benzyl group) and 395 nm 
(pseudo direct excitation of the Eu(III) centre). Both emission spectra gave the spectral lines for a 
Eu(III) complex, with the 255 nm emission having more defined spectral lines than at 395 nm. The 
signal intensity at 255 nm is also higher than when excited at 395 nm, confirming that there is 
energy transfer from the benzyl group to the Eu centre.  
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Figure 3.20 Emission spectra of 33 at λex 255 nm (top) with 2.5/2.5 slits, and 395 nm (bottom) 10/10 slits. The 
excitation spectrum corresponds to λem 595 nm. The 255 nm spectrum was recorded at smaller slits as higher 
slit gave a signal intensity >1000 that was not plottable. Samples recorded in H2O, 100 μM, 298 K, pH 7.4. 
 
The terbium complex Tb.L2 (34) was isolated as a pale yellow solid. High resolution ESI-MS gave an 
[M + H]+ peak at m/z = 705.1802. The excitation spectrum was monitored at λem = 545 nm (ΔJ = 1 
transition) and showed a maximum at λex 255 nm, but no peak at 355 nm. Nevertheless, the 
emission spectrum of 34 (Figure 3.21) was recorded at both wavelengths, 255 nm (excitation of the 
benzyl group) and 355 nm (pseudo direct excitation of the Tb(III) centre). Both emission spectra gave 
the expected spectral shape for Tb complex, with the various 5D4 → 
7FJ (J = 3 – 6) transitions. The 
emission spectrum at 255 nm has a higher intensity emission than 355 nm for the same slit (10/10) 
with the 255 nm emission going over the range (>1000) of recorded intensity. Therefore for the 
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255 nm graph (Figure 3.21), it is a plot of the emission at slit 2.5/2.5 which reduced the maximum 
intensity of the emission spectrum to an intensity that was plottable. This increase in intensity 
confirms that there is energy transfer from the benzyl group to the Tb centre.  
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Figure 3.21 Emission spectra of 34 at λex 255 nm (top) with 2.5/2.5 slits, and 355 nm (bottom) 10/10 slits. The 
excitation spectrum corresponds to λem 545 nm. The 255 nm spectrum was recorded at smaller slits as higher 
slit gave a signal intensity >1000 that was not plottable. Samples recorded in H2O, 100 μM, 298 K, pH 7.4. 
 
Luminescence decays of both 33 and 34 in H2O and D2O were measured. From the lifetime 
measurements, both 33 and 34 have hydration states close to 1 (Table 3.9), showing that both 
complexes are eight coordinate and will bind one water molecule. 
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Complex τH2O/ms kH2O/ms
-1 
τD2O/ms kD2O/ms
-1 
q 
33 0.63 1.59 1.93 0.52 0.90 
34 1.98 0.51 3.32 0.30 0.72 
Table 3.9 Lifetimes, rate constants and derived hydration states for 33 and 34. 
 
b) Small molecule cycloaddition reaction of M.L2 complexes to cyclooctyne 
 
Scheme 3.13 Cycloaddition reaction between M.L2 and cyclooctyne 13. 
 
Like the M.L1 complexes, M.L2 were also reacted with 13 in a copper-free cycloaddition reaction 
(Scheme 3.13). Fluorescence spectroscopy of 36 (Figure 3.22) and 37 (Figure 3.23) showed little to no 
change after the cycloaddition reaction, in both the excitation and emission spectra. The excitation 
spectra for 36 was obtained by monitoring at λem 595 nm, while for 37 this was at λem 545 nm. Both 
showed increased intensity for the λex 255 nm peak, which is most likely a contribution from the 
aromatic benzyl unit and possibly the triazole too. The emission spectra for both 36 and 37 at 255 
nm, and also at 395 nm (for 36 - Eu) and 355 nm (for 37 - Tb), were similar to the pre-cyclised 
species, with the 255 nm emission spectrum for 36 having higher intensity and more defined 
spectral shape. As previously discussed, sensitised emission is affected by the distance between the 
chromophore and the Ln(III) centre, and if the triazole formed during the cycloaddition reaction is 
far enough away from the Ln(III) centre, the spectra of the cyclised species should see very little 
change. 
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Figure 3.22 Emission spectra of 36 at λex 255 nm (top), and λex 395 nm (bottom). Excitation spectra in both 
were recorded for λem 595 nm. Samples recorded in H2O, 100 μM, 298 K, pH 7.4. 
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Figure 3.23 Emission spectra of 37 at λex 255 nm (top), and λex 395 nm (bottom). Excitation spectra in both 
were recorded for λ 545 nm. Samples recorded in H2O, 100 μM, 298 K, pH 7.4. 
 
36, 37 and 38 were also characterised by MALDI-MS (Table 3.10). High resolution ESI-MS was 
attempted, but no molecular ion or fragment peaks were observed.   
Complex Calc. m/z Found m/z 
36 880.3 881.3 
37 886.3 887.3 
38 885.4 886.4 
Table 3.10 m/z values for the cyclised complexes 36 - 38. 
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3.4.5 Copper-free cycloaddition reaction between Ln.L2 to NP-alkyne 
The copper-free cycloaddition reaction between the Ln.L2 complexes (Ln = Eu, Tb, Gd) and NP12 
(NP-alkyne) were carried out (Scheme 3.14), as previously with Ln.L1 and NP12, and fluorescence 
spectroscopy of the nanoparticles recorded, to determine if there would be any enhanced emission 
from the lanthanide conjugated to the nanoparticle. 
 
Scheme 3.14 Copper-free cycloaddition reactions between NP12 and Ln.L2 (Ln = Eu, Tb, Gd). 
 
As before, emission spectra for NP17 (Eu species) showed that there was an unexpected well 
defined emission from the nanoparticles when excited at 395 nm, but not the expected emission 
from the Eu(III) centre (Figure 3.26). When excited at 375 nm (Figure 3.25), the spectra show some 
similarities to the expected emission from a terbium metal centre (transitions at 490, 545, 580 and 
610 nm), although much less defined. When the NPs were excited at 255 nm (Figure 3.24), neither 
the Eu nor Tb spectral shape was observed. The same spectral pattern was observed for all the NP 
species at the specific wavelengths, including when the lanthanide centre was gadolinium, when 
there was no Ln centre, as well as for NP2 (alendronate) and NP12 (alkyne).  
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Figure 3.24 Emission spectrum of all the NP species at λex 255 nm, H2O, 0 ms delay, slits 10:10, 0.5 mg/mL Fe, 
pH 7, 25
 o
C. 
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Figure 3.25 Emission spectrum of all the NP species at λex 255 nm, H2O, 0 ms delay, slits 10:10, 0.5 mg/mL Fe, 
pH 7, 25
 o
C. 
Chapter 3: Further functionalisation of the nanoparticles 
 
150 
 
500 600 700
In
te
n
s
it
y
 (
a
.u
.)
Wavelength (nm)
 NP2
 NP12
 NP17
 NP18
 NP19
 NP20
emission at 
ex
 395 nm
 
Figure 3.26 Emission spectrum of all the NP species at λex 395 nm, H2O, 0 ms delay, slits 10:10, 0.5 mg/mL Fe, 
pH 7, 25
 o
C. 
 
The same emission spectral shape was observed for each NP species at a specific wavelength, and 
this emission spectral shape changes in the same way for all the NP species when the excitation 
wavelength applied is changed. This suggests that the emission observed is most likely not due to 
the lanthanide complex conjugated to the nanoparticle, but rather emission from the nanoparticle 
itself. This is similar to results observed by Fei et al where shifts in the emission peaks are observed 
for different excitation wavelengths.100 They describe nanosized particles as having a large number 
of lattice defects on the particle surface and when organic molecules are bound to the surface the 
electronic structure of the whole particle changes. As a result, the 4s and 4p states (over the 3d 
states) have an increased probability of being populated, and of being involved in energy transition 
to give emission. This could explain the spectral patterns observed for all the nanoparticle species, 
even when the surface molecules differ. However, in order to confirm this, further experiments on 
more sophisticated instruments with a high powered laser are required.  
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3.5 Conclusion 
The functionalisation of NP2 with PEG for biocompatibility purposes, and also with a cyclooctyne for 
pretargeted click reaction, were carried out. The PEGylated and alkyne functionalised nanoparticles 
were characterised by IR spectroscopy and colourimetric assays to determine yields and availability 
of reactive functional groups on the NP surface. Both NP2-PEG (NP3 – NP11) and NP2-alkyne (NP12) 
were successful but with variable yields. Even with an excess of reactants, the coupling yield of the 
alkyne was quite low, but this was due to the resultant low-solubility of the nanoparticle when a 
large excess was utilised.  
Copper-free cycloaddition reactions of the NP2-alkyne species with the azide-DOTA (L1) were 
characterised by following the luminescence of the Eu(III) and Tb(III) L1 complexes once on the 
nanoparticle. Unexpected results were obtained which suggested the emission observed was from 
the nanoparticles as opposed to the lanthanide, even though presence of the lanthanide was 
confirmed by ICP-MS. Modification to the DOTA chelate (to give the novel compound L2) and 
subsequent click reactions with the Ln.L2 complexes to NP2-alkyne still gave emission spectra that 
suggests nanoparticle luminescence. Unfortunately, due to time constraints, conjugation of the 
nanoparticles to the gallium-68 analogue of the azide-DOTA macrocycles (L1 and L2) were not 
carried out. 
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3.6 Experimental 
Syntheses of ligands were carried out under nitrogen unless stated otherwise. Chemical reagents 
were purchased from Sigma-Aldrich, TCI-UK, or VWR (Alfa Aesar). dPEG’s were obtained from both 
Quanta Biodesign and Iris Biotech. All the reagents were used as received without further 
purification. Dry solvents were obtained from the Imperial College Chemistry Department dry 
solvent towers which dried the solvents over alumina beads. All other solvents were analytical grade 
and were obtained from VWR. EDC couplings were carried out in MilliQ water under ambient 
conditions. Composition analysis of the nanoparticles was carried out by Dr Stanislav Strekopytov at 
the Natural History Museum, London on an ICP-MS (Agilent 7700x ICP-MS). UV-Vis spectra were 
recorded in a Perkin-Elmer Lambda 25 UV-Vis system. Fluorescence spectra were recorded in 
aqueous solutions on a Cary Varian luminescence spectrometer. Samples were held in 10 mm × 
4 mm quartz Hellma cuvettes. FT-IR spectra were acquired in a Perkin-Elmer Spectra 100 FT-IR 
spectrometer, neat on ATR plates. 1H NMR spectra and T1/T2 inversion recovery data were obtained 
in a Bruker DRX400 MHz spectrometer. Z-measurements were obtained in a Beckman Coulter 
Delsa™ Nano.  
 
3.6.1 Synthesis of PEGylated NP2 
a) NP-PEGn-NH2 (NP6, NP7, NP8) 
 
To NP2 in MilliQ water (0.5 mg NP, 1.43 nmol, typically about 250 μL from a 2.0 mg/mL NP solution) 
was added HOOC-PEGn-NH(fmoc) (300 eq) in the presence of EDC (excess). After overnight reaction, 
the mixture was centrifuged and the supernatant decanted. The black pellet was suspended in a 
piperidine/DMF (20/80) mixture for 15 mins, to remove the Fmoc group on the amine. This was 
followed by addition of acetone to precipitate the nanoparticles. The alternating piperidine/DFM 
and acetone steps were repeated three times in total to give the free amine, and the final 
nanoparticles were resuspended in water (250 μL). 
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b) NP-PEGn-OH (NP3, NP4, NP5) 
 
To NP2 in MilliQ water (0.5 mg NP, 1.43 nmol, typically about 250 μL from a 2.0 mg/mL NP solution) 
was added HOOC-PEGn-OH (300 eq) in the presence of EDC (excess). After overnight reaction, the 
mixture was centrifuged and the supernatant decanted. The black pellet was suspended in water 
and washed by precipitation with acetone. This was repeated three times and the resultant 
nanoparticles were resuspended in water (250 μL).  
 
c) NP-PEGn-COOH (NP9, NP10, NP11) 
 
Succinic anhydride (5 – 10 mg, excess) in water (250 μL) was adjusted to pH 8 with KOH. To this was 
added NP-PEGn-NH2 in water (0.5 mg NP, 250 μL). The pH was adjusted again to pH 8 and the 
mixture left to react for 1 hour. At the end of the reaction, the mixture was washed three times by 
precipitation with acetone, and the resultant nanoparticles were resuspended in water. 
 
3.6.2 Synthesis of the strained alkyne 
The following procedures to synthesise 11, 12 and 13 were according to a literature method, with no 
modifications.81 
a) 8,8-Dibromobicyclo[5.0.1]octane (11) 
 
Cycloheptene (1.00 g, 10.40 mmol) was dissolved in dry pentane (5 mL). Potassium tert-butoxide 
(2.33 g, 20.80 mmol, 2.0 eq) was added under nitrogen. The mixture was cooled to -10 °C and the 
addition of bromoform (3.94 g, 15.60 mmol, 1.5 eq) gave a brown mixture which was stirred at room 
temperature overnight. Water (50 mL) was then added and neutralised with 1 M HCl (approx. 1 mL). 
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The aqueous phase was washed with pentane (3 x 20 mL), the pentane layers combined and washed 
with water (3 x 20 mL), dried over MgSO4 and concentrated in vacuo to give a yellow-orange oil. This 
was purified by passing through a short silica column (95:5 cyclohexane/EtOAc) to give a clear oil 
(1.20 g, 4.51 mmol, 43 % yield). 1H NMR (400 MHz, CDCl3): δ 2.24 – 2.31 (2H, m), 1.80 – 1.95 (3H, m), 
1.69 – 1.79 (2H, m), 1.32 – 1.41 (2H, m), 1.10 – 1.28 (3H, m). EI-MS (m/z): 266 [M]+. 
 
b) Methyl 2-bromocyclooct-1-en-3-glycolate (12) 
 
8,8-Dibromobicyclo[5.0.1]octane (1.00 g, 3.76 mmol) and methyl glycolate (2.61 mL, 33.84 mmol) 
were dissolved in anhydrous toluene (5 mL) and protected from light by aluminium foil and N2. 
AgClO4 (1.56 g, 7.52 mmol) was added under N2 flow and stirred at room temperature for 1.5 h. 
Silver salts were then filtered and washed with EtOAc. The filtrate was concentrated and the residue 
purified immediately by column chromatography on silica (2-15 % EtOAc/cyclohexane) to give the 
product as a yellow oil (0.51 g, 1.83 mmol, 49 % yield). 1H NMR (400 MHz, CDCl3): δ 6.25 (1H, dd, 
3JH-H 
= 4.06, 11.56 Hz), 4.27 (1H, d, 2JH-H = 16.1 Hz), 4.15 (1H, dd, 
3JH-H = 4.83, 10.17 Hz), 4.01 (1H, d, 
2JH-H = 
16.1 Hz), 3.79 (3H, s), 0.79 – 2.81 (10H, m). ESI-MS (m/z): 299 [M + 23]+. 
 
c) Cyclooct-1-yn-3-glycolic acid (13) 
 
Methyl 2-bromocyclooct-1-en-3-glycolate (0.50 g, 1.81 mmol) was dissolved in anhydrous DMSO (2 
mL and 0.5 M NaOMe solution (24 mL) and stirred overnight. The methanol was removed in vacuo 
and the dark yellow residue taken up in DCM and 1 M HCl added until the solution was pH 4. The 
phases were separated and the aqueous phase extracted further with DCM. The combined DCM 
layers were concentrated and purified by column chromatography (silica, 0-8 % MeOH/DCM) to yield 
a pale yellow oil (0.18 g, 1.01 mmol, 56 % yield). 1H NMR (400 MHz, CDCl3): δ 9.10 (1H, br s, Hacid), 
4.30 – 4.63 (1H, m), 4.19 (1H, d, 2JH-H = 16.8 Hz), 4.03 (1H, d, 
2JH-H = 16.8 Hz), 1.30 – 2.30 (10H, m). 
13C{1H} NMR (100 MHz, CDCl3): δ 172.29, 101.06, 91.72, 72.67, 65.89, 42.17, 40.78, 34.23, 29.62, 
26.24, 20.65. CI-MS (m/z): 200 [M + NH4]
+.  
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3.6.3 Synthesis of NP2-alkyne (NP12) 
 
NP2 (0.5 mg NP, 1.43 nmol, typically about 250 μL from a 2.0 mg/mL NP solution) was adjusted to 
pH 8. The cyclooctyne 2.3 (0.078 mg, 0.43 μmol) was dissolved in MeOH (20 μL) and added to the 
nanoparticle solution. EDC (about 5 mg, excess) was added and the mixture left to shake overnight. 
The nanoparticles were precipitated out with acetone, centrifuged, and the supernatant decanted. 
This was repeated three times. Finally, the resultant nanoparticles were resuspended in water 
(250 μL). 
 
3.6.4 Complexation of L1 to M (M = Eu, Tb, Gd, Ga) 
a) Synthesis of Eu.L1(14) 
 
Ligand L1 (11.10 mg, 0.0186 mmol) was dissolved in MilliQ water (1 mL) and the pH adjusted to 5.5 
with 0.5 M KOH. EuCl3.6H2O (8.87 mg, 0.024 mmol, 1.3 eq) was added slowly, while maintaining the 
pH at 5.5. The mixture was stirred overnight. Unreacted Eu3+ was precipitated as Eu(OH)3 by the 
addition of 0.5 M KOH (pH of mixture at 10). The precipitate was separated from the supernatant by 
centrifugation. The supernatant was concentrated in vacuo, and the residue passed down a 
Sephadex G-10 column. Fractions containing the compound were tested for free metal by the 
xylenol orange test.115 Metal-free fractions were combined and the solvent removed by 
lyophilisation. Eu.L1 was obtained as a white solid (8.50 mg, 0.013 mmol, 72 %). ESI-HRMS calc. for 
C19H31EuN8O7 637.1606 found (m/z):  637.1610 [M + H]
+.  
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b) Synthesis of Tb.L1(15) 
 
Tb.L1 was synthesised according to the same method as the Eu analogue. L1 (12.30 mg, 0.021 mmol) 
and TbCl3.6H2O (10.02 mg, 0.026 mmol, 1.3 eq) were used. The complex was obtained as a white 
solid (9.50 mg, 0.0148 mmol, 72 %). ESI-HRMS calc. for C19H31N8O7Tb 643.1647 found (m/z):  
643.1656 [M + H]+.   
 
c) Synthesis of Gd.L1(16) 
 
Gd.L1 was synthesised according to the same method as the Eu analogue. L1 (11.60 mg, 
0.019 mmol) and GdCl3.6H2O (9.41 mg, 0.025 mmol, 1.3 eq) were used. The complex was obtained 
as a white solid (12.00 mg, 0.0187 mmol, 96 %). ESI-HRMS calc. for C19H31GdN8O7 642.1635 found 
(m/z):  642.1655 [M + H]+. 
 
d) Synthesis of Ga.L1(17) 
 
Ga.L1 was synthesised according to the same method as the Eu analogue, with the exception that 
the pH was adjusted to 4.5 instead. L1 (10.00 mg, 0.017 mmol) and anhydrous GaCl3 (5.90 mg, 0.034 
mmol, 2.0 eq) were used. The complex was obtained as a white solid (7.50 mg, 0.014 mmol, 80 %). 
ESI-HRMS calc. for C19H31GaN8O7 553.1650 found (m/z):  553.1637 [M + H]
+. 1H NMR (400 MHz, D2O): 
δ 8.34 (1H, t, 3JH-H = 6.22 Hz, NH), 3.94 – 4.10 (4H, m, CH2 propyl chain), 3.91 (4H, m, macrocycle CH2 
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adjacent to propyl azide arm), 3.70 (2H, s, α-CH2 on azide arm), 3.57 (4H, s, CH2 on carboxylate arm 
trans to each other), 3.55 (2H, s, CH2 on carboxylate arm trans to azide arm), 3.26 – 3.45 (12H, m, 
macrocycle ring CH2), 1.82 (2H, m, middle CH2 on propyl chain). 
 
3.6.5 Synthesis of modified azido-DOTA 
a) Synthesis of 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane 
hydrobromide (DO3A-tBu ester) 116,117 
 
DO3A-tBu ester was synthesised according to literature method.116,117 Cyclen (1.00 g, 5.81 mmol) 
and sodium acetate (1.57 g, 19.16 mmol) was suspended in N,N-dimethylacetamide (15 mL). The 
mixture was cooled to -20 °C. In a separate flask, tert-butyl bromoacetate (3.74 g, 4.31 mL, 19.16 
mmol) was dissolved in DMA (4 mL) and added dropwise over 30 min to the suspension of cyclen 
after which the reaction mixture was allowed to warm to room temperature and stirred for 24 h. A 
white precipitate formed during the reaction. After 24 h, the reaction mixture was added to water 
(90 mL) to give a clear yellow solution. NaHCO3 was added with stirring. Effervescence was observed 
and an off-white precipitate formed over time. This was filtered under suction and the solid 
dissolved in chloroform (50 mL). The yellow solution was washed with water (2 x 30 mL), dried over 
MgSO4, filtered then concentrated to about 2-3 mL. Ether (approx. 50 mL) was added which 
precipitated a white solid that was filtered under suction to give DO3A-tBu.HBr (1.71 g, 2.88 mmol, 
83 % yield). 1H NMR (400 MHz, CDCl3): δ 10.05 (1H, br s, NH), 3.39 (4H, s, CH2 
tBu arms), 3.30 (2H, s, 
CH2 middle 
tBu arm), 3.12 (4H, m, CH2 ring H), 2.92 (12H, m, CH2 ring H), 1.47 (27H, s, 
tBu H). 13C{1H} 
NMR (100 MHz, CDCl3): δ 171.3, 162.5, 80.9, 57.3, 52.1, 50.7, 47.6, 36.5, 31.4, 28.3. ESI-MS (m/z): 
515 [M – HBr + H]+, 459 [M – HBr – tBu + H]+. 
 
b) Synthesis of 4-(aminomethyl)benzyl alcohol (22)110,111 
 
22 was synthesised according to literature method.110,111 4-Cyanobenzaldehyde (1.0 g, 7.67 mmol, 
1 eq) in dry THF (10 mL) was added dropwise via a pressure-equalising funnel under nitrogen to a 
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suspension of LiAlH4 (1.75 g, 46.02 mmol, 6 eq) in THF (20 mL) at 0 °C. The mixture was heated to 
reflux and stirred for 5 hours, before cooling again to 0 °C and quenching with H2O (2 mL), 15 % 
NaOH (4 mL) and H2O again (6 mL). After stirring overnight at room temperature, the mixture was 
filtered on a pad of celite and washed through with EtOAc. Solvent was evaporated to give the 
desired compound 4-(aminomethyl)benzyl alcohol as a white solid (0.85 g, 6.21 mmol, 82 %). 1H 
NMR (400 MHz, CDCl3): δ 7.28 (4H, m, aromatic H), 4.65 (2H, s, -CH2-OH), 3.82 (2H, s, CH2-NH2). 
13C{1H} NMR (100 MHz, CDCl3): 127.3, 65.2, 46.2. EI-MS (m/z): 137 [M + H]
+. 
 
c) Synthesis of 4-(aminomethyl)benzyl TBDMS ether (23) 112,117 
 
23 was synthesised by a variation of literature methods.112,117 A solution of 4-(aminomethyl)benzyl 
alcohol (0.25 g, 1.82 mmol) and imidazole (0.31 g, 4.56 mmol) in DMF (10 mL) was cooled to 0 °C and 
TBDMS-Cl (0.30 g, 2.00 mmol) was added. The mixture was stirred at room temperature overnight. 
The reaction mixture was diluted with ethyl acetate, washed with H2O (3 x 15 mL) and brine (2 x 20 
mL). The organic layer was dried over anhydrous magnesium sulphate, filtered and concentrated in 
vacuo, to give 15 as a yellow oil (0.63 g, 2.76 mmol, 91 %). 1H NMR (400 MHz, CDCl3): δ 7.29 (4H, m, 
aromatic H), 4.75 (2H, s, -CH2-OTBDMS), 3.87 (2H, s, CH2-NH2), 1.60 (2H, br s, NH2), 0.96 (9H, s, 
tBu 
H’s TBDMS), 0.12 (6H, s, Me H’s TBDMS). 13C{1H} NMR (100 MHz, CDCl3): 142.0, 140.0, 127.0, 126.3, 
64.8, 46.3, 26.0, 18.4 , -5.2. ESI-HRMS calc. for C14H25NOSi – MeCN adduct 293.2049 found (m/z): 
293.2044 [M-MeCN adduct + H]+. 
 
d) Synthesis of 4-(2-chloro-N-methylacetamide)benzyl TBDMS ether (24) 
 
24 is a new compound, and was formed by reacting 23 with the acylating agent chloroacetyl 
chloride. 23 (0.35 g, 1.37 mmol) and NEt3 (0.15 g, 0.21 mL, 1.51 mmol) were dissolved in DCM (10 
mL) and cooled to 0 °C. This mixture was added dropwise, cold, to a solution of chloroacetyl chloride 
(0.17 g, 0.12 mL, 1.51 mmol) in DCM (3 mL). The reaction mixture was stirred for 2 hours, after 
which solvent and volatiles were evaporated in vacuo. The residue was dissolved in DCM and 
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washed with H2O (10 mL). The organic layer was dried over MgSO4, filtered and solvent evaporated 
to give 24 as a white solid (0.33 g, 1.00 mmol, 73 %). 1H NMR (400 MHz, CDCl3): δ 7.31 (4H, m, 
aromatic H), 6.87 (1H, br s, NH), 4.76 (2H, s, CH2-OTBDMS), 4.51 (2H, d, 
3JH-H = 5.60 Hz, -CH2-Cl), 4.13 
(2H, s, -CH2-NH2), 0.96 (9H, s, 
tBu H’s TBDMS), 0.12 (6H, s, Me H’s TBDMS). 13C{1H} NMR (100 MHz, 
CDCl3): 165.9, 141.2, 135.7, 127.8, 126.5, 64.6, 43.7, 42.6, 26.0 18.4, -5.2. IR (ν/cm
-1): 1651 (C=O), 
3278 (NH). ESI-HRMS calc. for C16H27NO2Si 293.2049 found (m/z): 293.2086 [M + H]
+. 
 
e) Synthesis of 2591 
 
25 is a new compound, and was synthesised following similar protocols from literature.91 1,4,7-
Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane hydrobromide (0.36 g, 0.61 mmol) 
was dissolved in acetonitrile (20 mL). K2CO3 (0.42 g, 3.05 mmol) was added and the suspension 
stirred for 30 mins before the addition of 24 (0.30 g, 0.92 mmol). The reaction mixture was heated to 
reflux overnight. When cooled to room temperature, the base and salts were filtered off, and the 
filtrate evaporated. The residue was dissolved in DCM, washed with water then dried over MgSO4, 
filtered and solvent evaporated to give 25 as a pale yellow oil (0.36 g, 0.44 mmol, 73 %). 1H NMR 
(400 MHz, CDCl3): δ 7.29 (4H, m,
 aromatic H), 4.68 (2H, m, -NH-CH2-benzyl), 4.38 (2H, m, -CH2-
OTBDMS), 2.40 – 3.44 (24H, m, CH2 backbone and those closest to the macrocycle, on arms), 1.45 
(18H, s, tBu on arms trans to each other), 1.43 (9H, s, tBu on arm trans to chromophore arm), 0.91 
(9H, s, tBu on TBDMS), 0.08 (6H, s, Me H’s on TBDMS). 13C{1H} NMR (100 MHz, CDCl3): 171.8, 171.7, 
128.0, 127.8, 127.1, 126.0, 82.0, 81.9, 81.6, 64.8, 58.0, 56.4, 42.7, 28.2, 28.0, 26.0, 18.4, -5.2. 
ESI-HRMS calc. for C42H76N5O8Si 806.5463 found (m/z): 806.5482 [M + H]
+. 
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f) Synthesis of 26 
 
25 (0.30 g, 0.37 mmol) was dissolved in DCM (2 mL) and trifluoroacetic acid added dopwise. The 
solution was stirred under nitrogen for 24 h. The solvents were removed in vacuo. The residue was 
taken up in DCM and then evaporated. This was repeated with ether, and again with DCM to give 26 
as a pale yellow sticky solid (0.18 g, 93 %). 1H NMR (400 MHz, D2O): δ 7.38 (4H, m, aromatic H), 3.85 
– 4.24 (6H, m, CH2 on benzyl arm), 2.62 – 3.83 (22H, CH2 on backbone and on COOH arms). 
13C{1H} 
NMR (100 MHz, D2O): 173.7, 163.0, 162.6, 162.3, 139.4, 127.7, 120.4, 117.4, 114.6, 63.5, 52.0, 42.8. 
ESI-HRMS calc. for C24H38N5O8 524.2720 found (m/z): 524.2709 [M + H]
+. 
 
g) Synthesis of 1,4-bis(azidomethyl) benzene (28) 114 
 
28 was synthesised according to a literature method.114 1,4-Bis(bromomethyl)benzene (0.50 g, 1.89 
mmol, 1 eq) was dissolved in dry DMF (10 mL) and NaN3 (0.25 g, 3.79 mmol, 2 eq) added. The 
mixture was heated at 60 °C overnight. At the end of the reaction, water (20 mL) was added to 
quench the reaction. The product was extracted with diethyl ether (3 x 15 mL). The combined 
organic extracts were washed with water (3 x 15 mL), then dried over MgSO4 and evaporated to 
dryness to give 28 as a pale yellow oil (0.31 g, 1.64 mmol, 86 %). No further purification was 
necessary. 1H NMR (400 MHz, CDCl3): δ 7.38 (4H, s, aromatic H), 4.39 (4H, s, -CH2-N3). 
13C{1H} NMR 
(100 MHz, CDCl3): 135.5, 128.7, 54.4. IR (ν/cm
-1): 2086 (N3). EI-MS (m/z): 188 [M]
+. Anal. Calc. for 
C8H8N6: C, 51.06; H, 4.28; N, 44.66. Found: C, 51.15 H, 4.21; N, 44.48.  
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h) Synthesis of 1-(aminomethyl)-4-(azidomethyl)benzene (29) 113 
 
29 was synthesised according to literature method.113 20 (0.30 g, 1.59 mmol) was suspended in a 
mixture of diethyl ether (8 mL) and 1 M HCl (6 mL). PPh3 (0.54 g, 2.08 mmol) was added and the 
heterogenous mixture stirred vigorously for 24 h. The layers were then separated and the aqueous 
layer extracted with ether (3 x 20 mL) to remove PPh3O and any remaining starting materials. The 
aqueous layer was basified to pH 10 by adding KOH solution (1 M), then extracted with DCM (4 x 20 
mL). The combined DCM extracts were washed with brine, dried over MgSO4, filtered and 
evaporated in vacuo to give the product 21 as a pale yellow oil (0.10 g, 0.62 mmol, 38 %). 1H NMR 
(400 MHz, CDCl3): δ 7.37 (2H, d, 
3JH-H = 8.14 Hz, aromatic H), 7.32 (2H, d, 
3JH-H = 8.14 Hz, aromatic H), 
4.35 (2H, s, -CH2-N3), 3.91 (2H, s, -CH2-NH2), 1.46 (2H, s, NH2). 
13C{1H} NMR (100 MHz, CDCl3): 143.5 (-
C-CH2-NH2), 133.8 (-C-CH2-N3), 128.5 (aromatic C), 127.6 (aromatic C), 54.6 (-CH2-N3), 46.2 (-CH2-
NH2). IR (ν/cm
-1): 2095 (N3), 3341 (NH2). CI-MS (m/z): 163 [M + H]
+, 180 [M + NH4]
+. Anal. Calc. for 
C8H10N4: C, 59.24; H, 6.21; N, 34.54. Found: C, 59.35 H, 6.25; N, 34.41.  
 
i) Synthesis of 1-(azidomethyl)-4-(2-chloro-N-methylacetamide)benzene (30) 
 
30 is a new compound, and was formed by reacting 29 with the acylating agent chloroacetyl 
chloride. 29 (0.14 g, 0.86 mmol) and NEt3 (0.10 g, 0.13 mL, 0.95 mmol) were dissolved in DCM (10 
mL) and cooled to 0 °C. This was added dropwise, cold, to chloroacetyl chloride (0.11 g, 76 L, 0.95 
mmol) in DCM (3 mL). The reaction mixture was stirred for 2 hours, after which solvent and volatiles 
were evaporated in vacuo. The residue was dissolved in DCM, washed with H2O (10 mL), organic 
layer dried over MgSO4, filtered and solvent evaporated to give 30 as a white solid (0.19 g, 0.83 
mmol, 96 %). 1H NMR (400 MHz, CDCl3): δ 7.33 (4H, s, aromatic H), 7.00 (1H, br s, NH), 4.52 (2H, d, 
3JH-H = 5.88 Hz, CH2-NH2), 4.35 (2H, s, -CH2-N3), 4.12 (2H, s, -CH2-Cl). 
13C{1H} NMR (100 MHz, CDCl3): 
165.9 (-C=O), 137.5 (quaternary C), 135.0 (quaternary C), 128.7 (aromatic C), 128.3 (aromatic C), 54.4 
(-CH2-N3), 43.5 (-CH2-NH-CO), 42.7 (-CH2-Cl). IR (ν/cm
-1): 1651 (C=O), 2091 (N3), 3278 (NH). CI-MS 
(m/z): 239 [M + H]+, 256 [M + NH4]
+. Anal. Calc. for C10H11N4OCl: C, 50.32; H, 4.65; N, 23.47. Found: C, 
50.40 H, 4.79; N, 23.31.  
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j) Synthesis of 31 
 
31 is a new compound, and was synthesised following similar protocols from literature.91 1,4,7-
Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane hydrobromide (0.68 g, 1.15 mmol) 
was dissolved in acetonitrile (20 mL). K2CO3 (0.24 g, 1.72 mmol) was added and the suspension 
stirred for 30 mins before the addition of 30 (0.30 g, 1.26 mmol). The reaction mixture was heated to 
reflux overnight. When cooled to room temperature, the base and salts were filtered off, and the 
filtrate evaporated. The residue was dissolved in DCM, washed with water then dried over MgSO4, 
filtered and solvent evaporated to give 23 as a pale orange oil (0.80 g, 1.12 mmol 89%). 1H NMR (400 
MHz, CDCl3): δ 9.12 (1H, t, 
3JH-H = 6.00 Hz, NH), 7.32 (2H, d,
 3JH-H = 7.89 Hz, aromatic H), 7.27 (2H, d,
 
3JH-H = 7.89 Hz, aromatic H), 4.50 (2H, d, 
3JH-H = 6.30 Hz, -CH2-NH-CO-CH2-macrocycle), 4.31 (2H, s, -
CH2-N3), 3.16 (2H, s, macrocycle-CH2-CONH-), 3.07 (4H, s, -CH2-COO
tBu trans to each other), 3.04 (2H, 
s, -CH2-COO
tBu trans to chromophore arm), 2.67 – 2.79 (12H, m, CH2 backbone), 2.48 – 2.56 (4H, m, 
CH2 backbone), 1.45 (27H, s, 
tBu H). 13C{1H} NMR (100 MHz, CDCl3): 172.2 (-CONH), 170.7 (-COO
tBu), 
139.7 (quaternary C), 133.9 (quaternary C), 128.4 (aromatic C), 128.1 (aromatic C), 57.9 (macrocycle-
CH2-CONH-), 56.5 (-CH2-COO
tBu trans to chromophore arm), 56.0 (-CH2-COO
tBu trans to each other), 
55.1 (CH2 backbone), 54.5 (-CH2-N3), 53.6 (CH2 backbone), 52.5 (CH2 backbone), 51.9 (CH2 backbone), 
42.6 (HN-CH2-aromatic), 28.2 (
tBu C). IR (ν/cm-1): 1651 (C=O), 2091 (N3), 3278 (NH). ESI-HRMS calcd. 
for C36H61N8O7 717.4663 found m/z 717.4674 [M + H]
+. Anal. Calc. for C36H60N8O7: C, 60.31; H, 8.44; 
N, 15.63. Found: C, 60.11; H, 8.32; N, 15.58. 
 
k) Synthesis of modified azide-DOTA [L2 (32)] 
 
31 (0.50 g, 0.697 mmol) was dissolved in DCM (2 mL) and trifluoroacetic acid added dopwise. The 
solution was stirred under nitrogen for 24 h. The solvents were removed in vacuo. The residue was 
taken up in DCM and then evaporated. This was repeated with ether, and again with DCM to give L2 
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(32) as a pale yellow sticky solid (0.35 g, 0.638 mmol, 92 %). 1H NMR (400 MHz, D2O): δ 7.32 (4H, m), 
2.81 – 3.97 (24H, m), 4.00 – 4.13 (2H, m), 4.22 – 4.39 (2H, m). 13C{1H} NMR (100 MHz, D2O): 173.4, 
168.8, 163.0, 162.6, 162.3, 130.1, 129.0, 128.1, 54.8, 53.9, 53.0, 51.9, 51.1, 49.1, 47.6, 42.7, 42.2. 
ESI-HRMS calcd. for C24H36N8O7 549.2785 found m/z 549.2788 [M + H]
+. 
 
3.6.6 Complexation of L2 to M (M = Eu, Tb, Gd) 
a) Synthesis of Eu.L2(33) 
 
Ligand L2 (57.00 mg, 0.104 mmol) was dissolved in MilliQ water (1 mL) and the pH adjusted to 5.5 
with 0.5 M KOH. EuCl3.6H2O (41.80 mg, 0.114 mmol) was added slowly, while maintaining the pH at 
5.5. The mixture was stirred overnight. Unreacted Eu3+ was precipitated out as Eu(OH)3 by the 
addition of 0.5 M KOH (pH of mixture at 10). The precipitate was separated from the supernatant by 
centrifugation. The supernatant was concentrated in vacuo, and the residue passed down a 
Sephadex G-10 column. Fractions containing the compound were tested for free metal by the 
xylenol orange test. Metal-free fractions were combined and the solvent removed by lyophilisation. 
Eu.L2 (33) was obtained as a pale yellow solid (19.90 mg, 0.028 mmol, 30 %). ESI-HRMS calc. for 
C24H33EuN8O7 697.1749 found (m/z):  697.1766 [M + H]
+.  
 
b) Synthesis of Tb.L2(34) 
 
Tb.L2 (34) was synthesised according to the same method as the Eu analogue. L2 (56.50 mg, 
0.104 mmol) and TbCl3.6H2O (42.70 mg, 0.114 mmol) were used. The complex was obtained as a 
pale yellow solid (23.30 mg, 0.033 mmol, 32 %). ESI-HRMS calc. for C24H33N8O7Tb 705.1848 found 
(m/z):  705.1802 [M + H]+.  
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c) Synthesis of Gd.L2(35) 
 
Gd.L2 (35) was synthesised according to the same method as the Eu analogue. L2 (57.50 mg, 
0.104 mmol) and GdCl3 (42.50 mg, 0.114 mmol) were used. The complex was obtained as a pale 
yellow solid (30.10 mg, 0.043 mmol, 41 %). ESI-HRMS calc. for C24H33GdN8O7 704.1792 found (m/z):  
704.1802 [M + H]+. 
 
3.6.7 Click procedures 
a) Cyclooctyne to Ln.L1/Ln.L2 
To Ln.L1 or Ln.L2 (1 mg) in water (1 mL), was added cyclooctyne 13 (1 eq, usually approximately 
0.25 mg dissolved in 50 μL methanol). The mixture was left to react for 6 hours. Without further 
purification, the reaction mixture was submitted for mass spectrometry.  
 
b) NP2-alkyne to Ln.L1/Ln.L2 
To NP2-alkyne (0.5 mg NP) in water (250 μL), was added Ln.L1 or Ln.L2 (200 eq with respect to NP-
alkyne). The mixture was left to shake for 6 hours, then centrifuged and the supernatant decanted. 
The pellet was resuspended in water, and washed by precipitating with acetone, and again 
centrifuged to isolate the nanoparticles. The nanoparticles were finally resuspended in water. 
The nanoparticle samples for fluorescence spectroscopy were made up to 1 mg/mL Fe concentration 
(1.67 mg/mL NP concentration).  
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4 Dual-weighted T1/T2 MR agents 
4.1 Introduction 
In the previous chapter, Gd.L1 and Gd.L2 conjugated to the nanoparticle surface were not possible 
to be characterised by fluorescence as Gd(III) does not have an emission in the visible range unlike 
the Eu(III) and Tb(III) analogues. However, an interesting consequence of having a T1 agent (the Gd 
chelate) conjugated to the iron oxide nanoparticle surface (T2 agent) is that the relaxivities of both 
moieties can be affected, as discussed below. To investigate this, a range of Gd-chelate conjugated 
nanoparticles with various modifications were synthesised, and their relaxivities measured. Instead 
of utilising a copper-free alkyne-azide cycloaddition reactions to form the Gd-NP conjugates, as was 
previously carried out with the Eu/Tb chelates, the Gd-NP conjugates here were synthesised by 
direct conjugation of DOTA to NP2 by stoichiometric activation of one carboxylic acid on the DOTA, 
followed by the Gd complexation (Scheme 4.1). The reason for this was two-fold, i) unsubstituted 
DOTA is considerably cheaper than L1 (azido-mono-amide-DOTA) for the large number of 
nanoparticle species to be synthesised here; and ii) the cyclooctyne is synthetically demanding and it 
was difficult to produce a substantial quantity for the whole series.  
 
Scheme 4.1 General scheme to conjugate mono-activated DOTA to NP2, followed by Gd complexation. 
 
As discussed in Chapter 1, T1 is the time constant for longitudinal or spin-lattice relaxation, and T2 is 
the time constant for transverse or spin-spin relaxation. Contrast agents (CA) work by reducing both 
T1 and T2 relaxation times of protons via the interaction between the electron spins of the contrast 
agent and the spins of the water protons in its surroundings. The inverse of the relaxation time 
constants (1/T1 and 1/T2) gives the relaxation rates (R1 and R2) respectively. Both T1/T2 and R1/R2 are 
concentration dependent, so another term known as the relaxivity constant (r1 and r2) that is 
independent of concentration can be derived from the linear relationship between R and the 
concentration of CA. The r1/r2 value therefore allows different species to be compared directly. 
Gadolinium-containing T1 contrast agents are the preferred CA for MR imaging as the enhanced 
signal produced is more favourable. T2 agents on the other hand give a darkened signal which can be 
misinterpreted as bleeding, calcification or other anomalies. Nevertheless, iron oxide nanoparticles 
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as T2 agents are more biocompatible compared to Gd due to its lower toxicity. Thus, having a dual 
contrast T1/T2 MRI probe can overcome the drawbacks of both MRI techniques, with compatible T1 
and T2 acquisitions allowing for artefacts to be reduced and diagnostics to be doubly verified.  
The earliest example of dual contrast T1/T2 MR imaging was carried out by Weissleder et al to image 
liver tumours in rats, whereby administration of both Gd-DTPA and ferrite together showed 
enhanced tumour signal from the Gd-DTPA while the liver showed a negative signal intensity from 
the accumulation of ferrite, compared to when they were administered separately.1 Their results 
show an increase in r1 but no effect on r2 when both agents are present at the same time. The same 
effect was observed when the contrast agents were administered sequentially in humans, in studies 
carried out by Semelka et al and Kubaska et al.2,3 More recently, there have been studies to integrate 
both T1 and T2 moieties into a single contrast agent, typically conjugating Gd chelates onto iron oxide 
nanoparticles.  
Besides iron oxide nanoparticles, Gd- and Mn-based nanoparticles have also been utilised to form 
dual T1/T2 contrast agents even though Gd and Mn nanoparticles (and their small molecule 
counterparts) have primarily been used as T1 contrast agents. Hybrid nanoparticle systems 
combining either Gd or Mn nanoparticles with iron oxide nanoparticles have recently been shown to 
exhibit both T1 and T2 relaxivity. Theoretically, integration of the T1 and T2 contrast as a single entity 
as opposed to having the T1 on the external part of the T2 moiety would result in the T1 spins aligning 
in the same direction as the magnetic field induced by the T2 material, enhancing the T1 effect while 
maintaining the T2 signal.
4,5 This is illustrated in Figure 4.1.5 
 
Figure 4.1 Spin interaction difference between T1 and T2 contrast agents in different locations. Left: When T1 is 
on the outside of T2, the magnetic field from T2 opposed the T1 field, reducing the T1 relaxivity. Right: The 
magnetic field of both contrast agents are simultaneously enhanced when both T1 and T2 are a single entity. 
 
This was confirmed by experimental evidence from Gao et al.5 They synthesised Gd2O3-embedded 
Fe3O4 nanoparticles (GdIO) which had enhanced T1 and T2 relaxivities. The GdIO had a higher r2 than 
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Fe3O4 as well as higher r1 than Gd2O3 and in addition, the Gd2O3 nanoparticles on their own showed 
no enhanced T2 contrast, while Fe3O4 nanoparticles on their own showed no enhanced T1 contrast. 
Gao’s results demonstrate a synergistic enhancement of r1 and r2 in GdIO.  
Kim et al 6 synthesised Gd-doped iron oxide nanoparticles (Figure 4.2) and showed that the Gd-
substituted nanoparticles produced both a T1 and T2 contrast, from images of a rat’s liver. However, 
they only compared their results to Fe3O4 nanoparticles as a control, and there was no comparison 
to a standard T1 agent. Im et al 
7 have also produced a hybrid nanoparticle system of iron oxide and 
manganese oxide (Fe3O4/MnO) with varying Fe3O4 sizes, the simplified structures are illustrated in 
Figure 4.2. MR imaging of the liver showed both T1 and T2 contrast effects, rationalised by the 
internalisation of the NP by Kupffer cells in the liver which releases Mn2+ ions. The released Mn2+ 
activates the T1 effect while the Fe3O4 retains its negative contrast. The T2 relaxivity was also shown 
to increase with Fe3O4 size, with no effect on the r1, although the r2 values were lower for the 
hybrids than for unmodified Fe3O4. 
 
Figure 4.2 Gd- and Mn-doped magnetite structure synthesised by Kim et al (left),
6
 and the Fe3O4/MnO hybrid 
systems of varying Fe3O4 sizes synthesised by Im et al (right).
7
 
 
Other systems such as the Mn-loaded silica spheres by Niu et al illustrated that the Mn can act as 
both T1 and T2 agents with r1 and r2 values of 10.1 and 169.7 mM
-1s-1 respectively, higher than other 
reported dual-mode contrast agents, and also higher than conventional T1 and T2 agents such as 
Gd-DTPA (r1 = 9.6 mM
-1s-1) and Feridex (r2 = 108 mM
-1s-1).8 They attributed the high r1 value to the 
mesoporous silica structure, allowing faster water diffusion into the mesopores, increasing the r1 
relaxivity. The enhanced r2 relaxivity was postulated to arise from the ultrasmall MnO nanocluster 
formed during synthesis. Being antiferromagnetic, these ultrasmall nanoclusters with high surface-
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to-volume ratio exhibit a larger proportion of uncompensated surface spins and therefore higher 
magnetisation values, leading to higher r2. 
Although hybrid nanoparticle systems have shown some promising results, simple conjugation of a 
paramagnetic chelate to the surface of the iron oxide nanoparticle is still an attractive method to 
produce dual-mode contrast agents. The theoretical assumption is that these simpler combined 
agents will have an increase in the r1 without the r2 being affected greatly. The actual results 
however are much more complex and four publications were chosen for comparison. Yang et al 9 
and Bae et al 10 showed independently with different T1/T2 systems, that r2 strongly decreases when 
iron oxide nanoparticles are conjugated to Gd chelates, with an enhancement in the r1. Choi et al 
11 
also observed the same trend with a possible dependence on distance between the Gd to the 
magnetic core. Finally, Huang et al 12 showed the opposite trend where both r1 and r2 increased with 
Gd concentration when the T1 and T2 moieties are coupled. In all these cases, r1 increases when Gd is 
incorporated. However, the r2 trends are not the same for all four publications. These contradicting 
results (summarised in Table 4.1) demonstrate that further studies are required to understand the 
relationship between the final relaxivities and the design and structure of the T1/T2 probes. Thus, in 
this research, a series of iron oxide nanoparticles functionalised with Gd chelates were prepared, 
with modifications as follows (overview in Figure 4.3): 
1) replacing the paramagnetic component for a different metal ion (Set 1, Table 4.2); 
2) changing the chelator for the paramagnetic component (Set 2, Table 4.3);  
3) modifying the distance between the magnetic core and the paramagnetic chelate (Set 3, 
Table 4.4);  
4) altering the organic coating/anchoring ligand on the nanoparticle cores, while keeping the 
Gd chelate and at the same time comparing the effect on distance, (Set 4, Table 4.5); 
nanoparticles for this set were provided by Dr. Gallo. 
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Figure 4.3 Overview of the different modifications to the T1/T2 systems, with the particular modification of 
each set highlighted by the dashed lines. 
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NP Core size (nm) Final size (nm) Z potential (mV) r2 (Fe) r1 (Fe) Ref 
 
 
 
 
6 
 
 
 
27 
 
 
 
+16 
 
 
 
↓with inc Gd 
 
 
 
↑ with inc Gd 
 
 
 
9
 
 
 
 
 
17 
 
 
 
73.8* 
 
 
 
-5 
 
 
 
↓ with inc Gd 
 
 
 
↑ with inc Gd 
 
 
 
10
 
 
 
 
 
 
 
22 
 
 
 
 
40 
 
 
 
 
+17 
 
 
 
 
↑ with inc Gd 
 
 
 
 
↑ with inc Gd 
 
 
 
 
12
 
 
 
 
 
15 
 
 
 
20 – 37.5 
 
 
 
n/a 
 
 
 
↓with inc Si 
thickness 
 
 
 
 
↑ with inc Si 
thickness 
 
 
 
11
 
Table 4.1 Literature T1/T2 probes with their respective data for comparison. 
*hydrodynamic diameter. All other sizes in the table were obtained via TEM measurements in the relevant publications. 
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NP Core 
size/nm 
Theoretical 
size/nm 
Z size/nm Z potential 
mV 
r2 (Fe) r2 (Fe+M) r1 (Fe) r1 (Gd) r1 (Fe+M) 
 
 
6 
 
8.12 
 
20.15 
 
-13 
 
329.75 
 
- 
 
1.84 
 
- 
 
- 
 
 
 
6 
 
 
8.84 
 
 
22.40 
 
 
-12 
 
 
480.14 
 
 
- 
 
 
1.72 
 
 
- 
 
 
- 
 
 
 
6 
 
 
9.10 
 
 
31.87 
 
 
-16 
 
 
282.49 
 
 
267.22 
 
 
3.14 
 
 
54.89 
 
 
2.96 
 
 
 
6 
 
 
9.22 
 
 
15.70 
 
 
-16 
 
 
224.45 
 
 
212.34 
 
 
1.51 
 
 
26.41 
 
 
1.42 
 
 
 
6 
 
 
9.34 
 
 
23.90 
 
 
-17 
 
 
305.66 
 
 
289.14 
 
 
1.49 
 
 
26.13 
 
 
1.41 
Table 4.2 Set 1 of the T1/T2 probes. Modification to the probes is the metal in the DOTA chelate. 
NP2 
NP21 
NP22 
NP23 
NP24 
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NP Core size/nm Theoretical 
size/nm 
Z size/nm Z potential 
mV 
r2 (Fe) r2 (Fe+M) r1 (Fe) r1 (Gd) r1 (Fe+M) 
 
 
 
 
 
6 
 
 
8.12 
 
 
20.15 
 
 
-13 
 
 
329.75 
 
 
- 
 
 
1.84 
 
 
- 
 
 
- 
 
 
 
 
 
 
 
6 
 
 
 
 
9.10 
 
 
 
 
31.87 
 
 
 
 
-16 
 
 
 
 
282.49 
 
 
 
 
267.33 
 
 
 
 
3.14 
 
 
 
 
54.89 
 
 
 
 
2.96 
 
 
 
 
 
 
6 
 
 
 
9.50 
 
 
 
20.84 
 
 
 
-12 
 
 
 
220.35 
 
 
 
212.87 
 
 
 
 
 
2.06 
 
 
 
58.93 
 
 
 
1.99 
Table 4.3 Set 2 with the replacement of Gd chelate from DOTA to NOTA.  
NP25 
NP22 
NP2 
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NP Core 
size/nm 
Theoretical 
size/nm 
Z 
size/nm 
Z potential 
mV 
r2 (Fe) r2 (Fe+M) r1 (Fe) r1 (Gd) r1 (Fe+M) 
 
 
 
 
 
 
6 
 
 
 
9.10 
 
 
 
31.87 
 
 
 
-16 
 
 
 
282.49 
 
 
 
267.22 
 
 
 
3.14 
 
 
 
54.89 
 
 
 
2.96 
 
 
 
 
 
 
6 
 
 
 
12.54 
 
 
 
37.70 
 
 
 
-10 
 
 
 
177.16 
 
 
 
167.59 
 
 
 
1.83 
 
 
 
32.00 
 
 
 
1.73 
 
 
 
 
 
 
6 
 
 
 
79.80 
 
 
 
40.70 
 
 
 
-15 
 
 
 
143.74 
 
 
 
135.98 
 
 
 
1.21 
 
 
 
21.19 
 
 
 
1.15 
Table 4.4 Set 3 with modifications to the distance between the magnetic core and paramagnetic Gd chelate. 
 
NP22 
NP26 
NP27 
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NP Core 
size/nm 
Theoretical 
size/nm 
Z 
size/nm 
Z potential 
mV 
r2 (Fe) r2 (Fe+M) r1 (Fe) r1 (Gd) r1 (Fe+M) 
 
 
 
 
 
 
6 
 
 
 
11.02 
 
 
 
82.91 
  
 
 
226.89 
 
 
 
- 
 
 
 
0.88 
 
 
 
- 
 
 
 
- 
 
 
 
 
 
 
6 
 
 
 
11.14 
 
 
 
82.91 
  
 
 
19.18 
 
 
 
18.79 
 
 
 
0.69 
 
 
 
33.20 
 
 
 
0.68 
 
 
 
 
 
 
6 
 
 
 
14.34 
 
 
 
- 
  
 
 
98.98 
  
 
 
0.70 
  
Table 4.5 Set 4 alteration of the anchoring ligand from alendronate to 11-aminoundecanoate (bisphosphonate to carboxylate anchor), while at the same time altering the 
distance between the core and the Gd chelate. 
  
NP28 
NP29 
NP30 
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4.2 Synthesis and characterisation of T1/T2 conjugate families 
NP21 was complexed with different metals in the DOTA cavity (Set 1) by reacting the 
DOTA-functionalised nanoparticles with the respective metal salts. DOTA is the most widely used 
Gd3+ chelator due to its biocompatibility and stability with a range of metals and was therefore used 
in the majority of the nanoparticles synthesised.13 NOTA replaced DOTA in one of the samples to 
observe if there would be an effect on hydration state about the gadolinium centre on the relaxivity 
(Set 2). Both NOTA and DOTA were conjugated to the surface of NP2 by stoichiometric peptide 
coupling (Scheme 4.2). In a typical experiment, 300 equivalents of DOTA or NOTA relative to the 
nanoparticle were added to a 0.5 mg solution of the NP in water, and left to react overnight.  
 
Scheme 4.2 Stoichiometric addition of DOTA (or NOTA) to NP2. 
 
The yields of the DOTA (and NOTA) couplings to NP2 and NP2-PEGn were determined via 
quantification of unreacted chelate by an indirect colorimetric method. The washings from the DOTA 
coupling reaction were incubated with Gd3+ and then a small aliquot added to a fixed volume of 
0.017 M xylenol orange solution. Free Gd3+ turns the solution from orange to purple, and this colour 
change can be measured by UV-Vis spectroscopy.14 Similar to the rhodamine coupling reactions of 
NP2 and NP12 previously, the amount of free and bound Gd3+ in the washings can be calculated 
from the calibration curve, and correlated back to the amount of unreacted DOTA/NOTA in the 
washings. The DOTA coupling yields for both PEGylated and non-PEGylated particles were > 70 %. 
The NOTA coupling was slightly lower at 50 % yield. The lower yield for the NOTA coupling could be 
due to the use of pre-activated NOTA-NHS which deactivates over time, compared to the DOTA 
coupling where the carboxylic acid was activated with EDC in situ. 
PEG chains were incorporated between the Gd-DOTA and nanoparticle core to observe the effect of 
distance between the T1 and T2 moieties on the resultant relaxivity (Set 3). The PEG molecules were 
of two different lengths (6 and 96 units) with a carboxylic acid on one end for conjugation by EDC 
coupling to the amine on the nanoparticle surface, and a protected Fmoc-amine on the other. After 
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coupling, the Fmoc is removed by treatment with three cycles of piperidine in DMF (20/80) for 
15 minutes each, to give the free amine which can be further reacted with DOTA. The same 
procedure and characterisation methods were employed as before in Section 3.1. 
The final nanoparticles were characterised by infrared spectroscopy and NMR relaxivity 
measurements. The PEGylated nanoparticles were confirmed by the presence of C=O amide stretch 
in the IR spectrum, as previously discussed in Chapter 3. C=O carboxylic acid stretching frequency in 
the infrared spectrum of the DOTA coupled nanoparticles further confirmed the coupling, alongside 
the xylenol orange assay. Further characterisation of the nanoparticles was made by DLS to obtain 
hydrodynamic size and surface charges. As previously explained in Chapter 2, the surface charge of 
NP2 is negative at pH 7.4. This number remains even after PEGylation, DOTA coupling and Gd 
complexation, as expected from the contribution of the hydroxyl group on the alendronate. 
Hydrodynamic sizes of the nanoparticles increased with increasing PEG length, as expected. The 
diameter of NP2 increased from 20.15 nm to 31.87 nm after DOTA-Gd conjugation and then to 37.70 
nm and 40.70 nm after PEGylation with PEG6 and PEG96 respectively. The theoretical diameter of the 
resultant nanoparticles were also calculated by determining the length of the total ligand on the 
nanoparticle surface using ChemBio 3D Ultra, and subsequently adding twice this value to the 
diameter of the nanoparticle core. This number was then compared to the hydrodynamic diameter 
and any effects they had on the relaxivities.  
 
4.3 Relaxivities 
Solutions of each nanoparticle sample of at least three different concentrations were prepared in 
pure water and placed in an NMR tube, containing a sealed capillary tube of D2O. NMR T1 and T2 
experiments to obtain T1 and T2 relaxation times respectively were performed on a 400 MHz Bruker 
NMR instrument. The relaxivity constants (both r1 and r2) were calculated through the curve fitting 
of T1
-1 and T2
-1 versus the metal concentrations in mM [Fe], [Gd] (or [Mn] or [Zn]), and ([Fe] + [Gd]).  
The results obtained were quite difficult to interpret and therefore the trends in r2 relaxivities will be 
discussed separately to the r1 relaxivities. The trend for each modification set will be discussed 
within each relaxivity effect. The r2 values with respect to [Fe] and ([Fe] + [Gd]) are very similar for 
each nanoparticle since the concentration of iron is far greater than that of gadolinium in any 
sample. Therefore, only the r2([Fe]) values were considered and compared for each nanoparticle set, 
over the r2([Fe] + [Gd]) values. For r1 values, both r1([Gd]) and r1([Fe] + [Gd]) were considered and 
compared as Gd is more relevant with respect to r1 compared to Fe. 
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4.3.1 T2 relaxivity 
The r2([Fe]) value for NP2 (329.7 mM
-1 s-1) was found to be much higher than other IONP contrast 
agent coated with carboxylate-based ligands (r2 = 50 - 150 mM
-1s-1).15–17 The relaxivity of the 
nanoparticles is related to the saturation magnetisation, and the method of nanoparticle 
preparation and the nature of the coating ligands (depending on the functional group of the anchor) 
changes the saturation magnetisation, resulting in differing relaxivities. Daou et al 18 have found that 
when nanoparticles are coated with an organic ligand, an oxidised layer is formed on the 
nanoparticle surface, whereby the nanoparticles consist of a stoichiometric core with an oxidised 
layer, and this was shown for both carboxylate and phosphate/phosphonate coated nanoparticles. 
However, the different anchoring functional groups affect the saturation magnetisation within the 
oxidised layer through spin canting, and therefore affect the net saturation magnetisation of the 
whole nanoparticle.18 Spin canting occurs when the spins are tilted slightly about the axis by a small 
angle resulting in a non-zero net magnetisation. This does not occur for phosphate-based ligands but 
does for carboxylate-based ligands, and thus the phosphate-coated nanoparticles have a higher 
magnetisation and therefore higher relaxivity.18 As previously discussed in Chapters 1 and 2, IONPs 
synthesised via the high temperature thermal decomposition method have a higher crystallinity 
which is also correlated to nanoparticle magnetisation.19,20 These two factors; the lack of spin 
canting, and the high crystallinity of the core; together justify the exceptionally high relaxivity of 
NP2. 
In comparing the r2 values of Set 1 (Table 4.2), the relaxivities follow the same trend as observed in 
the literature. The r2([Fe]) of NP2 (329.75 mM
-1s-1) decreased to 282.49 mM-1s-1 in NP22 when Gd is 
incorporated into the probe. This is due to the gadolinium interfering with the T2 relaxation of the 
nanoparticle.21,22 When the chelated metal was manganese (NP23) instead, the r2([Fe]) value also 
decreased to 224.45 mM-1s-1. This is as expected as Mn2+ is also a T1 paramagnetic agent, and will 
therefore have the same effect as Gd3+.23,24 The relaxivity of NP24 [r2([Fe]) = 305.66 mM
-1s-1] is still 
similar in value to NP2 and is as expected due to Zn2+ not being a paramagnetic ion like Mn2+ and 
Gd3+ and therefore should not affect the final relaxivity of the probe. The r2([Fe]+[M]) values for 
NP22, NP23 and NP24, where [M] is [Gd], [Mn] or [Zn], also decreased by the same relative 
amounts. 
When DOTA is replaced with NOTA as the Gd chelator (Set 2, Table 4.3), there is a decrease in the 
r2([Fe]) for NP25 (220.35 mM
-1s-1) compared to the r2([Fe]) value of NP2 (329.75 mM
-1s-1). Similar 
results are observed with NP22 (i.e. a decrease in r2([Fe]) to 282.49 mM
-1s-1 from NP2), and is in 
accordance with observations by Yang et al and Bae et al.9,10 The larger decrease for NP25 (Gd-
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NOTA) can be attributed to the gadolinium having one more free coordination site or electron spin 
availability that results in a larger interference of the magnetic field generated by the magnetic core. 
Thus, the magnetisation of the resultant nanoparticle is decreased, as was observed.  
Within Set 3 (Table 4.4), a decrease in the r2([Fe]) of NP22 (282.49 mM
-1s-1) to NP26 (177.16 mM-1s-1) 
is observed when a PEG chain is introduced. A further decrease to 143.74 mM-1s-1 was determined 
when the PEG length increased in NP27. This observation is in accordance with those made by Choi 
et al.11 The same trend is seen across the r2([Fe]+[Gd]) value. This decrease can be explained as an 
interference of the magnetic field generated by the magnetic core and the effect is distance-
dependent from the core. This interference in the field interacts with the water in the vicinity of the 
probe. A larger distance between the two moieties reduces the overall magnetic field that can 
interact with the water, thus resulting in a reduced T2 contrast. The larger distance between the T1 
and T2 moieties is confirmed by both the theoretical calculated size and hydrodynamic size 
measurement. There is a much larger increase in size for the calculated theoretical size values (9.10 
nm for no PEG, 9.50 nm for short PEG and 79.80 for long PEG), compared to the increase in 
hydrodynamic diameter (31.87 nm when there is no PEG to 37.7 nm and 40.7 nm for the short and 
longer PEG chains respectively). The measured hydrodynamic diameter however is more accurate as 
the PEG chains are more likely to be coiled than linear, which is the assumption made for the 
calculated theoretical size values. 
Changing the alendronate anchoring ligand for 11-aminoundecanoate (Set 4, Table 4.5) resulted in a 
similar trend in r2([Fe]) to that of Set 1 whereby a decrease in r2([Fe]) is observed when Gd is 
incorporated in accordance with Yang et al and Bae et al’s observations,9,10 with both the non-
PEGylated (NP29) and PEGylated conjugates (NP30) having lower r2[(Fe]) of 19.18 mM
-1s-1 and 
98.98 mM-1s-1 respectively compared to the r2([Fe]) of NP28 (226.89 mM
-1s-1). However, the increase 
in distance between the T1 and T2 moiety by the introduction of PEG had the opposite trend to that 
observed by Choi et al.11 NP30 had a higher r2([Fe]) value than NP29. In this particular case, this 
could be due to a different reason where the increased water solubility after PEGylation would allow 
the water molecules better access to the Gd and therefore have an increased effect on the r2. 
 
4.3.2 T1 relaxivity 
Since NP2 and NP2-DOTA have no r1([Gd]) or r1([Fe]+[Gd]), it was not possible to compare them to 
the values for the Gd-DOTA functionalised nanoparticles. The r1([Fe]) values in Set 1 (Table 4.2) only 
partially follow the general literature trend of increasing when a paramagnetic metal is present. 
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With NP22, there is an increase in the r1([Fe]) from 1.84 mM
-1s-1 (NP2) to 3.14 mM-1s-1. This is not the 
case when the metal ion is Mn2+ NP23 (r1([Fe]) = 1.51 mM
-1s-1). Since Mn2+ is less strongly 
paramagnetic than Gd3+, its weaker effect on the relaxivity may be insignificant such that it not 
observed. The r1 when the metal ion is Zn
2+ NP24 (r1 = 1.49 mM
-1s-1) is similar in value to when it is 
Mn2+. However, this is as expected as it is also similar in value to the non-metal containing NP2-
DOTA and Zn2+ should not have any effect on the final relaxivity of the nanoparticle. 
Replacement of DOTA with NOTA as the Gd chelator in Set 2 (Table 4.3) saw an increase in the 
r1([Gd]) relaxivity from 54.89 mM
-1s-1 to 58.93 mM-1s-1. There is no similar correlation to the 
literature trend for this set. However, the increase in relaxivity is as expected as the extra water 
coordination site allows water ligands to bind in the NOTA-Gd complex which results in faster water 
exchange and therefore a higher relaxivity.  
When the distance between the Gd chelate and the nanoparticle core was altered (Set 3, Table 4.4), 
the results were opposite to that observed by Choi et al.11 All the r1 values (relative to [Fe], [Gd], and 
([Fe]+[Gd])) decreased instead when the Gd was further from the core (i.e. r1([Fe]) was 1.83 mM
-1s-1 
for the short PEG chain NP26 and 1.21 mM-1s-1 for the longer chain NP27). One reason for the lower 
relaxivity of NP27 could be the conformation of the PEG chain. A larger PEG chain is more likely to 
coil into a mushroom conformation instead of remaining linear, wrapping the Gd chelate within the 
PEG chain. This can hinder the binding of water to the Gd resulting in lower relaxivities. The 
hydrodynamic size of NP27 (40.7 nm) was not much larger than NP26 (37.7 nm), which indicates 
that the PEG in NP26 is most likely linear while in NP27 the PEG is most likely coiled, even though 
the theoretical size of the NP27 was much larger.  
Set 4 (Table 4.5) r1 values also do not follow the literature trend of increasing when Gd is present, 
and there is no considerable effect on the r1 values with respect to distance between the T1 and T2 
moieties. The r1 of NP30 (0.70 mM
-1s-1) did not differ from that of NP29 (0.69 mM-1s-1). 
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4.4 Conclusion 
The relaxivities for the nanoparticles synthesised here have not followed one particular trend, and 
not always the specific trends mentioned in the selected literature. NP2 was found to have an 
exceptionally high relaxivity, and is higher than other T2 contrast agents with similarly sized cores 
reported in the literature. When the nanoparticles are conjugated to a Gd chelate, although the r2 
values decrease slightly, r1 values increase in comparison to NP2. This result makes these conjugates 
excellent candidates for dual-weighted T1/T2 contrast agents. Modification of the distance between 
the T1 and T2 moieties decreased both r2 and r1 with increasing distance and so shorter distances are 
desirable. 
Changing the DOTA macrocycle for NOTA also resulted in a favourable increase in r1([Gd]) value 
compared to NP22 (DOTA). However the use of NOTA in vivo is not currently clinically approved This 
modification was not discussed in the literature and so a comparison could not be drawn. 
Replacing the alendronate ligand for 11-aminoundecanoate decreased the r2 value due to the 
difference in functional group for the anchor. When the distance between the T1 and T2 centre for 
the 11-aminoundecanoate functionalised nanoparticles is increased, r2([Fe]) values also decreased 
while r1[(Gd)] values remained similar. Overall, alendronate ligand was found to be an ideal ligand to 
produce T1/T2 contrast agents with excellent relaxivities. 
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4.5 Experimental 
NOTA-NHS ester and DOTA were obtained from CheMatech and used without further purification. 
The metal salts and xylenol orange were obtained from Sigma-Aldrich and used without further 
purification. All solvents were analytical grade and were obtained from VWR. EDC couplings were 
carried out in MilliQ water under ambient conditions. FT-IR spectra were acquired in a Perkin-Elmer 
Spectra 100 FT-IR spectrometer, neat on ATR plates. 1H NMR spectra and T1/T2 inversion recovery 
data were obtained in a Bruker DRX400 MHz spectrometer. Z-measurements were obtained in a 
Beckman Coulter Delsa Nano.  
 
4.5.1 Synthesis of NP2-DOTA 
To NP2 in MilliQ water (0.5 mg NP, 1.43 nmol, typically about 250 μL from a 2.0 mg/mL NP solution) 
was added a solution of DOTA (300 eq) and EDC (1 eq with respect to DOTA). The mixture was left to 
shake overnight then centrifuged and the supernatant separated and isolated for yield quantification 
by a xylenol orange assay. The residue was taken up in water (100 μL) and washed by precipitating 
with acetone and the nanoparticles were isolated by centrifugation. This second supernatant was 
not used in the xylenol orange assay. The nanoparticles were then resuspended in water (250 μL). 
 
4.5.2 Synthesis of NP2-NOTA 
To NP2 in MilliQ water (0.5 mg NP, 1.43 nmol, typically about 250 μL from a 2.0 mg/mL NP solution) 
was added NOTA-NHS ester (300 eq). As the NOTA was pre-activated, no additional EDC was added. 
The mixture was left to shake overnight then centrifuged and the supernatant separated and 
isolated for yield quantification by a xylenol orange assay. The residue was taken up in water (100 
μL) and washed by precipitation with acetone and the nanoparticles were isolated by centrifugation. 
This second supernatant was not used in the xylenol orange assay. The nanoparticles were then 
resuspended in water (250 μL). 
 
4.5.3 Synthesis of NP2-PEGn-DOTA  
NP2 was PEGylated with HOOC-PEGn-NH2 by the same method as previously reported in Chapter 3. 
The subsequent DOTA conjugation was the same method as for the synthesis of NP2-DOTA.  
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4.5.4 Gd complexations 
NP2-DOTA (0.5 mg NP, in 250 μL water) was adjusted to pH 6 with 0.5 M HCl. GdCl3.6H2O in acetate 
buffer pH 6 (300 eq with respect to NP, 1 eq with respect to DOTA) was added to the nanoparticle 
solution and the mixture left to shake overnight. After centrifugation, the supernatant was decanted 
and the residue taken up in water. The nanoparticles were washed by precipitation with acetone 
and the nanoparticle were isolated by centrifugation. The nanoparticles were then resuspended in 
water (250 μL). 
The same complexation method was used for all the nanoparticle species (PEGylated and non-
PEGylated, and for the NOTA chelate) and for the different metals (Mn and Zn). 
 
4.5.5 Xylenol orange assay 
The amount of DOTA unreacted after the DOTA coupling reaction was determined by incubating the 
washings from the DOTA coupling reaction with a known quantity of Gd3+ (approximately the same 
equivalence as the DOTA added to the NP reaction). The amount of free Gd3+ remaining after the 
incubation can be determined by a xylenol orange assay and correlated back to the amount of Gd3+ 
that reacted with the DOTA in the washings, and therefore the amount of DOTA that coupled to the 
NP can be determined. This assay is based on the method by Barge et al.14 
Gd3+ calibration standards (50 μL each) between 0 – 10 μg Gd(III) were prepared from a 1 mg/mL 
Gd(III) stock solution of GdCl3.H2O in deionised water. The xylenol orange solution was prepared by 
dissolving xylenol orange (3 mg) in acetate buffer (250 mL, 50 mM, pH 5.8) to give a 0.017 mM 
solution. The 0.017 mM xylenol orange solution (500 μL each) was added to the standards (50 μL) 
and the UV-Vis of the solution recorded. The calibration curve is a plot of the ratio of the absorbance 
at 573 nm and 433 nm, against the concentration of Gd3+.  
The same volume of xylenol orange (500 μL) was added to an aliquot of the supernatant after 
incubation with Gd3+ (50 μL). UV-Vis of the solution was recorded and the ratio of the absorbance at 
(573/433) nm was correlated to the concentration of Gd3+ in the calibration curve. 
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5 Biological application of the functionalised nanoparticles 
5.1 Introduction 
One of the applications of the nanoparticles synthesised in this research, was to utilise them as 
contrast agents for the imaging of vulnerable plaque. This chapter will introduce the reader to a 
specific biological target, which when conjugated to the nanoparticle will then be used for the 
imaging of vulnerable plaque. Much of the work in this chapter is preliminary, and was carried out in 
collaboration with Dr Takayuki Homma in the Krams group, Bioengineering Department, Imperial 
College London.  
 
5.2 Fractalkine as a specific target for vulnerable plaque imaging 
As previously discussed in Chapter 1, macrophages are present at every stage of atherosclerosis. 
These macrophages have antigens on their surface, and secrete signalling proteins called 
chemokines that aid cell migration, as well as other proteins, chemicals and enzymes. One particular 
chemokine that has been well-documented in the literature to play a significant role in 
inflammation, including atherosclerosis, is Fractalkine, a CX3CL1 chemokine.1 First characterised by 
Bazan et al,2 this chemokine exists in both the membrane-bound and soluble form. When membrane 
bound, the firm adhesion of monocytes to the endothelial cells are promoted by the chemokine. 
When soluble, it acts as a chemoattractant for cells that express the Fractalkine receptor (CX3CR1).3 
The two processes are outlined in Figure 5.1. The CX3CR1 receptor is expressed on various cells such 
as monocyte-derived macrophages, smooth muscle cells, and T-cells. Fractalkine (or CX3CL1) 
interacts with only a single receptor (CX3CR1), unlike other chemokine molecules that have an 
affinity for multiple receptors. The inflammation process repeats itself continuously, due to the 
continual presence of the chemokines on the macrophages and other Fractalkine-expressing cells, 
and this can ultimately result in the formation of vulnerable plaque. Therefore, Fractalkine as a 
target is an ideal candidate in the imaging of vulnerable plaque.  
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Figure 5.1 Diagram showing the dual-role of Fractalkine (CX3CL1) in atherosclerosis. When bound to the 
endothelial membrane, it promotes the adhesion of CX3CR1-expressing monocytes in the blood to the vessel 
wall (B) and subsequently the migration of the monocytes into the endothelial cells (C). CX3CL1 becomes 
soluble after cleavage by TNF-alpha converting enzyme, and acts as a chemoattractant for CX3CR1-expressing 
cells (A). Image taken from ref 
3
. 
 
Both the Fractalkine molecule itself, as well as its receptor can be utilised as targets for the imaging 
of vulnerable plaque. Therefore, the primary aim of this section of work was to synthesise a single-
chain variable fragment (scFv) of an antibody that will be conjugated to the nanoparticles. It is 
proposed that the scFv will then either be targeted towards macrophages that express the 
chemokine Fractalkine receptor, or the endothelial cells that express the Fractalkine itself, in order 
to image vulnerable plaque (Figure 5.2).  
Chemotaxis Adhesion Migration 
Monocytes 
soluble CX3CL1 
CX3CR1 
CX3CL1 
Endothelial cells 
TNF-alpha converting enzyme 
A B C 
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Figure 5.2 Proposed target routes towards the imaging of vulnerable plaque. Route 1 is the targeting of an 
anti-Fractalkine receptor antibody on the nanoparticle towards the Fractalkine receptor on a macrophage that 
also has a chemoattraction towards the Fractalkine molecule on the endothelial cells of plaque. Route 2 is the 
targeting of an anti-Fractalkine antibody on the nanoparticle towards the Fractalkine molecule either soluble 
or bound to the surface of the endothelial cells. 
 
5.3 Preliminary results 
The preparation of antibodies against both Fractalkine and the receptor were attempted – an anti-
Fractalkine receptor antibody for the Fractalkine receptor; and an anti-Fractalkine antibody for the 
Fractalkine protein. As antibodies are very large molecules, the preparation of a shorter chain 
fragment (single chain variable fragment, scFv) of the desired antibody was attempted, in order to 
achieve higher selectivities with the target. The anti-Fractalkine receptor antibody was not 
successfully identified by the Krams group. However, the anti-Fractalkine antibody was successfully 
identified and plasmid containing scFv against Fractalkine was isolated and provided by the Krams 
group. The scFv was screened from the Tomlinson I and J library (data not shown) previously within 
the group, but its specificity towards Fractalkine was not confirmed. Two clones of the scFv were 
isolated and inserted into plasmids. Both clones had identical protein sequences confirmed from the 
promoter to terminator region, but may contain differences in the other areas of the plasmid. In 
order to confirm that these possible differences did not have an effect on the specificity towards 
Fractalkine, both clones should be used and compared. 
 
1 
2 
Fractalkine CX3CL1 
Monocytes/macrophage 
Iron oxide nanoparticle 
CX3CR1 receptor 
Anti-fractalkine antibody 
Anti-fractalkine receptor antibody 
soluble CX3CL1 
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5.3.1 Initial macrophage uptake experiments 
The uptake of nanoparticles by macrophages before their conjugation to scFv is an undesirable 
process, since macrophages are present all over the body. Uptake of nanoparticles in this case 
means a high non-specific uptake. There are two subpopulations of macrophages, M1 and M2, 
which differentiate from monocytes when the monocytes enter tissue and are exposed to growth 
factors and other compounds.4–6 Exposure of the monocytes to granulocyte macrophage colony 
stimulating factor (GM-CSF) and macrophage colony stimulating factor (M-CSF) differentiate the 
monocytes into macrophages.7 Monocytes are polarised into M1 macrophages by GM-CSF while M-
CSF polarises monocytes into M2 macrophages. Both M1 and M2 polarised macrophages are 
present in atherosclerotic plaque, although there is some evidence of a higher population of M1 in 
vulnerable plaque.8–10 Therefore, the preferential uptake of the particles by a subpopulation of the 
macrophages (M1) may still be acceptable. 
The nanoparticles tested here were the PEGylated nanoparticles (NP6, NP7 and NP8, ) synthesised 
earlier in Chapter 3. The PEG molecules were of three different lengths, but each featuring NH2 
terminal groups as these would be the functional groups utilised for subsequent scFv conjugation.  
 
Figure 5.3 Structures of NP6, NP7 and NP8 tested in the macrophage uptake experiments. 
 
The M1 and M2 macrophages for the uptake experiments were obtained by harvesting white blood 
cells from the bone marrow of mice, and subsequently polarising the cells by the addition of the 
respective macrophage colony stimulating factors. HeLa cells, a human cancer cell line, were used as 
control cells. Despite the need for macrophages in the research of inflammation, no appropriate cell 
model is available. Therefore macrophage polarisation protocol utilises monocytes which are either 
bone marrow-derived or blood-derived. Bone marrow-derived monocytes are preferred as the 
maturity of the cells is at its lowest and therefore can be controlled. Blood-derived monocytes 
usually contain cells at different stages of maturation. 
After incubation of the two subpopulations of macrophages, and the control HeLa cells, with the 
nanoparticles, the cells were washed to remove any unbound/non-uptaken nanoparticles and the 
remaining nanoparticles were stained with Prussian blue dye. Prussian blue is a dye that binds to 
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non-haemoglobin iron.11 The nuclei of the cells were then counter-stained with nucleus red. The 
cells were then imaged by microscopy. 
From the images (Table 5.1), it appears that all the nanoparticle samples were taken up by both the 
M1 and M2 macrophages. However, it is not possible to definitively distinguish between preferential 
M1 or M2 uptake. The conditions for this experiment however, have not been fully optimised. The 
cell density of the M1/M2 macrophages and the amount of nanoparticle used in the incubation still 
need to be optimised in order to improve the quality of images obtained. Nevertheless, with 
optimisation, this method can still be used for future screening of nanoparticles. 
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 M1 M2 HeLa 
 
 
 
NP6 
   
 
 
 
NP7 
   
 
 
 
NP8 
   
 
 
 
no NP 
   
Table 5.1 Microscopy images of macrophage incubated with nanoparticles, with HeLa cells as a control cell line. 
Magnification of the images are x40. Iron is stained blue while the nucleus of the cells are stained red. When the cells take up 
the nanoparticles, the blue colour from the iron should overlap the red nucleus. The above images show nanoparticle uptake 
by both M1 and M2 macrophages, and no uptake by the control HeLa cells. 
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5.3.2 scFv preparation and specificity test 
In order to produce a candidate of scFv against Fractalkine by E. coli, the phage containing the scFv 
DNA was transformed into E. coli then stored as a glycerol stock at -80 °C. A microspatula of the 
frozen glycerol stock of the bacteria was inoculated into a small volume of the medium to make a 
preculture. A portion of the preculture was subsequently inoculated into the main culture medium 
and incubated to produce the scFv. This experiment was run in parallel with three separate protein 
expressing bacterium; two scFv from different plasmid clones, and a control containing Ubiquitin 
(which is not Fractalkine specific).  
After incubation of the bacteria overnight with IPTG, the scFvs were purified. Purification begins by 
separating the bacterial cells from the medium, by centrifugation. The media was filtered through 
0.45 μm and 0.2 μm syringe filters to remove any last traces of cells. The filtered media was then 
passed through AcroSep MEP Hyper cell column, a protein purification column. The column retains 
the protein and prior to elution with a buffer, phosphate buffered saline (PBS) was passed through 
to wash out any unbound protein. The protein was isolated from the column by elution with a 
second buffer that reduces the pH of the column. The fractions of eluted buffer containing the scFv 
were analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to confirm 
the molecular weight of the protein. At each stage of the purification, a small aliquot of the filtered 
media (labelled “S” for the sample after the syringe filtration, and labelled “FT” after passing down 
the column) as well as the PBS washing (W1 – W10) and eluted buffers (E1 – E6), were isolated for 
SDS-PAGE analysis. 
The SDS-PAGE (Figure 5.4) of each fraction after purification on column did not show the desired 
molecular weight of the scFv (expected around 29 kDa). Both scFv had identical SDS-PAGE results. 
The SDS-PAGE of the Ubiquitin also did not show the expected molecular weight. 
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Figure 5.4 SDS-PAGE after initial purification of (A) scFv and (B) Ubiquitin. Arrowheads represent the region 
where the scFv and Ubiquitin MW were expected to appear. The following samples were in the labelled wells: 
1) filtered supernatant “S”, 2) flow through “FT”, 3) washing “W1”, 4) washing “W10”, 5 – 10) elutions “E1 – 
E6”.  
 
Two different hypotheses could account for the results of this experiment: 1) glucose was added to 
the medium, to minimise the early expression of protein that can be toxic to the bacteria. The 
glucose can inhibit the action of the IPTG (which was added to allow the E. coli to express the 
proteins); 2) the bacteria did express the proteins, but did not release it into the media. 
Therefore, first the scFv preparation was repeated on a small scale with no glucose added, but 
keeping all other conditions the same. The same results as before were observed, with the desired 
scFv or Ubiquitin molecular weights not detected on SDS-PAGE (Figure 5.5). This suggests that 
glucose does not have an effect of the bacterial expression of scFv. 
 
Figure 5.5 SDS-PAGE of scFv preparation with no glucose added. Arrowhead represents the region where the 
MW of the proteins were expected to appear. Wells 1, 2 and 3 are the same as 4, 5 and 6 respectively, but at 
two different concentrations. Wells 1 and 4, and 2 and 5, are the supernatant from scFv samples. Wells 3 and 6 
are the supernatant from the Ubiquitin sample.  
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To examine if reason 2 was the culprit, the pellet from the initial scFv preparation was lysed by 
sonication. The lysate was separated from the cell debris by centrifugation and the supernatant 
analysed by SDS-PAGE (Figure 5.6). As before, the desired molecular weight was not detected by the 
SDS-PAGE.  
 
 
Figure 5.6 SDS-PAGE after the pellet was sonicated. Arrowhead represents the region where the MW of the 
proteins were expected to appear. Wells 1, 2 and 3 are identical to wells 4, 5 and 6 respectively, but at two 
different concentrations. Wells 1 and 4, and 2 and 5, are from scFv samples. Wells 3 and 6 are from the 
Ubiquitin sample. 
 
The experiment was then repeated with fresh E. coli transformant. Newly transformed E. coli with 
monoclonal phage was prepared, from a HB2151 competent cell and scFv coded plasmid. The 
competent cells are mixed with the plasmids (three different samples; two anti-Fractalkine scFvs and 
one control anti-Ubiquitin). The transformed bacteria were then plated on petri dishes and 
incubated overnight. After counting the colonies, one colony from each transformant was selected 
and added to a preculture medium, and the scFv preparation repeated as before for all three 
different bacteria. After purification, each fraction was analysed by SDS-PAGE (Figure 5.7).  
 
Figure 5.7 SDS-PAGE of (A) scFv and (B) Ubiquitin. Arrowhead represents the region where the MW of the 
proteins were expected to appear. The following samples were in the labelled wells: 1) filtered supernatant 
“S”, 2) flow through “FT”, 3 – 8) elutions “E1 – E6”, 9) washing “W9”, 10) washing “W10”. 
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From the SDS-PAGE, the eluted samples (wells 5 – 8) containing the scFv had the expected molecular 
weight of 29 kDa. This result suggested that the scFv was present. To confirm that the scFv was 
Fractalkine specific, an enzyme-linked immunosorbent assay (ELISA) test was carried out. The 
resulting colourimetric indicator can be measured (OD450) and the values obtained used to 
determine the quantity of scFv binding to the antigen. The scFv (both clones) were tested against the 
Fractalkine antigen (at two different concentrations), as well as the Ubiquitin antigen. PBS(-) and BSA 
were used as negative controls. The results from the ELISA was plotted (Graph 5.1).  
 
Graph 5.1 Plot of (OD450 – OD650) values for the relevant samples (scFv 1 - blue, scFv 2 - red, α-Ubiquitin - green 
and BSA - purple), against the different antigen coatings (Fractalkine, Ubiquitin and PBS(-)). 
 
The ELISA results are very preliminary and cannot confirm the specificity of the scFv towards 
Fractalkine. However, scFv 2 does show a degree of specificity towards Fractalkine which is 
promising. The Ubiquitin antigen coating showed the correct binding results, with the Ubiquitin 
binding strongly as expected, no binding for scFv 1 and some binding for scFv 2 (potentially a false 
positive).  When the coating was PBS, no binding in all samples were observed, as expected. ELISA 
measurements are highly susceptible to false positive readings, as cross contamination between 
wells is very easy.  
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5.4 Conclusion 
Preliminary uptake experiments of non-targeted conjugated nanoparticles with M1 and M2 
polarised macrophages showed uptake by both subpopulations of macrophage. It was not possible 
to distinguish preferential uptake between M1 and M2 macrophage. Optimisation of the method, 
such as determining the ideal cell density and concentration of nanoparticle during incubation, is 
required, and will be the subject of future studies.  
A human Fractalkine specific scFv fragment was successfully prepared following the transformation 
of an E. coli strain with plasmid containing the scFv DNA. Initial problems in the preparation of the 
scFv were identified and the protocol improved to obtain the desired scFv. The molecular weight of 
the scFv was determined by SDS-PAGE. Unfortunately, specificity towards the human Fractalkine 
was not confirmed by preliminary ELISA. Due to time constraints, further ELISA measurements were 
not able to be carried out to confirm the specificity of the scFv, and conjugation to nanoparticles 
were not possible. Once conjugated to the nanoparticles, the specificity of the scFv on the 
nanoparticles towards Fractalkine would be further tested by histology experiments, as well as by 
MRI with mice injected with the nanoparticles.  
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5.5 Experimental 
All reagents and media were prepared as sterile and autoclaved, unless otherwise stated. MilliQ 
water was purified by the PURITE system. 
The following reagents were obtained from Sigma: Phosphate buffered saline without calcium or 
magnesium [PBS(-)] (P4417), D-(+)-Glucose (G8270), Tween20 (P5927), Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (I6758-10G), 3,3’,5,5’-Tetramethylbenzidine (TMB) (T5525), Red blood 
cell lysing buffer (R7757). Potassium acetate (60035), RbCl (R2252), MnCl2.4H2O (221279), 
CaCl2.2H2O (C3306), 3-(N-morpholino)propanesulfonic acid (MOPS, 69947), glycerol (G7893). 
The following reagents were obtained from Invitrogen: SDS-PAGE 10-20 % Tris-Glycine Gel 
(EC66252), Tris-Glycine SDS Sample Buffer (2x) (LC2676), Tris-Glycine SDS running buffer (10x) 
(LC2675), Dry Ease Mini-Gel Dryer System (NI2387A), Gel Dry solution (LC4025). 
Sodium Chloride was obtained from VWR (BDH, 102415K). Tryptone (VM371131 147), yeast extract 
(VM077526 919), LB medium (1.10285.0500) and LB agar (1.10283.0500) were obtained from 
Merck. DMSO (EC200-664-3) and Ampicillin (BP1760-5) were obtained from Fisher Scientific. 
Macrophage colony-stimulating factor (MCSF, 315-02), Interleukin 4 (IL-4, 214-14), Interleukin 13 (IL-
13, 210-13), Interferon gamma (IFN-γ, 315-05), Human Fractalkine (0.1 mg/mL, 300-31) were all 
obtained from PeproTech EC Ltd. Lipopolysaccharide (LPS) (tlr-pelps) was purchased from Invivogen. 
Dulbecco's Modified Eagle Medium (DMEM) (BE12-604F) was purchased from Lonza. β-
mercaptoethanol (60-24-2) was purchased from Laiwu Hehui Chemical Co. 
Labtech Chamber Slide Labtek II 4 pk16 (154526) for nanoparticle incubation with macrophages was 
purchased from Nalge Nunc International. Petri dishes (90 x 14.2 mm) for growing E. coli were 
obtained from VWR (391-0455). AcroSep MEP Hyper cell column (1 mL capacity, 12035-C001) was 
obtained from Pall.  
25 and 50 mL falcon tubes were centrifuged by Rotanta 460R rotor no. 5624 (Hettich). OD600 values 
were recorded on a BioPhotometer Plus (Eppendorf). Bright field images were captured on a PALM 
MicroBeam from Zeiss (optical microscope). 
Full DMEM was prepared complementing DMEM with 10 % fetal calf serum (FCS) obtained from 
Gibco and 1 % Penicillin Streptomycin (P11-010) purchased from PAA. 
TMB solution was made by dissolving 1 TMB tablet in 1 mL DMSO and adding this into 9 ml of 
phosphate-citrate buffer aqueous solution (the content of 1 capsule in 100 mL water).  
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2xYT solution was made by mixing tryptone (8 g), yeast extract (5 g) and NaCl (2.5 g) in water 
(500 mL). 
 
5.5.1 Polarisation of M1 and M2 macrophages from mouse femurs and tibias 
All experimental procedures were performed in accordance with protocols approved by Imperial 
College Animal Care and Use Committee. Five female C57BL/6 mice aged between 8 - 20 weeks were 
included in the study. 
The femurs and tibias from euthanised mice were harvested and the bones were cleaned from 
muscle tissues in DMEM for 1 min. Using a sterile razor blade, both ends of the bones were cut. A 
needle was placed into the cut ends and the bone flushed with DMEM and collected into a 50 mL 
falcon tube. The alcon tubes were topped up to 50 mL before centrifugation at room temperature 
for 5 min at 490 g. The cells (pellet) were separated with red blood cell lysing buffer (5 mL) at room 
temperature and then topped up with DMEM to 50 mL and centrifuged as previously. The cells 
(pellet) were suspended in full DMEM (3 mL) and counted with hematocytometer under microscope 
and diluted to a density of 1 x 106 cells/mL with full DMEM. To this, a macrophage colony-stimulating 
factor (M-CSF, 1/1,000 dilution) was added. The solution was plated into T75 and T25 flasks (20 mL 
and 7 mL respectively), and incubated at 37 °C for 5 days to mature. At the day of the maturation 
period, the supernatant was removed and fresh DMEM (10 mL) was added, removed, and then more 
fresh DMEM added (5 mL). The cells were scratched off from the plates and the suspension 
transferred to a falcon tube, centrifuged, and the pellet suspended in full DMEM (3 mL) and counted 
as previously before dilution to a density of 0.5 x 106 cells/mL with full DMEM. The solution of cells 
were plated subsequently in the desired wells of Labtech’s chamber slides (0.5 – 1.0 mL/well), then 
left overnight at 37 °C to adhere. HeLa cells (0.5 x 106 cells/mL, 0.5 – 1.0 mL/well) were added into 
desired wells as a non-phagocytic negative control and adherence allowed. For the macrophage 
cultures, once adhered, the supernatant was removed, and the following polarisation factors added 
to the relevant wells: for M1 polarisation - 100 ng/mL IFN-γ + LPS (1/1,000 and 1/500 vol., 
respectively) and M2 polarisation - 50 ng/mL IL-4 + IL-13 (each 1/500 vol.); and left to polarize for 24 
hours. Nanoparticle samples (25 μg/well) were added to wells and incubated for 4 to 5 hours at 
37 °C. The phagocytosis was stopped by adding ice cold PBS (1 mL) and washed 4 times with PBS. 
The slides were air dried for 30 min, then the cells fixed in acetone for 30 min on ice, subsequently 
washed with PBS for 5 min and air dried at room temperature, before being stained with Prussian 
blue. 
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5.5.2 Prussian blue staining 
No metal components were used (e.g. tweezers/racks) in this stain as the basis of the stain is the 
reaction between Fe(III) ions and potassium hexacyanoferrate (II) which forms a blue pigment. The 
following solutions were prepared at room temperature:  
(A): Potassium hexacyanoferrate(II) (1.0 g) was dissolved in MilliQ water (50 mL).  
(B): 37 % HCl (2.5 mL) diluted with MilliQ water (47.5 mL).  
Equal portions of A and B were mixed to form the iron staining solution. Cells fixed on slides (see 
previous) were suspended in the iron staining solution for 15 min, then rinsed with MilliQ water and 
counter-stained (nuclei) with neutral red for 5 min. The slides were then rinsed with tap water, 
dehydrated in 100 % ethanol for 1 min, then cleared in HistoClear for 1 min before mounted on a 
microscope. 
 
5.5.3 scFv preparation 
All procedures with bacterial cell culture were performed under aseptic manipulation. 
Day 1: A pre-culture medium was prepared which contained 2YxT (5 mL), 100 μg/mL Ampicillin and 
1 % glucose in a 14 mL Falcon tube. A microspatula-full of a stock E. coli was inoculated and shaken 
at 37 °C, 180 rpm overnight. 
Day 2: Main culture medium containing 2xYT (300 mL), 50 mg/mL Ampicillin (200 μL) and 40 % 
glucose (250 μL) was prepared. The pre-culture (2 mL) was inoculated and shaken at 37 °C, 180 rpm 
until OD600 = 0.9 (about 3 hours). OD600 was measured on an Eppendorf Biophonate Plus 
photometer. To the mixture was added 0.1 M isopropyl β-D-1-thiogalactopyronoside IPTG (1 mL so 
the final concentration was 1 mM) and shaken at 30 °C, 180 rpm overnight.  
 
Day 3: To confirm that the cultured bacteria were successfully grown, the OD600 of the “Day 2” 
prepared solutions were measured. The cultured media were divided into Falcon tubes and 
centrifuged at 1800 g (2870 rpm) for 10 minutes at 4 °C. Subsequently, the supernatant was stored 
on ice until purified. 
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5.5.4 Purification of scFv 
The following stock solutions for running of the column were prepared: 
a) PBS (-): 1 tablet of PBS (Sigma Aldrich) was dissolved in MilliQ water (200 mL) then filtered  
with a 0.2 μm syringe filter and stored at 4 °C.  
b) Elution buffer: 50 mM sodium acetate at pH 4.96 combined with 50 mM NaCl solution. A 
stock solution of 1 M sodium acetate was prepared by dissolving sodium acetate (8.02 g) in 
MilliQ water (100 mL). A stock solution of 1 M NaCl was prepared by dissolving NaCl (5.85 g) 
in MilliQ water (100 mL). The elution buffer was prepared by combining the 1 M sodium 
acetate solution (5 mL) and the 1 M NaCl (5 mL) and diluted with MilliQ water up to 100 mL.  
c) Tris.HCl: 5.463 g of Tris Base was dissolved in MilliQ water (30 mL) then adjusted to pH 8.8.  
 
The previously obtained supernatant was first filtered with a 0.45 μm syringe filter then with a 
0.2 μm syringe filter. The filtered supernatant (250 μL) was combined with 2x sample buffer (250 μl) 
and β-mercaptoethanol (25 μL) and labelled as sample “S”. AcroSep MEP Hyper cell column was 
equilibrated with PBS(-) (5 mL) using a 20 mL syringe. All filtered supernatant were applied keeping 
the flow through in an autoclaved bottle. The columned flow through (250 μL) was combined with 2x 
sample buffer (250 μL) and β-mercaptoethanol (25 μL) and labelled as “FT”. The column was then 
washed with PBS(-) (10 mL), with the flow through isolated as 1 mL fractions each in separate 
Eppendorf tubes. Each of the 1 mL fractions of the PBS washings (250 μL) was combined with 2x 
sample buffer (250 μL) and β-mercaptoethanol (25 μl) and labelled as W1 to W10 respectively. 
Following that, ScFv was eluted from the column with elution buffer (6 mL), with the flow through 
again isolated as 1 mL fractions in separate Eppendorf tubes. To each fraction, 1.5 M Tris HCl pH 8.8 
(50 μl) was added to neutralise the sample. As before, each of the eluted fractions (250 μl each) was 
combined with 2x sample buffer (250 μl) and β-mercaptoethanol (25 μl) and labelled as sample E1 to 
E6 respectively. The column was washed with PBS (-) (10 mL) for later use. All the samples S, FT, W1-
W10, E1-E6, were stored on ice until the SDS-PAGE. 
  
5.5.5 Preparation of new competent cells (HB 2151 E. Coli) 
LB media was prepared by dissolving LB powder (25 g) in MilliQ water (1 L), and then autoclaved.  
TfbI was prepared by dissolving potassium acetate (0.15 g, 30 mM), RbCl (0.61 g, 100 mM), 
CaCl2.2H2O (0.07 g, 10 mM), MnCl2.4H2O (0.50 g, 50 mM), and glycerol (7.5 mL) in MilliQ water 
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(30 mL). The volume of the solution was topped up with MilliQ water to 50 mL. The pH was adjusted 
to 5.8 with 0.2 M acetic acid and sterilised by filtration with a 0.2 μm syringe filter. 
TfbII was prepared by dissolving 3-(N-morpholino)propanesulfonic acid (MOPS) (0.10 g, 10 mM), 
CaCl2.2H2O (0.55 g, 75 mM), RbCl (0.06 g, 10 mM) and glycerol (7.5 mL) in MilliQ water (30 mL). The 
volume of the solution was topped up with MilliQ water to 50 mL. The pH was adjusted to 6.5 with 
1 M KOH and sterilised by filtration with a 0.2 μm syringe filter. 
To an aliquot of the LB broth (2 mL), a spatula of previously frozen HB 2151 E. Coli was inoculated 
and this preculture incubated at 37 °C overnight. A portion of the preculture (1 mL) was added into 
LB broth (100 mL) and incubated at 37 °C until the OD600 = 0.3 (approximately 1.5 h). The media was 
transferred into two 50 mL falcon tubes and placed on ice for 5 min, then centrifuged at 4200 rpm 
for 10 min at 4 °C. The pellet was resuspended in TfbI (20 mL per falcon tube), vortexed and placed 
on ice for 5 min. The solution was centrifuged as before and the pellet resuspended in TfbII (2 mL 
per falcon tube), vortexed and placed on ice for 15 min. To store the competent cells, the TfbII 
solutions of the cells were dispensed into ice cold Eppendorf tubes and snap freezed in liquid N2 
before storage at -80 °C.  
 
5.5.6 Transformation (insertion of plasmid into competent cells) 
LB agar was prepared by dissolving LB agar powder (37 g) in MilliQ water (1 L). The mixture was 
autoclaved, then kept at 55 °C until the pouring stage. Prior to pouring into the petri dishes, 
ampicillin (1 mL) was added. The dishes were allowed to cool until the agar solidified and then 
labelled, sealed with parafilm and stored at 4 °C.  
To the competent cells in TfbII solution (100 μL aliquots) was added the following plasmids 
separately (0.5 μL each): 
a) scFv 1 
b) scFv 2 
c) Ubiquitin 
d) pUC19 vector as a control. 
The mixtures were placed on ice for 30 min then heat shocked at 42 °C for 1 min before cooling on 
ice for 2 min. To each mixture was added LB broth containing 0.4 % glucose and 20 mM MgSO4 
(1 mL, where 100 mL LB broth requires 100 μL of 40 % glucose stock and 200 μL MgSO4 1 M stock). 
The mixtures were incubated at 37 °C for 1 h, before plating on LB agar plates that were incubated at 
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37 °C overnight. The colonies were counted and one from each (except the pUC19 control) were 
incubated in a preculture for scFv synthesis as previously outlined.  
 
5.5.7 SDS-PAGE 
All samples “S”, “FT”, “W1-10”, “E1-E6” from the scFv purification, were boiled using Techne Dri-
Block DB2D for 5 minutes before application of each (25 μL) onto a 12 well, 1.0 mm, 12 % Tris-
glycine gel cassette with a commercial marker (10 μL) applied as a reference in the first and last well. 
The gel was run in a tank containing Tris-glycine running buffer (x10 dilution), at 185 V (constant 
voltage), for 1 h, or until the dye has reached the bottom of the gel. The gel was removed from the 
holder and stained with a Coomassie Brilliant Blue (CBB) dye for 20 min. The stain was discarded and 
washed with deionised water, then left to destain overnight. Finally the gels were dried overnight 
according to manufacturer’s instructions.  
 
5.5.8 ELISA 
All amounts described are per well. A 96 well plate was coated with the relevant antigens: 1) a 
recombinant Human Fractalkine antigen (100 μL from 10 μg/mL); 2) Ubiquitin (100 μL from 20 μM); 
3) PBS (-) as control. After leaving to coat overnight at 4 °C, the wells were washed 3 times with PBS 
(-). After the final wash, 3 % BSA in PBS (-) (200 μL) were added and incubated at room temperature 
for 2 h. This acts as a blocking agent for non-specific binding sites. The wells were washed again 3 
times with PBS (-), then scFv samples (or anti-Ubiquitin as control) (10 μL) suspended in 3 % BSA/PBS 
(-) (100 μL) was added. The plate was incubated for 1 h at room temperature. The wells were 
washed 3 times with PBS (-)/0.1 % Tween 20. Finally, TMB colourimetric substrate (100 μL) was 
added and left to develop a blue colour for 2 – 15 mins at room temperature. The reaction was 
stopped by the addition of 1 M H2SO4 (50 μL), which turned the solutions varying degrees of yellow. 
The absorbances of the solutions in each well were recorded at OD450 and OD650 on a plate reader, 
and the OD650 value subtracted from the OD450 value. 
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6 Conclusions and future work 
6.1 General conclusions 
The use of iron oxide nanoparticles as MRI contrast agents has been extensively researched in 
literature. Their mode of imaging is different to gadolinium-based contrast agents and so would not 
completely replace them as MRI contrast agents. However, nanoparticles do offer a slight advantage 
over Gd contrast agents, as they can achieve exceptionally high relaxivities, and due to the large 
surface area can be decorated with various moieties, enabling multiple functions within one 
construction. 
Dual-modal MRI/PET contrast agents have been synthesised and studied in the literature, mostly 
with a non-nanoparticle agent as the MRI moiety, and the combined contrast agent as one entity. 
This poses several problems where a large dual-modal nanoparticulate based contrast agent would 
move slowly in vivo and reduce the lifetime of the PET radioisotope. To overcome this, a pre-
targeting concept to bring the two separate contrast agents together in vivo was proposed. 
Conjugation of a cyclooctyne (strained alkyne) to the nanoparticle would enable copper-free azide-
alkyne cycloaddition to a PET-moiety (68Ga-azido-DOTA complex). 
The surface of the nanoparticles were decorated firstly with a small molecule ligand bearing a strong 
binding anchor, and subsequently with PEG for improved water solubility and biocompatibility. The 
two step functionalisation, first with a small molecule and then the PEG allows for a more versatile 
approach, compared to simply coating the nanoparticles with a biocompatible polymer such as 
dextran (the binding mode of which is usually by weak electrostatic interactions).  
Prior to using the radioactive gallium, luminescent lanthanides were utilised to enable 
characterisation of the resultant nanoparticles after the cycloaddition reaction by traditional 
methods. In addition to the luminescent lanthanides, paramagnetic gadolinium was also conjugated 
to the nanoparticles by the copper-free alkyne-azide cycloaddition reaction. This gave a dual-
weighted T1/T2 contrast agent with enhanced r1 relaxivities. This was an interesting area of the 
nanoparticles to investigate, therefore a range of Gd-conjugated NPs, with various modifications 
were synthesised, and their physical properties studied.  
With respect to biological application, the nanoparticles were intended for use as a contrast agent in 
the imaging of vulnerable plaque. An attempt was made to functionalise the nanoparticles with a 
biological targeting agent, by conjugation to a short chain antibody fragment that is specific to a 
protein called Fractalkine.  
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Bearing all of this in mind, the general outline of the progression of the project is described again in 
the scheme below (Scheme 6.1). 
 
Scheme 6.1 Overview of the synthesis and structure of the final nanoparticle target. 
 
In Chapter 2, several methods to synthesise iron oxide nanoparticles were discussed, however the 
high temperature thermal decomposition of an iron precursor, iron acetylacetonate, produced the 
most ideal nanoparticles with a low size dispersion and high crystallinity. The nanoparticles were of 
6 nm diameter on average, and coated with hydrophobic oleic acid. Different ligands to replace the 
oleic acid were investigated to obtain water-soluble nanoparticles. Ligands with sulfonate, 
phosphonate and bisphosphonate as anchoring groups were investigated. Sodium alendronate, a 
ligand with a bisphosphonate group as the anchor, was determined to be the most successful as the 
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resultant nanoparticles (NP2) were water-soluble. This excellent stability is due to the strong 
interaction between the nanoparticle surface and the bisphosphonate group.1,2  
Chapter 3 described the conjugation of NP2 to PEG of different lengths with different terminal 
functional groups, as well as conjugation to a cyclooctyne (NP12). Both conjugations were successful 
and characterised accordingly. Initial copper-free cycloaddition reactions between NP12 and Ln-
azide-DOTA complexes (where Ln = Eu and Tb) were attempted, however unexpected fluorescence 
results were observed. This led to work investigating the relaxivity effects on nanoparticles when the 
metal conjugated to the NP surface was Gd (Chapter 4). The T1/T2 conjugates gave relaxivities that 
did not always have a defined trend, nor followed a particular literature trend. However the 
enhanced r1 relaxivities on conjugation of the Gd to the NP makes these nanoparticles ideal for use 
as dual-weighted T1/T2 contrast agents. Reaction between NP12 and 
68Ga-azide-DOTA was not 
achieved in the time available.  
In Chapter 5, the preparation of scFv specific towards Fractalkine was attempted using E. coli. The 
scFv was intended to be conjugated to the nanoparticle for vulnerable plaque imaging. Work is still 
ongoing to determine the specificity of the scFv towards the Fractalkine antigen. Preliminary uptake 
experiments with macrophages indicate that the nanoparticles are taken up by both M1 and M2 
polarised macrophages which is not ideal, and it was not possible to determine preferential uptake 
between the two macrophage populations.  
 
6.2 Future work 
As an extension of work with respect to the synthesis of nanoparticles, hybrid nanoparticles such as 
manganese ferrite (MnFe2O4) could be another nanoparticle core to be investigated. MnFe2O4 
nanoparticles have a higher magnetisation than Fe3O4 and so would have even higher relaxivities 
than those already synthesised here.3–6 MnFe2O4 can be synthesised via a similar method to the high 
temperature thermal decomposition of iron(III) acetylacetonate to form Fe3O4.
7 Partial substitution 
of Fe(acac)3 for Mn(acac)2 in a 1:2 ratio at the same conditions gives MnFe3O4 (Scheme 6.2). 
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Scheme 6.2 Synthesis of MnFe2O4 via the high temperature thermal decomposition of Fe(acac)3 and 
Mn(acac)2. 
 
Various molecules can act as capping agents for a nanoparticle; polymers and inorganic shells among 
others. Only small molecules were investigated here to allow for versatility in conjugation of further 
moieties. Polymers such as polyacrylic acid and polyethylenimine could serve as potential polymeric 
coatings for nanoparticles. The stability of the resultant nanoparticles could then be investigated and 
compared to those coated by small molecules in this project. 
With respect to the fluorescence of the nanoparticles in Chapter 3, further investigation with a 
higher-powered laser or a fluorimeter capable of measuring shorter gating times would help 
elucidate the results observed. Lifetime measurements of the Ln-conjugated nanoparticles would 
also be carried out.  
The use of the cyclooctyne here can be improved upon, by the use of the later generation modified 
cyclooctynes. This would require a more difficult and multi-step synthesis, or directly purchasing the 
costly cyclooctynes. However, another catalyst-free efficient cycloaddition reaction that has been 
identified in the literature is between tetrazine (some examples in Figure 6.1) and a strained alkene 
or alkyne.8–10 This reaction (Scheme 6.3) has been suggested to have extremely fast kinetics, and is 
more tolerant to water.  
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Figure 6.1 Structures of tetrazines that have been used in reported cycloaddition reactions. a) (4-(1,2,4,5-
tetrazin-3-yl)phenyl)methanamine, b) 6-(6-pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridine-3-amine, c) 4-(6-
pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid.  
 
 
Scheme 6.3 Cycloaddition reaction between a trans-cyclooctene and tetrazine.
11
 
 
With respect to the dual-weighted T1/T2 nanoparticle conjugates, further modifications such as 
changing the size of the nanoparticle core as well as the type of nanoparticle core itself, and 
measuring the relaxivities to understand their effects on the magnetisation of the nanoparticles. 
Larger nanoparticles are expected to have higher magnetisation and this should be reflected in the 
T1 and T2 measurements. 
The biological aspects of this project have not been addressed sufficiently mainly due to time 
constraints. Radiolabelling experiments with gallium-68 would need to be carried out to form the 
68Ga-azido-DOTA complexes and subsequently testing the copper-free cycloaddition reaction with 
the alkyne functionalised nanoparticles in vitro and in vivo. If successful, conjugation of tetrazine to 
the PET moiety or the nanoparticle and subsequently the cycloaddition reaction could be carried out 
in order to compare the reaction kinetics for the azide-alkyne cycloaddition and the tetrazine-
strained alkene/alkyne.  
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With respect to the preparation of the scFv, confirmation of the specificity against Fractalkine by 
ELISA is the first step. Once confirmed, conjugation to the nanoparticle will be carried out and the 
specificity again confirmed, by ELISA as well as histology experiments.  
From the macrophage uptake experiments, it has not been possible to distinguish between M1 or 
M2 macrophage uptake for the nanoparticle not functionalised with scFv. Unfortunately, obtaining 
bone marrow-derived monocytes are time consuming (and require the euthanisation of mice), and 
therefore the macrophage polarisation protocol has been slow to optimisation to improve the cell 
density of the cells. Nevertheless, once optimised, the uptake experiments themselves will also 
require optimisation. Experimentation with varying concentrations of nanoparticles per well, and 
different cell densities per well should be carried out.  
If all this is successful, MR imaging in live mice and eventually pigs would be ideal, alongside the 
possible dual-modal MRI/PET imaging. Distribution studies should also be carried out. In the long 
term, comparison of the imaging of vulnerable plaque by the nanoparticles to that via other imaging 
modalities such as OCT could be carried out to determine the efficacy and success of this method.  
In summary, this work has showcased a promising methodology towards the synthesis of a dual-
modal MRI/PET contrast agent with hopes for use in the imaging of vulnerable plaque. However, 
more work needs to be carried out in order to refine the system and chemistry in order to develop 
this as a viable tool for the required application. 
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